[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TWI576345B - Morpholine-pyridine derivative - Google Patents

Morpholine-pyridine derivative Download PDF

Info

Publication number
TWI576345B
TWI576345B TW104113768A TW104113768A TWI576345B TW I576345 B TWI576345 B TW I576345B TW 104113768 A TW104113768 A TW 104113768A TW 104113768 A TW104113768 A TW 104113768A TW I576345 B TWI576345 B TW I576345B
Authority
TW
Taiwan
Prior art keywords
pyridyl
morpholin
pyrazole
carboxamide
chloro
Prior art date
Application number
TW104113768A
Other languages
Chinese (zh)
Other versions
TW201546067A (en
Inventor
古托 葛立
菲利浦 弗里傑
羅傑 諾可洛斯
吉賽普 西西爾
紅 沈
胡逸民
Original Assignee
赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赫孚孟拉羅股份公司 filed Critical 赫孚孟拉羅股份公司
Publication of TW201546067A publication Critical patent/TW201546067A/en
Application granted granted Critical
Publication of TWI576345B publication Critical patent/TWI576345B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

嗎啉-吡啶衍生物 Morpholine-pyridine derivative

本發明係關於式I之化合物， The present invention relates to a compound of formula I,

其中X係CR或N；R係氫、鹵素或低碳數烷基；L係鍵結、-C(O)-或-C(O)NH-；Ar係苯基或含有一個或兩個N原子之五員或六員雜芳基；R1係鹵素、低碳數烷基、經鹵素取代之低碳數烷基、低碳數烷氧基、經鹵素取代之低碳數烷氧基或環烷基；n係0、1、2或3；或其醫藥上合適之酸加成鹽、所有外消旋混合物、所有其等相應之鏡像異構物及/或光學異構物。 Wherein X is CR or N; R is hydrogen, halogen or lower alkyl; L is bonded, -C(O)- or -C(O)NH-; Ar is phenyl or contains one or two N a five or six membered heteroaryl group; R 1 is a halogen, a lower alkyl group, a halogen substituted lower alkyl group, a lower alkoxy group, a halogen substituted lower alkoxy group or Cycloalkyl; n is 0, 1, 2 or 3; or a pharmaceutically suitable acid addition salt thereof, all racemic mixtures, all such corresponding mirror image isomers and/or optical isomers.

已經發現式I之化合物對痕量胺相關受體(TAARs)，特別係對TAAR1具有良好的親和性。該等化合物可用於治療抑鬱症、焦慮症、躁鬱症、注意力不足過動症(ADHD)、壓力相關障礙症、精神性失常(諸如精神分裂症)、神經性疾病(諸如帕金森氏病)、神經退行性疾病(諸如阿茲海默氏病)、癲癇、偏頭痛、高血壓、藥物濫用及代謝失調 (諸如飲食障礙症、糖尿病、糖尿病併發症、肥胖症、異常血脂症)、能量消耗及同化失調症、體溫穩衡失調症及功能障礙、睡眠及晝夜節律性異常及心血管疾病。 Compounds of formula I have been found to have good affinity for trace amine related receptors (TAARs), particularly for TAAR1. These compounds are useful in the treatment of depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress related disorders, mental disorders (such as schizophrenia), neurological disorders (such as Parkinson's disease). , neurodegenerative diseases (such as Alzheimer's disease), epilepsy, migraine, hypertension, drug abuse and metabolic disorders (such as eating disorders, diabetes, diabetic complications, obesity, abnormal dyslipidemia), energy expenditure and assimilation disorders, body temperature imbalance disorders and dysfunction, sleep and circadian rhythm and cardiovascular disease.

在旨在治療如上所述之中樞神經系統疾病之藥劑之情況下，已報告之可結合至腎上腺髓質素受體之化合物(WO02/076950、WO97/12874或EP 0717 037)之一些生理效應(即，心血管效應、低血壓、鎮靜誘導)可視為非所需之副作用。因此，希望獲得具有對TAAR1受體優於腎上腺髓質素受體之選擇性之藥劑。本發明之目標顯示對TAAR1受體優於腎上腺髓質素受體之選擇性，特定言之，優於對人類及大鼠α1及α2腎上腺髓質素受體之良好選擇性。 In the case of an agent intended to treat a central nervous system disorder as described above, some of the physiological effects of compounds (WO02/076950, WO97/12874 or EP 0717 037) that have been reported to bind to the adrenomedullin receptor have been reported (ie Cardiovascular effects, hypotension, and sedation induction can be considered as undesirable side effects. Therefore, it is desirable to obtain an agent having selectivity for the TAAR1 receptor over the adrenomedullin receptor. The object of the present invention is to show a selectivity for the TAAR1 receptor over the adrenomedullin receptor, in particular, superior to the human and rat alpha 1 and alpha 2 adrenomedullin receptors.

經典生物胺(5-羥色胺、去甲腎上腺素、腎上腺素、多巴胺、組織胺)作為神經遞質在中樞及周邊神經系統中起重要作用[1]。其等合成及儲存以及其等降解及釋放後之再吸收受到嚴密調控。已知生物胺濃度失衡可導致在許多病理條件下之腦功能變化[2-5]。第二類內生性胺化合物(所謂之蹤胺(TAs))與經典生物胺之結構、代謝及次細胞定位明顯重疊。TAs包含p-酪胺、β-苯基乙胺、色胺及章魚胺，且其等通常以低於經典生物胺之濃度存在於哺乳類神經系統中[6]。 Classical biogenic amines (serotonin, norepinephrine, adrenaline, dopamine, histamine) act as neurotransmitters in the central and peripheral nervous systems [1]. Its recombination after synthesis and storage and its degradation and release are closely regulated. It is known that imbalances in biogenic amine levels can lead to changes in brain function under many pathological conditions [2-5]. The second class of endogenous amine compounds (so-called trace amines (TAs)) overlaps significantly with the structure, metabolism and subcellular localization of classical biogenic amines. TAs contain p-tyramine, beta-phenylethylamine, tryptamine and octopamine, and they are usually present in the mammalian nervous system at concentrations lower than the classical biogenic amines [6].

痕量胺失調與諸如精神分裂症及抑鬱症之各種精神性疾病[7]及諸如注意力不足過動症、偏頭痛、帕金森氏病、藥物濫用及飲食障礙症之其他病症[8、9]相關。 Trace amine disorders and various psychiatric disorders such as schizophrenia and depression [7] and other disorders such as attention deficit hyperactivity disorder, migraine, Parkinson's disease, drug abuse and eating disorders [8, 9 ] related.

長久以來，僅基於人類及其他哺乳類動物之CNS中之解剖學離散高親和性TA結合位點來假設TA特異性受體[10、11]。因此，據信TAs之藥理效應係透過熟知的經典生物胺機制，藉由觸發其等釋放、抑制其等再吸收或藉由與其等受體系統「交叉反應」來介導[9、12、13]。此觀點隨最近識別出新GPCRs家族之若干成員(痕量胺相關受體(TAARs))而發生改變[7、14]。人類有9個TAAR基因(包含3個偽基因) 及小鼠有16個基因(包含1個偽基因)。該等TAAR基因不含有內含子(有一個除外，TAAR2含有1個內含子)且彼此相鄰地定位在同一染色體片段上。與深度GPCR藥效團相似性比較及藥理學資料一致之該等受體基因之親緣關係顯示此等受體形成三個不同的亞族[7、14]。TAAR1係在人類與齧齒類之間高度保守之四種基因(TAAR1至4)之第一亞類中。TAs經由Gαs活化TAAR1。TAs之失調顯示導致諸如抑鬱症、精神病、注意力不足過動症、藥物濫用、帕金森氏病、偏頭痛、飲食障礙症、代謝失調之各種疾病之病原學及因此TAAR1配體具有治療此等疾病之巨大潛力。 For a long time, TA-specific receptors have been hypothesized based on anatomically discrete high-affinity TA binding sites in the CNS of humans and other mammals [10, 11]. Therefore, it is believed that the pharmacological effects of TAs are mediated through the well-known classical biogenic amine mechanism by triggering their release, inhibiting their reabsorption or by "cross-reacting" with their receptor systems [9, 12, 13 ]. This view has changed with the recent identification of several members of the new GPCRs family (trace amine related receptors (TAARs)) [7, 14]. Humans have 9 TAAR genes (including 3 pseudogenes) And the mouse has 16 genes (including 1 pseudo gene). These TAAR genes do not contain introns (except one, TAAR2 contains 1 intron) and are located adjacent to each other on the same chromosome fragment. The similarity between the similarity of the deep GPCR pharmacophores and the pharmacological data of the receptor genes showed that these receptors formed three different subfamilies [7, 14]. TAAR1 is among the first subclasses of the four genes (TAAR1 to 4) that are highly conserved between humans and rodents. TAs activate TAAR1 via Gαs. The imbalance of TAs indicates the etiology of various diseases such as depression, psychosis, attention deficit hyperactivity disorder, drug abuse, Parkinson's disease, migraine, eating disorders, metabolic disorders, and therefore TAAR1 ligands have treatments The enormous potential of the disease.

因此，增長痕量胺相關受體之相關知識受到極大關注。 Therefore, the knowledge about the growth of trace amine-related receptors has received great attention.

所用參考文獻：1 Deutch, A.Y.及Roth, R.H. (1999) Neurotransmitters. In Fundamental Neuroscience (第2版) (Zigmond, M.J., Bloom, F.E., Landis, S.C., Roberts, J.L及Squire, L.R.編)，第193-234頁，Academic Press; 2 Wong, M.L.及Licinio, J. (2001) Research and treatment approaches to depression. Nat. Rev. Neurosci. 2, 343-351; 3 Carlsson, A.等人(2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237-260; 4 Tuite, P.及Riss, J. (2003) Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin. Investig. Drugs 12, 1335-1352; 5 Castellanos, F.X.及Tannock, R. (2002) Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci. 3, 617-628; 6 Usdin, Earl; Sandler, Merton編。Psychopharmacology Series，第1卷：Trace Amines and the Brain. [Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychoparmacology, San Juan, Puerto Rico] (1976); 7 Lindemann, L.及Hoener, M. (2005) A renaissance in trace amines inspired by a novel GPCR family. Trends in Pharmacol. Sci. 26, 274-281; 8 Branchek, T.A.及Blackburn, T.P. (2003) Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr. Opin. Pharmacol. 3, 90-97; 9 Premont, R.T.等人(2001) Following the trace of elusive amines. Proc. Natl. Acad. Sci. U. S. A. 98, 9474-9475; 10 Mousseau, D.D.及Butterworth, R.F. (1995) A high-affinity [3H] tryptamine binding site in human brain. Prog. Brain Res. 106, 285-291; 11 McCormack, J.K.等人(1986) Autoradiographic localization of tryptamine binding sites in the rat and dog central nervous system. J. Neurosci. 6, 94-101; 12 Dyck, L.E. (1989) Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor. Life Sci. 44, 1149-1156; 13 Parker, E.M.及Cubeddu, L.X. (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245, 199-210; 14 Lindemann, L.等人(2005) Trace amine associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85, 372-385。 References used: 1 Deutch, AY and Roth, RH (1999) Neurotransmitters. In Fundamental Neuroscience (2nd Edition) (Zigmond, MJ, Bloom, FE, Landis, SC, Roberts, JL and Squire, LR), 193 -234 pages, Academic Press; 2 Wong, ML and Licinio, J. (2001) Research and treatment approaches to depression. Nat. Rev. Neurosci. 2, 343-351; 3 Carlsson, A. et al. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia : new evidence Annu Rev. Pharmacol Toxicol 41, 237-260; 4 Tuite, P. and Riss, J. (2003) Recent developments in the pharmacological treatment of Parkinson's disease Expert..... Opin. Investig. Drugs 12, 1335-1352; 5 Castellanos, FX and Tannock, R. (2002) Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci. 3, 617-628; Usdin, Earl; edited by Sandler, Merton. Psychopharmacology Series , Volume 1: Trace Amines and the Brain. [ Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychoparmacology , San Juan, Puerto Rico] (1976); 7 Lindemann, L. and Hoener, M (2005) A renaissance in trace amines inspired by a novel GPCR family. Trends in Pharmacol. Sci. 26, 274-281; 8 Branchek, TA and Blackburn, TP (2003) Trace amine receptors as targets for novel therapeutics: legend, Myth and fact. Curr. Opin. Pharmacol. 3, 90-97; 9 Premont, RT et al. (2001) Following the trace of elusive amines. Proc. Natl. Acad. Sci. USA 98, 9474-9475; 10 Mousseau, DD and Butterworth, RF (1995) A high-affinity [3H] tryptamine binding site in human brain. Prog. Brain Res. 106, 285-291; 11 McCormack, JK et al. (1986) Autoradiographic localization of tryptamine binding sites in the J. Neurosci. 6, 94-101; 12 Dyck, LE (1989) Release of some endogenous trace amines from rat striatal slices in the presence and abse nce of a monoamine oxidase inhibitor Life Sci 44, 1149-1156;.. 13 Parker, EM and Cubeddu, LX (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding J. Pharmacol.. Exp. Ther. 245, 199-210; 14 Lindemann, L. et al. (2005) Trace amine associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85, 372-385.

本發明之目標係新穎式I化合物及其等醫藥上可接受之鹽、其等在製造用於治療關於痕量胺相關受體之生物功能之疾病的藥劑中之用途、其等製造及基於本發明之化合物之藥劑，該等藥劑可控制或預防諸如以下疾病：抑鬱症、焦慮症、躁鬱症、注意力不足過動症、壓力相關障礙症、精神性失常(諸如精神分裂症)、神經性疾病(諸如帕金森氏病)、神經退行性疾病(諸如阿茲海默氏病)、癲癇、偏頭痛、藥物濫用及代謝失調(諸如飲食障礙症)、糖尿病、糖尿病併發症、肥胖症、異常血脂症、能量消耗及同化失調症、體溫穩衡失調症及功能障礙、睡眠及晝夜節律性異常及心血管疾病。 The object of the present invention is the use of the novel compounds of the formula I and their pharmaceutically acceptable salts, their use in the manufacture of a medicament for the treatment of diseases relating to the biological function of trace amine-related receptors, their manufacture and on the basis of the present invention. Agents of the compounds of the invention which control or prevent diseases such as depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder, stress related disorders, mental disorders (such as schizophrenia), neuropathy Diseases (such as Parkinson's disease), neurodegenerative diseases (such as Alzheimer's disease), epilepsy, migraine, substance abuse and metabolic disorders (such as eating disorders), diabetes, diabetic complications, obesity, abnormalities Lipidemia, energy expenditure and assimilation disorders, body temperature imbalance disorders and dysfunction, sleep and circadian rhythm and cardiovascular disease.

使用本發明之化合物之較佳適應症係抑鬱症、精神病、帕金森氏病、焦慮症、注意力不足過動症(ADHD)及糖尿病。 Preferred indications for the use of the compounds of the invention are depression, psychosis, Parkinson's disease, anxiety, attention deficit hyperactivity disorder (ADHD) and diabetes.

如本文中所使用，術語「低碳數烷基」表示含有1至7個碳原子之飽和直鏈或支鏈基團，例如，甲基、乙基、丙基、異丙基、正丁基、異丁基、2-丁基、第三丁基及類似物。較佳之烷基係具有1至4個碳原子之基團。 As used herein, the term "lower alkyl" means a saturated straight or branched chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl. , isobutyl, 2-butyl, tert-butyl and the like. Preferred alkyl groups are those having from 1 to 4 carbon atoms.

如本文中所使用，術語「低碳數烷氧基」表示其中烷基殘基如上文定義且其係經由氧原子附接的基團。 As used herein, the term "lower alkoxy" refers to a group wherein the alkyl residue is as defined above and which is attached via an oxygen atom.

術語「鹵素」表示氯、碘、氟及溴。較佳之鹵素基團係氟或氯。 The term "halogen" means chlorine, iodine, fluorine and bromine. Preferred halogen groups are fluorine or chlorine.

如本文中所使用，術語「經鹵素取代之低碳數烷基」表示如術語「低碳數烷基」所定義之含有1至7個碳原子之飽和直鏈或支鏈基團，其中至少一個氫原子被鹵素原子置換。較佳之鹵素原子係氟。此類基團之實例係CF3、CHF2、CH2F、CH2CF3或CH2CHF2。 As used herein, the term "lower alkyl substituted by halogen" means a saturated straight or branched chain group having from 1 to 7 carbon atoms as defined by the term "lower alkyl group", wherein at least A hydrogen atom is replaced by a halogen atom. A preferred halogen atom is fluorine. Examples of such groups are CF 3 , CHF 2 , CH 2 F, CH 2 CF 3 or CH 2 CHF 2 .

如本文中所使用，術語「經鹵素取代之低碳數烷氧基」表示如 上文定義之烷氧基，且其中至少一個氫原子被鹵素置換。 As used herein, the term "lower number alkoxy substituted by halogen" means as An alkoxy group as defined above, wherein at least one of the hydrogen atoms is replaced by a halogen.

術語「環烷基」表示含有3至6個碳原子之飽和碳環，例如，環丙基、環丁基、環戊基或環己基。 The term "cycloalkyl" denotes a saturated carbocyclic ring containing from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

術語「含有一個或兩個N原子之五或六員雜芳基」表示環狀芳族5或6員環，其中至少一個碳原子被氮原子置換，例如，基團吡啶基、嘧啶基或吡唑基。 The term "five or six membered heteroaryl containing one or two N atoms" means a cyclic aromatic 5 or 6 membered ring wherein at least one carbon atom is replaced by a nitrogen atom, for example, a pyridyl group, a pyrimidinyl group or a pyridyl group. Azolyl.

術語「醫藥上可接受之酸加成鹽」包括與諸如以下之無機酸及有機酸形成之鹽：鹽酸、硝酸、硫酸、磷酸、檸檬酸、蟻酸、延胡索酸、馬來酸、乙酸、琥珀酸、酒石酸、甲磺酸、對甲苯磺酸及類似物。 The term "pharmaceutically acceptable acid addition salt" includes salts formed with inorganic acids and organic acids such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, Tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.

本發明之一項實施例係式I之化合物，其中「L」係鍵結，例如下列化合物：(RS)-N-(4-氯苯基)-6-嗎啉-2-基-吡啶-3-胺 An embodiment of the invention is a compound of formula I wherein the "L" linkage is, for example, the following compound: (RS)-N-(4-chlorophenyl)-6-morpholin-2-yl-pyridine- 3-amine

(RS)-N-(4-溴苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-bromophenyl)-6-morpholin-2-yl-pyridin-3-amine

(RS)-N-(4-乙氧苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-ethoxyphenyl)-6-morpholin-2-yl-pyridin-3-amine

(RS)-N-(3-氯苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(3-chlorophenyl)-6-morpholin-2-yl-pyridin-3-amine

(RS)-N-(4-氟苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-fluorophenyl)-6-morpholin-2-yl-pyridin-3-amine

(RS)-6-嗎啉-2-基-N-[4-(三氟甲基)苯基]吡啶-3-胺 (RS)-6-morpholin-2-yl-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine

(RS)-N-(6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)嘧啶-4-胺 (RS)-N-(6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyrimidine-4-amine

N-(4-氯苯基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺 N-(4-chlorophenyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

6-[(2S)-嗎啉-2-基]-N-[4-(三氟甲基)苯基]吡啶-3-胺 6-[(2S)-morpholin-2-yl]-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine

N-(5-氯-2-吡啶基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺 N-(5-chloro-2-pyridyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

N-(5-溴-2-吡啶基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺 N-(5-bromo-2-pyridyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

6-[(2S)-嗎啉-2-基]-N-[6-(三氟甲基)-3-吡啶基]吡啶-3-胺 6-[(2S)-morpholin-2-yl]-N-[6-(trifluoromethyl)-3-pyridyl]pyridin-3-amine

6-[(2S)-嗎啉-2-基]-N-[4-(三氟甲基)-2-吡啶基]吡啶-3-胺 6-[(2S)-morpholin-2-yl]-N-[4-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

N-(4-氯苯基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺 N-(4-chlorophenyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine

6-[(2R)-嗎啉-2-基]-N-[4-(三氟甲基)苯基]吡啶-3-胺 6-[(2R)-morpholin-2-yl]-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine

N-(5-氯-2-吡啶基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺 N-(5-chloro-2-pyridyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine

6-[(2R)-嗎啉-2-基]-N-[6-(三氟甲基)-3-吡啶基]吡啶-3-胺 6-[(2R)-morpholin-2-yl]-N-[6-(trifluoromethyl)-3-pyridyl]pyridin-3-amine

6-[(2R)-嗎啉-2-基]-N-[4-(三氟甲基)-2-吡啶基]吡啶-3-胺 6-[(2R)-morpholin-2-yl]-N-[4-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(三氟甲基)吡啶-2-胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(trifluoromethyl)pyridin-2-amine

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-6-(三氟甲基)吡啶-2-胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-6-(trifluoromethyl)pyridin-2-amine

N-(5-溴-2-吡啶基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺 N-(5-bromo-2-pyridyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-(三氟甲基)吡啶-2-胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-(trifluoromethyl)pyridin-2-amine

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-6-(三氟甲基)吡啶-2-胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-6-(trifluoromethyl)pyridin-2-amine

(RS)-N-(4-氯苯基)-2-嗎啉-2-基-嘧啶-5-胺 (RS)-N-(4-chlorophenyl)-2-morpholin-2-yl-pyrimidine-5-amine

(RS)-2-嗎啉-2-基-N-[4-(三氟甲基)苯基]嘧啶-5-胺 (RS)-2-morpholin-2-yl-N-[4-(trifluoromethyl)phenyl]pyrimidin-5-amine

(RS)-5-氯-N-(5-氯-2-吡啶基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-5-chloro-N-(5-chloro-2-pyridyl)-6-morpholin-2-yl-pyridin-3-amine

(RS)-5-氯-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺 (RS)-5-chloro-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

(RS)-5-甲基-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺 (RS)-5-methyl-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

(RS)-N-(5-氯-2-吡啶基)-5-氟-6-嗎啉-2-基-吡啶-3-胺或 (RS)-5-氟-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺。 (RS)-N-(5-chloro-2-pyridinyl)-5-fluoro-6-morpholin-2-yl-pyridin-3-amine or (RS)-5-Fluoro-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine.

本發明之另一實施例係式I之化合物，其中「L」係-C(O)-，例如下列化合物：(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 Another embodiment of the invention is a compound of formula I, wherein "L" is -C(O)-, for example the following compound: (RS)-4-chloro-N-(6-morpholin-2-yl-3 -pyridyl)benzamide

(RS)-3-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-3-chloro-N-(6-morpholin-2-yl-3-pyridyl)benzamide

(RS)-4-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-4-ethoxy-N-(6-morpholin-2-yl-3-pyridyl)benzamide

(RS)-4-氟-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-4-fluoro-N-(6-morpholin-2-yl-3-pyridyl)benzamide

(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

(RS)-N-(6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]benzamide

3-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 3-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]benzamide

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-4-(三氟甲基)苯甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-4-(trifluoromethyl)benzamide

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(三氟甲基)吡啶-4-甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(trifluoromethyl)pyridine-4-carboxamide

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)苯甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)benzamide

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-6-(2,2,2-三氟乙氧基)吡啶-3-甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide

2-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]嘧啶-5-甲醯胺 2-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]pyrimidine-5-carboxamide

3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

4-氯-3-環丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-Chloro-3-cyclopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

4-氯-3-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-1-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-丙基-吡唑-3-甲醯胺 4-chloro-1-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-propyl-pyrazole-3-carboxamide

4-氯-1-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-丙基-吡唑-3-甲醯胺 4-chloro-1-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-propyl-pyrazole-3-carboxamide

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]benzamide

3-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 3-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]benzamide

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-4-(三氟甲基)苯甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-4-(trifluoromethyl)benzamide

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-2-(三氟甲基)吡啶-4-甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-2-(trifluoromethyl)pyridine-4-carboxamide

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)苯甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)benzamide

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-6-(2,2,2-三氟乙氧基)吡啶-3-甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide

2-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]嘧啶-5-甲醯胺 2-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]pyrimidine-5-carboxamide

3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

4-氯-3-環丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-cyclopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

4-氯-3-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

(R)-3-乙基-4-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-1H-吡唑-5-甲醯胺 (R)-3-Ethyl-4-methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-1H-pyrazole-5-carboxamide

(S)-3-乙基-4-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-1H-吡唑-5-甲醯胺 (S)-3-Ethyl-4-methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-1H-pyrazole-5-carboxamide

(R)-6-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-2-(三氟甲基)嘧啶-4-甲醯胺 (R)-6-Methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-2-(trifluoromethyl)pyrimidine-4-carboxamide

(S)-6-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-2-(三氟甲基)嘧啶-4-甲醯胺 (S)-6-Methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-2-(trifluoromethyl)pyrimidine-4-carboxamide

(RS)-4-氯-N-(2-嗎啉-2-基嘧啶-5-基)苯甲醯胺 (RS)-4-chloro-N-(2-morpholin-2-ylpyrimidin-5-yl)benzamide

(RS)-4-氯-3-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)-1H-吡唑-5-甲醯胺 (RS)-4-chloro-3-ethoxy-N-(6-morpholin-2-yl-3-pyridyl)-1H-pyrazole-5-carboxamide

(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazole-5- Guanamine

4-氯-3-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-乙基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-ethyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-溴-3-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

3-環丙基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-cyclopropyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-溴-3-環丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-cyclopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-3-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-乙基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-ethyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-溴-3-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

3-環丙基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-cyclopropyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-溴-3-環丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-cyclopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isobutyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氟-3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isobutyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-丁基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

5-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺 5-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3-methyl Guanamine

2-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺 2-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole-3- Formamide

3-異丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isobutyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氟-3-異丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isobutyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-丁基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

3-丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

5-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺 5-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3-methyl Guanamine

2-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺 2-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole-3- Formamide

4-氯-3-乙氧基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethoxy-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(2,2,2-trifluoroethoxy)-1H-pyrazole-5 -Procarbamide

4-氯-3-乙氧基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethoxy-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

(RS)-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(5-chloro-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

(RS)-4-氯-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(5-chloro-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

(RS)-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(5-fluoro-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

(RS)-4-氯-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(5-fluoro-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

4-氯-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

4-氟-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

(RS)-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(5-methyl-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

(RS)-4-氯-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(5-methyl-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

4-氯-3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺或 4-chloro-3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide or

4-氟-3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺。 4-Fluoro-3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide.

本發明之另一實施例係式I之化合物，其中「L」係-C(O)NH-，例如下列化合物： (RS)-1-(3-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲 Another embodiment of the invention is a compound of formula I, wherein "L" is -C(O)NH-, for example the following compounds: (RS)-1-(3-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

(RS)-1-(4-氟苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(4-fluorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

(RS)-1-(6-嗎啉-2-基-3-吡啶基)-3-[4-(三氟甲基)苯基]脲 (RS)-1-(6-morpholin-2-yl-3-pyridyl)-3-[4-(trifluoromethyl)phenyl]urea

(RS)-1-(4-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(4-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

1-(3-氯苯基)-3-[6-[(2S)-嗎啉-2-基]-3-吡啶基]脲 1-(3-chlorophenyl)-3-[6-[(2S)-morpholin-2-yl]-3-pyridyl]urea

1-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-[3-(三氟甲基)苯基]脲 1-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-[3-(trifluoromethyl)phenyl]urea

1-(3-氯苯基)-3-[6-[(2R)-嗎啉-2-基]-3-吡啶基]脲 1-(3-chlorophenyl)-3-[6-[(2R)-morpholin-2-yl]-3-pyridyl]urea

1-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-[3-(三氟甲基)苯基]脲 1-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-[3-(trifluoromethyl)phenyl]urea

(RS)-1-(3-氯苯基)-3-(2-嗎啉-2-基嘧啶-5-基)脲 (RS)-1-(3-chlorophenyl)-3-(2-morpholin-2-ylpyrimidin-5-yl)urea

(RS)-1-(5-氯-6-嗎啉-2-基-3-吡啶基)-3-(3-氯苯基)脲 (RS)-1-(5-chloro-6-morpholin-2-yl-3-pyridyl)-3-(3-chlorophenyl)urea

(RS)-1-(3-氯苯基)-3-(5-氟-6-嗎啉-2-基-3-吡啶基)脲或 (RS)-1-(3-氯苯基)-3-(5-甲基-6-嗎啉-2-基-3-吡啶基)脲。 (RS)-1-(3-chlorophenyl)-3-(5-fluoro-6-morpholin-2-yl-3-pyridyl)urea or (RS)-1-(3-chlorophenyl)-3-(5-methyl-6-morpholin-2-yl-3-pyridyl)urea.

可以順序性或收斂性合成途徑進行本發明之式I之化合物之製備。本發明之化合物之合成顯示於下列流程圖1、2 & 3及121個特定實例之說明中。熟習此項技術者已知進行該反應所需之技術及所得產物之純化。除非另作相反說明，否則下文中該等方法之說明中所用的取代基及指標具有前文給出之意義。 The preparation of the compounds of formula I of the present invention can be carried out in a sequential or astringent synthetic route. The synthesis of the compounds of the invention is shown in the following Schemes 1, 2 & 3 and 121 specific examples. The techniques required to carry out the reaction and the purification of the resulting product are known to those skilled in the art. Unless otherwise stated to the contrary, the substituents and indicators used in the description of the methods below have the meanings given above.

更詳細言之，可藉由下文給出之方法、藉由實例中給出之方法或藉由類似方法製造式I之化合物。熟習此項技術者已知用於個別反應步驟之合適的反應條件。然而，反應順序不限於流程圖1、2 & 3中展示之順序，視初始材料及其等各自反應性，可自由改變反應步驟之順序。初始材料既可購買獲得亦可藉由類似於下文所給方法之方法、藉由說明中所引用之參考文獻或實例中描述之方法或藉由此項技術中已知的方法製備。 In more detail, the compound of formula I can be produced by the methods given below, by the methods given in the examples or by analogous methods. Suitable reaction conditions for individual reaction steps are known to those skilled in the art. However, the order of the reaction is not limited to the order shown in the schemes 1, 2 & 3, and the order of the reaction steps can be freely changed depending on the respective materials and their respective reactivity. The starting materials are either commercially available or can be prepared by methods analogous to those exemplified below, by methods described in the references or examples cited in the description, or by methods known in the art.

可藉由此項技術中已知的方法製備本發明之式I之化合物及其等醫藥上可接受之鹽，例如，藉由下文描述之方法，該方法包括： a)使式14之化合物 The compounds of formula I of the present invention and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by the methods described below, which comprise: a) bringing a compound of formula 14

與式15-a之化合物反應 Reacts with the compound of formula 15-a

以形成式16-a之化合物 ，接著使Boc基團脫除保護基，以形成式I之化合物 To form a compound of formula 16-a And then removing the protecting group from the Boc group to form a compound of formula I

其中L係-C(O)-及其他取代基係如上所述，或b)使式14之化合物 Wherein the L-form-C(O)- and other substituents are as described above, or b) the compound of formula 14

與式15-b之化合物反應 Reacts with the compound of formula 15-b

以形成式16-b之化合物 ，接著使Boc基團脫除保護基，以形成式I之化合物 To form a compound of formula 16-b And then removing the protecting group from the Boc group to form a compound of formula I

其中L係-NHC(O)-及其他取代基係如上所述，或c)使式8、9或10之化合物 Wherein the L-form-NHC(O)- and other substituents are as described above, or c) the compound of formula 8, 9 or 10

與式11之化合物反應 Reacts with the compound of formula 11

以形成式12之化合物 ，接著使Boc基團脫除保護基，以形成式I之化合物 To form a compound of formula 12 And then removing the protecting group from the Boc group to form a compound of formula I

其中L係鍵結及其他取代基係如上所述，或若需要，可將獲得之該等化合物轉化為醫藥上可接受之酸加成鹽。 Wherein the L-linkages and other substituents are as described above, or if desired, the obtained compounds can be converted to pharmaceutically acceptable acid addition salts.

一般程序General procedure

取代基係如上所述。 The substituents are as described above.

步驟A：可以諸如氯、溴、N-氯代丁二醯亞胺(NCS)、N-溴代丁二醯亞胺(NBS)或三氯化四乙基銨之鹵化劑，視需要以諸如HBr、HCl、HOAc、對甲苯磺酸之酸作為添加劑，在諸如CH2Cl2、CHCl3、二噁烷、THF、乙腈之溶劑中在室溫至高溫下處理來完成酮1至α-鹵化酮3之轉化。 Step A: a halogenating agent such as chlorine, bromine, N-chlorobutylimine (NCS), N-bromosuccinimide (NBS) or tetraethylammonium trichloride may be used, such as HBr, HCl, HOAc, p-toluenesulfonic acid as an additive, in a solvent such as CH 2 Cl 2 , CHCl 3 , dioxane, THF, acetonitrile at room temperature to high temperature to complete ketone 1 to α-halogenation Conversion of ketone 3 .

較佳條件係在70℃下溴在HBr/HOAc溶液中3小時以形成α-溴酮3(鹵素=Br)。 Preferred conditions are bromine in HBr/HOAc solution at 70 ° C for 3 hours to form α-bromo ketone 3 (halogen = Br).

步驟A’：或者，α-鹵化酮3可獲得自涉及醯基鹵中間物之步進式方法。可以諸如(COCl)2、SOCl2、PCl3、PBr3或Ph3P‧Br2之鹵化劑，視需要在諸如CH2Cl2、CHCl3、苯或甲苯之溶劑中，在0℃至高溫下處理使羧酸2轉化為相應之醯基鹵。在第二步驟中，可以(三甲基甲矽烷基)重氮甲烷處理醯基鹵中間物及然後以濃縮HCl或HBr處理。可使用乙腈、THF及乙醚之混合物作為溶劑在0℃與室溫之間之溫度下進行該反應。 Step A': Alternatively, the alpha-halogenated ketone 3 can be obtained from a stepwise process involving a mercapto halide intermediate. A halogenating agent such as (COCl) 2 , SOCl 2 , PCl 3 , PBr 3 or Ph 3 P‧Br 2 may be optionally used in a solvent such as CH 2 Cl 2 , CHCl 3 , benzene or toluene at a temperature of from 0 ° C to high temperature. The lower treatment converts the carboxylic acid 2 to the corresponding mercapto halide. In the second step, the mercapto halide intermediate can be treated with (trimethylformamidinyl)diazomethane and then treated with concentrated HCl or HBr. The reaction can be carried out using a mixture of acetonitrile, THF and diethyl ether as a solvent at a temperature between 0 ° C and room temperature.

較佳條件係第一步驟中，(COCl)2在CH2Cl2中於0℃至室溫時並在0-5℃下混合反應物，接著容許在室溫下反應30分鐘以形成α-氯酮3(鹵素=Cl)。 Preferably, in the first step, (COCl) 2 is mixed in CH 2 Cl 2 at 0 ° C to room temperature and at 0-5 ° C, and then allowed to react at room temperature for 30 minutes to form α- Chloroketone 3 (halogen = Cl).

步驟B：可透過與N-苄基胺基乙醇之親核取代完成C-N鍵之形成以提供α-胺基酮4。可以諸如三乙胺、二異丙基乙胺、K2CO3、Na2CO3、Cs2CO3、KOtBu之鹼，在諸如DMF、乙腈、DMSO、THF、DME或二噁烷之非質子性溶劑中在室溫至高溫時進行該反應。 Step B: The formation of a CN bond can be accomplished by nucleophilic substitution with N-benzylaminoethanol to provide an alpha-amino ketone 4 . It may be a base such as triethylamine, diisopropylethylamine, K 2 CO 3 , Na 2 CO 3 , Cs 2 CO 3 , KO t Bu, such as DMF, acetonitrile, DMSO, THF, DME or dioxane. The reaction is carried out in an aprotic solvent at room temperature to elevated temperature.

較佳條件係K2CO3作為鹼在無水DMF中在室溫下。 Preferred conditions are K 2 CO 3 as a base in anhydrous DMF at room temperature.

步驟C：可藉由諸如LiBH4、NaBH4、LiAlH4或DIBAL-H之還原劑，在諸如MeOH、EtOH、THF、乙醚或甲苯之溶劑中在-78℃至室溫下之處理完成酮4至二醇5之轉化。 Step C: The ketone 4 can be completed by treatment with a reducing agent such as LiBH 4 , NaBH 4 , LiAlH 4 or DIBAL-H in a solvent such as MeOH, EtOH, THF, diethyl ether or toluene at -78 ° C to room temperature. Conversion to diol 5 .

較佳條件係NaBH4在乙醇中在室溫下1小時。 Preferred conditions are NaBH 4 in ethanol at room temperature for 1 hour.

步驟D：可藉由酸介導之陽離子環化或涉及磺酸酯中間物之步進式方法完成二醇5之環化。 Step D: The cyclization of the diol 5 can be accomplished by acid mediated cationic cyclization or a stepwise process involving a sulfonate intermediate.

在酸介導之陽離子環化中，可藉由以諸如H2SO4或H3PO4之無機酸在高溫下處理來完成該轉化。 In acid-mediated cationic cyclization, the conversion can be accomplished by treatment with a mineral acid such as H 2 SO 4 or H 3 PO 4 at elevated temperatures.

在步進式方法中，可藉由以一當量之磺醯化試劑(諸如1-(對甲苯磺醯基)咪唑、甲磺醯氯或甲苯磺醯氯)；或在無機鹼(諸如NaH及KOtBu)或有機鹼(諸如吡啶、三乙胺、N,N-二異丙基乙胺或N-甲基嗎啉)之存在下在醚性溶劑(諸如乙醚、二噁烷、THF或TBME)中；或使用有機鹼作為溶劑在0℃至50℃下處理二醇5來完成該轉化。可藉由以諸如氫化鈉、第三丁醇鉀或2-甲基-2-丁醇鉀之非親核性鹼，在諸如乙醚、二噁烷、THF或TBME之醚性溶劑中之處理使所得之磺酸酯轉化為嗎啉6。 In a stepwise process, by using one equivalent of a sulfonating reagent such as 1-(p-toluenesulfonyl)imidazole, methanesulfonyl chloride or toluenesulfonyl chloride; or in an inorganic base such as NaH and In the presence of KO t Bu) or an organic base such as pyridine, triethylamine, N,N-diisopropylethylamine or N-methylmorpholine in an ethereal solvent such as diethyl ether, dioxane, THF or The conversion is carried out in TBME); or by treating the diol 5 at 0 ° C to 50 ° C using an organic base as a solvent. It can be treated by a non-nucleophilic base such as sodium hydride, potassium butoxide or potassium 2-methyl-2-butoxide in an ethereal solvent such as diethyl ether, dioxane, THF or TBME. The resulting sulfonate is converted to morpholine 6 .

較佳條件係使用NaH作為鹼及1-(對甲苯磺醯基)咪唑作為磺醯化試劑在THF中在室溫下16小時之步進式方法。 Preferred conditions are a stepwise method using NaH as a base and 1-(p-toluenesulfonyl)imidazole as a sulfonating reagent in THF at room temperature for 16 hours.

步驟E：可藉由以Pd觸媒催化之氫化反應或以諸如ClCOOCH2CH2Cl、ClCOOCH(Cl)Me、ClCOOCH2Ph及ClCOOCH2CCl3之氯甲酸酯及視需要以諸如三乙胺、二異丙基乙胺及氫氧化鈉之鹼在諸如二氯甲烷、1,2-二氯乙烷、甲苯、THF、乙醚、二噁烷、TBME、甲醇及乙醇之溶劑中在室溫至高溫下之處理來完成苄基保護基團之移除。 Step E: by hydrogenation reaction catalyzed by Pd catalyst or by chloroformate such as ClCOOCH 2 CH 2 Cl, ClCOOCH(Cl)Me, ClCOOCH 2 Ph and ClCOOCH 2 CCl 3 and optionally such as triethylamine , diisopropylethylamine and sodium hydroxide base in a solvent such as dichloromethane, 1,2-dichloroethane, toluene, THF, diethyl ether, dioxane, TBME, methanol and ethanol at room temperature to Treatment at elevated temperatures completes the removal of the benzyl protecting group.

較佳條件係使用ClCOOCH(Cl)Me在二氯甲烷中在室溫下4小時，接著在MeOH及甲苯中在回流溫度下1小時。 Preferred conditions are the use of ClCOOCH(Cl)Me in dichloromethane at room temperature for 4 hours followed by MeOH and toluene at reflux temperature for 1 hour.

步驟F：可藉由以碳酸二第三丁酯，視需要在諸如三乙胺、N,N-二異丙基乙胺、N-甲基嗎啉、碳酸鉀、碳酸鈉或碳酸銫之有機或無機鹼之存在下，在諸如二氯甲烷或1,2-二氯乙烷之鹵化溶劑或諸如乙醚、二噁烷、THF或TBME之醚性溶劑中之處理來完成嗎啉7之保護。 Step F: may be carried out by using dibutyl butyl carbonate, optionally in an organic state such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, potassium carbonate, sodium carbonate or cesium carbonate. The protection of morpholine 7 is accomplished by treatment with a halogenated solvent such as dichloromethane or 1,2-dichloroethane or an ethereal solvent such as diethyl ether, dioxane, THF or TBME in the presence of an inorganic base.

較佳條件係THF在碳酸鉀作為鹼之存在下在室溫下2小時。 Preferred conditions are THF at room temperature for 2 hours in the presence of potassium carbonate as a base.

步驟G：可使用掌性HPLC分離8之鏡像異構物。較佳條件係使用SFC(管柱：Chiralpak AD-3 100×4.6mm I.D.，3um)並以乙醇(0.05%DEA)於CO2中，從5%至40%作為流動相。 Step G: The image isomer of 8 can be separated using palm HPLC. Preferred conditions are the use of SFC (column: Chiralpak AD-3 100 x 4.6 mm ID, 3 um) and ethanol (0.05% DEA) in CO 2 from 5% to 40% as the mobile phase.

步驟A：可藉由以鈀或銅觸媒、配體及鹼在諸如二噁烷、DMF、THF、甲苯、DMF及DMSO之溶劑中在高溫下之處理來完成芳基溴8、9或10與芳胺11之偶合，例如，使用經鈀催化之布赫瓦爾德-哈特維希(Buchwald-Hartwig)反應。 Step A: aryl bromide 8 , 9 or 10 can be completed by treatment with palladium or copper catalyst, ligand and base in a solvent such as dioxane, DMF, THF, toluene, DMF and DMSO at elevated temperature. Coupling with the aromatic amine 11 , for example, a palladium-catalyzed Buchwald-Hartwig reaction.

較佳條件係催化性叁(二亞苄基丙酮)二鈀(0)、催化性4,5-雙(二苯基膦基)-9,9-二甲基呫噸(Xantphos)及Cs2CO3在二噁烷中在90℃下12小時。 Preferred conditions are catalytic hydrazine (dibenzylideneacetone) dipalladium (0), catalytic 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) and Cs 2 CO 3 was taken in dioxane at 90 ° C for 12 hours.

步驟B：可以諸如HCl、H2SO4或H3PO4之礦酸或諸如CF3COOH、CHCl2COOH、HOAc或對甲苯磺酸之有機酸在諸如CH2Cl2、CHCl3、THF、MeOH、EtOH或H2O之溶劑中於0至80℃下實現Boc N-保護基團之移除。 Step B: a mineral acid such as HCl, H 2 SO 4 or H 3 PO 4 or an organic acid such as CF 3 COOH, CHCl 2 COOH, HOAc or p-toluenesulfonic acid such as CH 2 Cl 2 , CHCl 3 , THF, the solvent MeOH, EtOH or H 2 O to achieve the removal of Boc N- protecting group in 0 to 80 ℃.

較佳條件係CF3COOH作為酸在CH2Cl2中在室溫下1小時。 Preferred conditions are CF 3 COOH as the acid in CH 2 Cl 2 at room temperature for 1 hour.

步驟A：可藉由以二苯甲酮亞胺在鈀或銅觸媒、配體及鹼之存在下在諸如二噁烷、DME、THF、甲苯及DMSO之溶劑中在高溫下處理溴化物8、9或10來完成C-N鍵的形成，例如，使用經鈀催化之布赫瓦爾德-哈特維希反應。 Step A: Treatment of bromide by high temperature in a solvent such as dioxane, DME, THF, toluene and DMSO in the presence of palladium or copper catalyst, ligand and base in the presence of benzophenone imine 8 , 9 or 10 to complete the formation of the CN bond, for example, using a palladium-catalyzed Buchwald-Hartwig reaction.

較佳條件係催化性叁(二亞苄基丙酮)二鈀(0)、催化性4,5-雙(二苯基膦基)-9,9-二甲基呫噸(Xantphos)及Cs2CO3在二噁烷中在90℃下12小時。 Preferred conditions are catalytic hydrazine (dibenzylideneacetone) dipalladium (0), catalytic 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) and Cs 2 CO 3 was taken in dioxane at 90 ° C for 12 hours.

步驟B：可藉由在正常壓力或高壓下以氫氣氫化或藉由使用甲酸 銨或環己二烯作為氫源及諸如PtO2、Pd-C或雷氏鎳之觸媒在諸如MeOH、EtOH、H2O、二噁烷、THF、EtOAc、二氯甲烷、氯仿、DMF或其混合物之溶劑中轉移氫化來完成二苯基亞甲基N-保護基團之移除。 Step B: by hydrogenation under normal pressure or high pressure or by using ammonium formate or cyclohexadiene as a hydrogen source and a catalyst such as PtO 2 , Pd-C or Raney nickel in such as MeOH, EtOH, H 2 O, dioxane, solvent THF, EtOAc, methylene chloride, chloroform, DMF or mixtures thereof in the transfer hydrogenation to remove the complete diphenylmethylene of the N- protecting group.

亦可藉由以羥胺鹽酸鹽連同諸如乙酸鈉、乙酸鉀、碳酸鈉、碳酸鉀、碳酸銫之鹼在諸如MeOH、EtOH、二噁烷、THF、DMF或其混合物之溶劑中之處理來實現該轉移。 It can also be achieved by treatment with hydroxylamine hydrochloride together with a base such as sodium acetate, potassium acetate, sodium carbonate, potassium carbonate or cesium carbonate in a solvent such as MeOH, EtOH, dioxane, THF, DMF or a mixture thereof. The transfer.

較佳條件係羥胺鹽酸鹽連同乙酸鈉在MeOH中於室溫下反應1小時。 Preferably, the hydroxylamine hydrochloride is reacted with sodium acetate in MeOH at room temperature for 1 hour.

步驟C：可藉由以羧酸15-a及諸如DCC、EDC、TBTU、HBTU或HATU之偶合試劑在諸如三乙胺、N,N-二異丙基乙胺或N-甲基嗎啉之有機鹼之存在下在諸如二氯甲烷、1,2-二氯乙烷、DMF、DMS之溶劑中或包含乙醚、二噁烷、THF、DME或TBME之醚性溶劑中之處理來完成醯胺之形成。 Step C: by means of a coupling reagent such as triethylamine, N,N-diisopropylethylamine or N-methylmorpholine with a carboxylic acid 15-a and a coupling reagent such as DCC, EDC, TBTU, HBTU or HATU Treatment of indoleamine in the presence of an organic base in a solvent such as dichloromethane, 1,2-dichloroethane, DMF, DMS or an ethereal solvent containing diethyl ether, dioxane, THF, DME or TBME Formation.

較佳條件係HATU及N,N-二異丙基乙胺在DMF中於室溫下反應16小時。 Preferred conditions are HATU and N,N-diisopropylethylamine in DMF at room temperature for 16 hours.

步驟D：可藉由以異氰酸酯15-b在諸如三乙胺、N,N-二異丙基乙胺或N-甲基嗎啉之有機鹼之存在下在諸如二氯甲烷、1,2-二氯乙烷或氯苯之鹵化溶劑中之處理來完成脲之形成。 Step D: by using isocyanate 15-b in the presence of an organic base such as triethylamine, N,N-diisopropylethylamine or N-methylmorpholine in, for example, dichloromethane, 1,2- Treatment in a halogenated solvent of dichloroethane or chlorobenzene completes the formation of urea.

較佳條件係三乙胺作為鹼在二氯甲烷中在室溫下。 Preferred conditions are triethylamine as a base in dichloromethane at room temperature.

步驟E：以諸如HCl、H2SO4或H3PO4之礦酸或諸如CF3COOH、CHCl2COOH、HOAc或對甲苯磺酸之有機酸在諸如CH2Cl2、CHCl3、THF、MeOH、EtOH或H2O之溶劑下於0至80℃下實現Boc N-保護基團之移除。 Step E: using a mineral acid such as HCl, H 2 SO 4 or H 3 PO 4 or an organic acid such as CF 3 COOH, CHCl 2 COOH, HOAc or p-toluenesulfonic acid in such as CH 2 Cl 2 , CHCl 3 , THF, Removal of the Boc N-protecting group is achieved at 0 to 80 ° C under a solvent of MeOH, EtOH or H 2 O.

較佳條件係CF3COOH作為酸在CH2Cl2中於室溫下反應1小時。 Preferably, CF 3 COOH is reacted as an acid in CH 2 Cl 2 at room temperature for 1 hour.

化合物之單離及純化Isolation and purification of compounds

若需要，可藉由諸如(例如)過濾、萃取、結晶、管柱層析法、薄層層析法、厚層層析法、低壓或高壓液體製備型層析法或此等程序之組合之任何合適之分離或純化程序實現本文描述之化合物及中間物之單離及純化。合適之分離及單離程序之特定說明可參照下文之製法及實例。然而，當然亦可使用其他等效之分離或單離程序。可使用掌性HPLC分離式I之掌性化合物之外消旋混合物。亦可使用掌性HPLC分離掌性合成中間物之外消旋混合物。 If desired, by, for example, filtration, extraction, crystallization, column chromatography, thin layer chromatography, thick layer chromatography, low pressure or high pressure liquid preparative chromatography or a combination of such procedures Any suitable separation or purification procedure accomplishes the isolation and purification of the compounds and intermediates described herein. Specific descriptions of suitable separation and separation procedures can be found in the following recipes and examples. However, it is of course also possible to use other equivalent separation or separation procedures. The racemic mixture of the palm compound of Formula I can be isolated using palm HPLC. The racemic mixture of the palmitic synthesis intermediate can also be separated using palm HPLC.

式I化合物之鹽Salt of a compound of formula I

式I之化合物係鹼性且可轉化為相應之酸加成鹽。該轉化係藉由以至少化學計量之合適之酸(諸如鹽酸、氫溴酸、硫酸、硝酸、磷酸及類似物)及有機酸(諸如乙酸、丙酸、乙醇酸、丙酮酸、草酸、蘋果酸、丙二酸、琥珀酸、馬來酸、延胡索酸、酒石酸、檸檬酸、苯甲酸、肉桂酸、杏仁酸、甲磺酸、乙磺酸、對甲苯磺酸、水楊酸及類似物)處理來完成。通常，將游離鹼溶解於諸如乙醚、乙酸乙酯、氯仿、乙醇或甲醇及類似物之惰性有機溶劑中，並在類似溶劑中添加酸。溫度維持在0℃與50℃之間。所得之鹽自發地沉澱或可以少量極性溶劑使其自溶液中析出。 The compounds of formula I are basic and can be converted to the corresponding acid addition salts. The conversion is carried out by using at least a stoichiometric amount of a suitable acid (such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like) and an organic acid (such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid). , malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like) carry out. Usually, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and an acid is added in a similar solvent. The temperature is maintained between 0 ° C and 50 ° C. The salt obtained precipitates spontaneously or can be precipitated from the solution with a small amount of a polar solvent.

實例1 Example 1

(RS)-N-(4-氯苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-chlorophenyl)-6-morpholin-2-yl-pyridin-3-amine

a)2-溴-1-(5-溴-2-吡啶基)乙酮a) 2-bromo-1-(5-bromo-2-pyridyl)ethanone

在70℃下，將在HBr/HOAc溶液(35%~39%，80mL)中之2-乙醯基-5-溴吡啶(10.0g，CAS：214701-49-2)攪拌5min。滴加Br2(9.6 g)。該反應在70℃下持續3h，TLC分析顯示初始材料之完全消耗。使該混合物冷卻至室溫並濾過濾紙。於減壓下移除揮發物，並在高真空下進一步乾燥殘餘物，以獲得呈褐色油之粗2-溴-1-(5-溴-2-吡啶基)乙酮(16.8g，產率：93.3%)。該粗產物無需純化即可用於下一步驟中。 MS(ESI)：281.9([{81Br}M+H]+)、277.9([{79Br}M+H]+)。 2-Ethyl-5-bromopyridine (10.0 g, CAS: 214701-49-2) in HBr/HOAc solution (35% to 39%, 80 mL) was stirred at 70 ° C for 5 min. Br 2 (9.6 g) was added dropwise. The reaction was continued at 70 ° C for 3 h and TLC analysis showed complete consumption of the starting material. The mixture was allowed to cool to room temperature and the filter paper was filtered. The volatiles were removed under reduced pressure and the residue was dried <mjjjjjjjjjjjjjjjjjj : 93.3%). This crude product was used in the next step without purification. MS (ESI): 281.9 ([{ 81 Br}M+H] + ), 277.9 ([{ 79 Br}M+H] + ).

b)2-[苄基(2-羥乙基)胺基]-1-(5-溴-2-吡啶基)乙酮b) 2-[Benzyl(2-hydroxyethyl)amino]-1-(5-bromo-2-pyridyl)ethanone

在室溫下，向2-溴-1-(5-溴-2-吡啶基)乙酮(16.8g)在無水DMF(150mL)中之溶液中分批添加K2CO3(19.5g)。然後滴加N-苄基胺基乙醇(10.2g，CAS：104-63-2)。該反應在室溫下持續至藉由TLC分析顯示反應完成。將該混合物倒入水(1000mL)中並用EtOAc(2 x 1000mL)萃取。合併有機層並使用Na2SO4乾燥。於減壓下移除揮發物。藉由急驟層析法(矽膠，以體積計石油醚/EtOAc=10：1)純化殘餘物，以產生呈淺褐色油之2-[苄基(2-羥乙基)胺基]-1-(5-溴-2-吡啶基)乙酮(9g，產率：55%)。 K 2 CO 3 (19.5 g) was added portionwise to a solution of 2-bromo-1-(5-bromo-2-pyridyl)ethanone (16.8 g) in anhydrous DMF (150 mL). Then, N-benzylaminoethanol (10.2 g, CAS: 104-63-2) was added dropwise. The reaction was continued at room temperature until the reaction was completed by TLC analysis. The mixture was poured into water (1000 mL) and extracted with EtOAc EtOAc. The organic layers were combined and dried with Na 2 SO 4. The volatiles were removed under reduced pressure. The residue was purified by flash chromatography (EtOAc EtOAc (EtOAc:EtOAc) (5-Bromo-2-pyridyl) ethyl ketone (9 g, yield: 55%).

c)(RS)-2-[苄基(2-羥乙基)胺基]-1-(5-溴-2-吡啶基)乙醇c) (RS)-2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromo-2-pyridyl)ethanol

在室溫下，向2-[苄基(2-羥乙基)胺基]-1-(5-溴-2-吡啶基)乙酮(4.1g)在EtOH(40mL)中之溶液中分批添加NaBH4(540mg，14mmol)。藉由TLC分析顯示反應完成後，藉由添加飽和水性NH4Cl溶液(200mL)小心地中止該反應。於減壓下移除EtOH。用EtOAc(2x100mL)萃取殘餘物。藉由Na2SO4乾燥合併之有機萃取物並於減壓下濃縮。於高真空下進一步乾燥殘餘物，以提供粗(RS)-2-[苄基(2-羥乙基)胺基]-1-(5-溴-2-吡啶基)乙醇(3g，73%)，其無需純化即可用於下一步驟中。 MS(ESI)：352.9([{81Br}M+H]+)、350.9([{79Br}M+H]+)。 To a solution of 2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromo-2-pyridyl)ethanone (4.1 g) in EtOH (40 mL) NaBH 4 (540 mg, 14 mmol) was added in portions. After completion of the reaction by TLC analysis, the reaction was carefully quenched by the addition of saturated aqueous NH 4 Cl (200 mL). The EtOH was removed under reduced pressure. The residue was extracted with EtOAc (2×100 mL). With Na 2 SO 4 the combined organic extracts were dried and concentrated under reduced pressure. The residue was further dried under high vacuum to give crude (RS)-2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromo-2-pyridyl)ethanol (3 g, 73% ), which can be used in the next step without purification. MS (ESI): 352.9 ([{ 81 Br}M+H] + ), 350.9 ([{ 79 Br}M+H] + ).

d)(RS)-4-苄基-2-(5-溴-2-吡啶基)嗎啉d) (RS)-4-benzyl-2-(5-bromo-2-pyridyl)morpholine

在室溫下，向(RS)-2-[苄基(2-羥乙基)胺基]-1-(5-溴-2-吡啶基)乙醇(12g)在THF(100mL)中之溶液中分批添加氫化鈉(60%，2.7g)。在 室溫下將反應混合物攪拌2h。使該混合物冷卻至0℃，並分批添加1-(對甲苯磺醯基)咪唑(7g，CAS：2232-08-8)。30分鐘後，將該混合物升溫至室溫。持續攪拌整夜。以飽和水性氯化銨中止該反應。以乙酸乙酯萃取該混合物，以鹽水清洗並以Na2SO4乾燥。藉由層析法(矽膠，以體積計石油醚：乙酸乙酯=3：1)之純化提供(RS)-4-苄基-2-(5-溴-2-吡啶基)嗎啉(4g，產率：34.5%)。 To a solution of (RS)-2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromo-2-pyridyl)ethanol (12 g) in THF (100 mL) Sodium hydride (60%, 2.7 g) was added portionwise. The reaction mixture was stirred at room temperature for 2 h. The mixture was cooled to 0 ° C and 1-(p-toluenesulfonyl) imidazole (7 g, CAS: 2232-08-8) was added portionwise. After 30 minutes, the mixture was warmed to room temperature. Continue to stir overnight. The reaction was quenched with saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate, washed with brine and dried over Na 2 SO 4 . Purification of (RS)-4-benzyl-2-(5-bromo-2-pyridyl)morpholine (4 g) by chromatography (methylene chloride, petroleum ether: ethyl acetate = 3:1) , yield: 34.5%).

MS(ESI)：335.0([{81Br}M+H]+)、333.0([{79Br}M+H]+)。 MS (ESI): 335.0 ([{ 81 Br}M+H] + ), 333.0 ([{ 79 Br}M+H] + ).

1H NMR(DMSO-d6)：8.60(1 H)、8.05(1H)、7.42(1H)、7.30(5H)、4.51(1H)、3.97(1H)、3.82(1H)、3.59(1H)、3.47(1H)、3.07(1H)、2.75(1H)、2.19(1H)、1.91(m,1H)。 1 H NMR (DMSO-d 6 ): 8.60 (1 H), 8.05 (1H), 7.42 (1H), 7.30 (5H), 4.51 (1H), 3.97 (1H), 3.82 (1H), 3.59 (1H) 3.47 (1H), 3.07 (1H), 2.75 (1H), 2.19 (1H), 1.91 (m, 1H).

e)(RS)-2-(4-溴苯基)嗎啉e) (RS)-2-(4-bromophenyl)morpholine

在室溫下，將(RS)-4-苄基-2-(5-溴-2-吡啶基)嗎啉(4.35g)及氯甲酸1-氯乙酯(2.5g，CAS：50893-53-3)在CH2Cl2(50mL)中之溶液攪拌4h。TLC分析顯示初始材料完全消耗。於減壓下移除揮發物，並在高真空下進一步乾燥殘餘物。將殘餘物溶解於MeOH(40mL)中。在回流溫度下將該溶液攪拌一小時。TLC分析證明該反應完成。於減壓下移除揮發物，並在高真空下進一步乾燥殘餘物，以提供(RS)-2-(4-溴苯基)嗎啉(4.35g，13mmol產率：100%)。粗產物直接用於下一步驟中。 (RS)-4-benzyl-2-(5-bromo-2-pyridyl)morpholine (4.35 g) and 1-chloroethyl chloroformate (2.5 g, CAS: 50893-53) -3) was stirred for 4h in the (50mL) solution of CH 2 Cl 2. TLC analysis showed complete consumption of the starting material. The volatiles were removed under reduced pressure and the residue was dried further under high vacuum. The residue was dissolved in MeOH (40 mL). The solution was stirred at reflux temperature for one hour. TLC analysis confirmed the completion of the reaction. The volatiles were removed under reduced pressure and dried <RTI ID=0.0></RTI> to </RTI><RTIID=0.0> The crude product was used directly in the next step.

MS(ESI)：244.9([{81Br}M+H]+)、242.9([{79Br}M+H]+)。 MS (ESI): 244.9 ([{ 81 Br}M+H] + ), 242.9 ([{ 79 Br}M+H] + ).

f)(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯f) (RS)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

在室溫下，將K2CO3(5.38g)、二碳酸二第三丁酯(3.4g，CAS：424-99-5)及來自於以上反應(步驟e)之(RS)-2-(4-溴苯基)嗎啉(4.35g，13mmol)在THF(50mL)中之溶液中攪拌2小時。TLC分析顯示該反應完成。添加水(200mL)。用乙酸乙酯(2 x 100mL)萃取該混合物。用水(200mL)清洗合併之有機層。於減壓下濃縮有機層。急驟層析法 (矽膠，以體積計石油醚/EtOAc=3：1)產生(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯(3.95g，產率：89%)。 K 2 CO 3 (5.38 g), dibutyl butyl dicarbonate (3.4 g, CAS: 424-99-5) and (RS)-2- derived from the above reaction (step e) at room temperature (4-Bromophenyl)morpholine (4.35 g, 13 mmol) was stirred in THF (50 mL TLC analysis showed the reaction was complete. Water (200 mL) was added. The mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (200 mL). The organic layer was concentrated under reduced pressure. Flash chromatography (tank, petroleum ether / EtOAc = 3:1 by volume) yielded (RS)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (3.95 g) , yield: 89%).

MS(ESI)：344.8([{81Br}M+H]+)、342.8([{79Br}M+H]+)。 MS (ESI): 344.8 ([{ 81 Br}M+H] + ), 342.8 ([{ 79 Br}M+H] + ).

1H NMR(DMSO-d6)：8.69(1 H)、8.09(1H)、7.46(1H)、4.45(2H)、4.00(1H)、3.82(1H)、3.63(1H)、2.89(2H)、1.43(9H)。 1 H NMR (DMSO-d 6 ): 8.69 (1 H), 8.09 (1H), 7.46 (1H), 4.45 (2H), 4.00 (1H), 3.82 (1H), 3.63 (1H), 2.89 (2H) , 1.43 (9H).

g)(RS)-2-[5-(4-氯苯胺基)-2-吡啶基]嗎啉-4-羧酸第三丁酯g) (RS)-2-[5-(4-chloroanilino)-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

在90℃下於N2氣氛下，將(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯(60mg)、4-氯苯胺(25mg，CAS：106-47-8)、4,5-雙(二苯基膦基)-9,9-二甲基呫噸(Xantphos，20mg，CAS：161265-03-8)、叁(二亞苄基丙酮)二鈀(0)(16mg，CAS：51364-51-3)及Cs2CO3(170mg)在二噁烷(3mL)中之混合物攪拌12小時。LCMS顯示該反應完成。用水(100mL)稀釋混合物並用乙酸乙酯(2 x 100mL)萃取。用水(100mL)清洗合併之有機層。於減壓下濃縮有機層，以提供呈褐色油之粗(RS)-2-[5-(4-氯苯胺基)-2-吡啶基]嗎啉-4-羧酸第三丁酯。該粗產物無需純化即可用於下一步驟中。 (RS)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (60 mg), 4-chloroaniline (25 mg, CAS) at 90 ° C under N 2 atmosphere :106-47-8), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 20 mg, CAS: 161265-03-8), hydrazine (dibenzylidene) A mixture of diacetone (0) (16 mg, CAS: 51364-51-3) and Cs 2 CO 3 (170 mg) in dioxane (3 mL) was stirred for 12 hours. LCMS showed the reaction was completed. The mixture was diluted with water (100 mL) and EtOAc (EtOAc) The combined organic layers were washed with water (100 mL). The organic layer was concentrated under reduced pressure to afford crude <RTI ID=0.0>(</RTI></RTI><RTIgt;</RTI><RTIgt;</RTI><RTIgt; This crude product was used in the next step without purification.

h)(RS)-N-(4-氯苯基)-6-嗎啉-2-基-吡啶-3-胺h)(RS)-N-(4-chlorophenyl)-6-morpholin-2-yl-pyridin-3-amine

在室溫下，將來自於以上反應(步驟g)之粗(RS)-2-[5-(4-氯苯胺基)-2-吡啶基]嗎啉-4-羧酸第三丁酯溶解於CH2Cl2(3mL)中。添加三氟乙酸(TFA，1mL，CAS：76-05-1)。該反應在室溫下持續一小時，於減壓下移除揮發物。藉由製備型HPLC(流動相A：H2O，B：含有0.1%TFA之CH3CN，C18管柱)之純化產生呈淺黃色蠟狀固體之(RS)-N-(4-氯苯基)-6-嗎啉-2-基-吡啶-3-胺(25mg)。 Dissolving the crude (RS)-2-[5-(4-chloroanilino)-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester from the above reaction (step g) at room temperature In CH 2 Cl 2 (3 mL). Trifluoroacetic acid (TFA, 1 mL, CAS: 76-05-1) was added. The reaction was continued at room temperature for one hour and the volatiles were removed under reduced pressure. Purification by preparative HPLC (mobile phase A: H 2 O, B: CH 3 CN with 0.1% TFA, C18 column) gave (RS)-N-(4-chlorobenzene as a pale yellow waxy solid. 6-morpholin-2-yl-pyridin-3-amine (25 mg).

MS(ESI)：292.1([{37Cl}M+H]+)、290.1([{35Cl}M+H]+)。 MS (ESI): 292.1 ([ {37 Cl} M + H] +), 290.1 ([{35 Cl} M + H] +).

實例2 Example 2

(RS)-N-(4-溴苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-bromophenyl)-6-morpholin-2-yl-pyridin-3-amine

以類似實例1之方式在步驟(g)中使用4-溴苯胺(CAS：106-40-1)代替4-氯苯胺獲得標題化合物。淺黃色蠟狀固體。MS(ESI)：336.0([{81Br}M+H]+)、334.1([{79Br}M+H]+)。 The title compound was obtained in a similar manner to Example 1 using 4-bromoaniline (CAS: 106-40-1) instead of 4-chloroaniline in step (g). Light yellow waxy solid. MS (ESI): 336.0 ([{ 81 Br}M+H] + ), 334.1 ([{ 79 Br}M+H] + ).

實例3 Example 3

(RS)-N-(4-乙氧苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-ethoxyphenyl)-6-morpholin-2-yl-pyridin-3-amine

以類似實例1之方式在步驟(g)中使用4-乙氧基苯胺(CAS：156-43-4)代替4-氯苯胺獲得標題化合物。淺黃色油。MS(ESI)：300.2([M+H]+)。 The title compound was obtained in the same manner as in Example 1 in the step (g) using 4-ethoxyaniline (CAS: 156-43-4) instead of 4-chloroaniline. Light yellow oil. MS (ESI): 300.2 ([M+H] + ).

實例4 Example 4

(RS)-N-(3-氯苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(3-chlorophenyl)-6-morpholin-2-yl-pyridin-3-amine

以類似實例1之方式在步驟(g)中使用3-氯苯胺(CAS：108-42-9)代替4-氯苯胺獲得標題化合物。淺黃色油。MS(ESI)：292.0([{37Cl}M+H]+)、290.0([{35Cl}M+H]+)。 The title compound was obtained in a similar manner to Example 1 using 3-chloroaniline (CAS: 108-42-9) instead of 4-chloroaniline in step (g). Light yellow oil. MS (ESI): 292.0 ([ {37 Cl} M + H] +), 290.0 ([{35 Cl} M + H] +).

實例5 Example 5

(RS)-N-(4-氟苯基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(4-fluorophenyl)-6-morpholin-2-yl-pyridin-3-amine

以類似實例1之方式在步驟(g)中使用4-氟苯胺(CAS：371-40-4)代替4-氯苯胺獲得標題化合物。淺黃色油。MS(ESI)：274.1([M+H]+)。 The title compound was obtained in a similar manner to Example 1 using 4-fluoroaniline (CAS: 371-40-4) instead of 4-chloroaniline in step (g). Light yellow oil. MS (ESI): 274.1 ([M+H] + ).

實例6 Example 6

(RS)-6-嗎啉-2-基-N-[4-(三氟甲基)苯基]吡啶-3-胺 (RS)-6-morpholin-2-yl-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine

以類似實例1之方式在步驟(g)中使用4-(三氟甲基)苯胺(CAS：455-14-1)代替4-氯苯胺獲得標題化合物。淺黃色蠟狀固體。MS(ESI)：324.1([M+H]+)。 The title compound was obtained in the same manner as in Example 1 using 4-(trifluoromethyl)aniline (CAS: 455-14-1) instead of 4-chloroaniline. Light yellow waxy solid. MS (ESI): 324.1 ([M+H] + ).

實例7 Example 7

(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)benzamide

a)(RS)-2-[5-(二苯亞甲基胺基)-2-吡啶基]嗎啉-4-羧酸第三丁酯a) (RS)-2-[5-(diphenylmethyleneamino)-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯(1.0g)(實例1(f))、二苯甲酮亞胺(580mg，CAS：1013-88-3)、4,5-雙(二苯基膦基)-9,9-二甲基呫噸(Xantphos，500mg，CAS：161265-03-8)、叁(二亞苄基 丙酮)二鈀(0)(265mg，CAS：51364-51-3)及Cs2CO3(2.8g)在二噁烷(40mL)中之混合物藉由將氬氣鼓泡進入該混合物中數分鐘脫氣。在90℃下於Ar氣氛下將該反應混合物攪拌12小時。TLC分析顯示該反應完成。使該粗反應混合物冷卻至室溫並過濾。於真空中濃縮濾液並用水(100mL)稀釋殘餘物。用乙酸乙酯(2 x 100mL)萃取該混合物。用水(100mL)清洗合併之有機層並濃縮至乾。藉由急驟層析法(矽膠，以體積計CH2Cl2：MeOH=30：1)純化殘餘物，以產生呈黃色固體之(RS)-2-[5-(二苯亞甲基胺基)-2-吡啶基]嗎啉-4-羧酸第三丁酯(1.28g，產率：99.9%)。 (RS)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (1.0 g) (example 1 (f)), benzophenone imine (580 mg, CAS: 1013-88-3), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 500mg, CAS: 161265-03-8), hydrazine (dibenzylideneacetone) a mixture of dipalladium (0) (265 mg, CAS: 51364-51-3) and Cs 2 CO 3 (2.8 g) in dioxane (40 mL) by bubbling argon into the mixture for a few minutes gas. The reaction mixture was stirred at 90 ° C for 12 hours under an Ar atmosphere. TLC analysis showed the reaction was complete. The crude reaction mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated in vacuo and the residue was crystallised eluted with water. The mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (100 mL) and evaporated. By flash chromatography (silica gel, by volume of CH 2 Cl 2: MeOH = 30 : 1) The residue was purified to yield a yellow solid of (RS) -2- [5- (diphenylmethylene group )-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester (1.28 g, yield: 99.9%).

b)(RS)-2-(5-胺基-2-吡啶基)嗎啉-4-羧酸第三丁酯b) (RS)-2-(5-Amino-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

在室溫下，將來自於以上反應(步驟a)之(RS)-2-[5-(二苯亞甲基胺基)-2-吡啶基]嗎啉-4-羧酸第三丁酯(1.28g)、羥胺鹽酸鹽(320mg，CAS：5470-11-1)及NaOAc(2.38g，CAS：127-09-3)在甲醇(50mL)中之混合物攪拌3小時。TLC分析顯示該反應完成。過濾該混合物並濃縮。藉由急驟層析法(矽膠，以體積計CH2Cl2：MeOH=100：1至50：1)之純化產生呈白色固體之(RS)-2-(5-胺基-2-吡啶基)嗎啉-4-羧酸第三丁酯(450mg，產率：55.4%)。 (RS)-2-[5-(diphenylmethyleneamino)-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester from the above reaction (step a) at room temperature (1.28 g), a mixture of hydroxylamine hydrochloride (320 mg, CAS: 5470-11-1) and NaOAc (2.38 g, CAS: 127-09-3) in methanol (50 mL) was stirred for 3 hours. TLC analysis showed the reaction was complete. The mixture was filtered and concentrated. By flash chromatography (silica gel, by volume of CH 2 Cl 2: MeOH = 100 : 1 to 50: 1) purification of a white solid of (RS) -2- (5- amino-2-pyridinyl ) Doctyline-4-carboxylic acid tert-butyl ester (450 mg, yield: 55.4%).

MS(ESI)：280.0([M+H]+)。 MS (ESI): 280.0 ([M+H] + ).

c)(RS)-2-[5-[(4-氯苯甲醯基)胺基]-2-吡啶基]嗎啉-4-羧酸第三丁酯c) (RS)-2-[5-[(4-chlorobenzylidenyl)amino]-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

將(RS)-2-(5-胺基-2-吡啶基)嗎啉-4-羧酸第三丁酯(35mg)、4-氯苯甲酸(23mg，CAS：74-11-3)、HATU(57mg，CAS：148893-10-1)及N,N-二異丙基乙胺(DIPEA，49mg，CAS：7087-68-5)溶解於DMF(1.5mL)中。在室溫下，攪拌該溶液直至TLC分析顯示該反應完成。用水(30mL)稀釋該反應。用乙酸乙酯(2 x 20mL)萃取該混合物。用Na2SO4乾燥合併之有機層並於減壓下濃縮。於高真空下進一步乾燥提 供呈黃色固體之粗(RS)-2-[5-[(4-氯苯甲醯基)胺基]-2-吡啶基]嗎啉-4-羧酸第三丁酯，其無需純化即可用於下一步驟中。 (RS)-2-(5-Amino-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (35 mg), 4-chlorobenzoic acid (23 mg, CAS: 74-11-3), HATU (57 mg, CAS: 148893-10-1) and N,N-diisopropylethylamine (DIPEA, 49 mg, CAS: 7087-68-5) were dissolved in DMF (1.5 mL). The solution was stirred at room temperature until TLC analysis indicated the reaction was complete. The reaction was diluted with water (30 mL). The mixture was extracted with ethyl acetate (2 x 20 mL). With 2 SO 4 organic layers were dried and concentrated under the reduced pressure Na. Further drying under high vacuum afforded crude (RS)-2-[5-[(4-chlorobenzylidenyl)amino]-2-pyridyl]morpholine-4-carboxylic acid tert-butyl as a yellow solid. The ester was used in the next step without purification.

d)(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺d) (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)benzamide

將來自於以上反應(步驟c)之(RS)-2-[5-[(4-氯苯甲醯基)胺基]-2-吡啶基]嗎啉-4-羧酸第三丁酯溶解於CH2Cl2(2mL)及三氟乙酸(1mL)之混合物中。在室溫下，將該溶液攪拌一小時直至LCMS顯示該反應完成。於減壓下濃縮該溶液。藉由製備型HPLC(流動相A：H2O，B：含有0.1%TFA之CH3CN，C18管柱)之純化產生呈白色固體之(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺(32mg)。 Dissolving (RS)-2-[5-[(4-chlorobenzylidinyl)amino]-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester from the above reaction (step c) In a mixture of CH 2 Cl 2 (2 mL) and trifluoroacetic acid (1 mL). The solution was stirred for one hour at room temperature until LCMS showed the reaction was completed. The solution was concentrated under reduced pressure. Purification by preparative HPLC (mobile phase A: H 2 O, B: CH 3 CN with 0.1% TFA, C18 column) gave (RS)-4-chloro-N- (6-? Phenyridin-2-yl-3-pyridyl)benzamide (32 mg).

MS(ESI)：320.1([{37Cl}M+H]+)、318.1([{35Cl}M+H]+)。 MS (ESI): 320.1 ([ {37 Cl} M + H] +), 318.1 ([{35 Cl} M + H] +).

實例8 Example 8

(RS)-1-(3-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(3-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

a)(RS)-2-[5-[(3-氯苯基)胺甲醯基胺基]-2-吡啶基]嗎啉-4-羧酸第三丁酯a) (RS)-2-[5-[(3-chlorophenyl)aminecarboxyamino]-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

將(RS)-2-(5-胺基-2-吡啶基)嗎啉-4-羧酸第三丁酯(80mg)(實例7(b))、異氰酸3-氯苯酯(44mg，CAS：2909-38-8)及三乙胺(90mg，CAS：121-44-8)溶解於CH2Cl2(1mL)中。在室溫下，攪拌該溶液直至TLC分析顯示該反應完成。添加水(20mL)。藉由乙酸乙酯(2 x 20mL)萃取混合物。用Na2SO4乾燥合併之有機層並於減壓下濃縮。於高真空下之進一步乾燥提供呈黃色油之粗(RS)-2-[5-[(3-氯苯基)胺甲醯基胺基]-2-吡啶基]嗎啉-4-羧酸第三丁酯，其無需純化即可用於下一步驟中。 (RS)-2-(5-Amino-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (80 mg) (Example 7(b)), 3-chlorophenyl isocyanate (44 mg) , CAS: 2909-38-8) and triethylamine (90 mg, CAS: 121-44-8) were dissolved in CH 2 Cl 2 (1 mL). The solution was stirred at room temperature until TLC analysis indicated the reaction was complete. Water (20 mL) was added. The mixture was extracted with ethyl acetate (2 x 20 mL). With 2 SO 4 organic layers were dried and concentrated under the reduced pressure Na. Further drying under high vacuum afforded crude (RS)-2-[5-[(3-chlorophenyl)aminecarboxamido]-2-pyridyl]morpholine-4-carboxylic acid as a yellow oil The third butyl ester was used in the next step without purification.

b)(RS)-1-(3-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲b) (RS)-1-(3-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

將來自於以上反應(步驟a)之(RS)-2-[5-[(3-氯苯基)胺甲醯基胺基]-2-吡啶基]嗎啉-4-羧酸第三丁酯溶解於三氟乙酸(0.5mL)及CH2Cl2(2mL)之混合物中。在室溫下，攪拌該溶液直至TLC分析顯示該反應完成。添加水(20mL)。用乙酸乙酯(2 x 20mL)萃取該混合物。用飽和水性NaHCO3溶液中和水層至中性pH，並用CH2Cl2/CH3OH(以體積計10：1，20mL)萃取。於減壓下濃縮合併之有機層。藉由製備型HPLC(流動相A：H2O，B：含有0.1%TFA之CH3CN，C18管柱)純化殘餘物，以產生呈白色固體之(RS)-1-(3-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲(40mg)。 (RS)-2-[5-[(3-chlorophenyl)aminecarguanylamido]-2-pyridyl]morpholine-4-carboxylic acid tributyl from the above reaction (step a) ester mixture was dissolved in trifluoroacetic acid (0.5mL) and CH 2 Cl 2 (2mL) in the. The solution was stirred at room temperature until TLC analysis indicated the reaction was complete. Water (20 mL) was added. The mixture was extracted with ethyl acetate (2 x 20 mL). The aqueous layer was neutralized to a neutral pH with a saturated aqueous NaHCO 3 solution and extracted with CH 2 Cl 2 /CH 3 OH (10:1, 20 mL by volume). The combined organic layers were concentrated under reduced pressure. By preparative HPLC (mobile phase A: H 2 O, B: 0.1% TFA containing of CH 3 CN, C18 column) to give the residue, to yield a white solid of (RS) -1- (3- chlorophenyl 3-(6-morpholin-2-yl-3-pyridyl)urea (40 mg).

MS(ESI)：335.1([{37Cl}M+H]+)、333.1([{35Cl}M+H]+)。 MS (ESI): 335.1 ([ {37 Cl} M + H] +), 333.1 ([{35 Cl} M + H] +).

1H NMR(甲醇-d4)：8.75(1H)、8.10(1H)、7.68(1H)、7.59(1H)、7.30(2H)、7.16(1H)、4.91(1H)、4.15(1H)、4.37(1H)、3.67(1H)、3.36(1H)、3.29(2H)。 1 H NMR (methanol-d 4 ): 8.75 (1H), 8.10 (1H), 7.68 (1H), 7.59 (1H), 7.30 (2H), 7.16 (1H), 4.91 (1H), 4.15 (1H), 4.37 (1H), 3.67 (1H), 3.36 (1H), 3.29 (2H).

實例9 Example 9

(RS)-1-(4-氟苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(4-fluorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

以類似實例8之方式在步驟(a)中使用異氰酸4-氟苯酯(CAS：1195-45-5)代替異氰酸3-氯苯酯獲得標題化合物。淺黃色油。MS(ESI)：317.1([M+H]+)。 The title compound was obtained by substituting 4-fluorophenyl isocyanate (CAS: 1195-45-5) for 3-chlorophenyl isocyanate in the step (a). Light yellow oil. MS (ESI): 317.1 ([M+H] + ).

實例10 Example 10

(RS)-1-(6-嗎啉-2-基-3-吡啶基)-3-[4-(三氟甲基)苯基]脲 (RS)-1-(6-morpholin-2-yl-3-pyridyl)-3-[4-(trifluoromethyl)phenyl]urea

以類似實例8之方式在步驟(a)中使用異氰酸4-(三氟甲基)苯酯(CAS：1548-13-6)代替異氰酸3-氯苯酯獲得標題化合物。淺黃色固體。MS(ESI)：367.1([M+H]+)。 The title compound was obtained in the same manner as in Example 8 by using 4-(trifluoromethyl)phenyl isocyanate (CAS: 1548-13-6) in the step (a) instead of 3-chlorophenyl isocyanate. Light yellow solid. MS (ESI): 367.1 ([M+H] + ).

實例11 Example 11

(RS)-1-(4-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(4-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea

以類似實例8之方式在步驟(a)中使用異氰酸4-氯苯酯(CAS：104-12-1)代替異氰酸3-氯苯酯獲得標題化合物。灰白色固體。MS(ESI)：335.1([{37Cl}M+H]+)、333.1([{35Cl}M+H]+)。 The title compound was obtained in the same manner as in Example 8 by using 4-chlorophenyl isocyanate (CAS: 104-12-1) in the step (a) instead of 3-chlorophenyl isocyanate. Off-white solid. MS (ESI): 335.1 ([ {37 Cl} M + H] +), 333.1 ([{35 Cl} M + H] +).

實例12 Example 12

(RS)-3-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-3-chloro-N-(6-morpholin-2-yl-3-pyridyl)benzamide

以類似實例7之方式在步驟(c)中使用3-氯苯甲酸(CAS：535-80-8)代替4-氯苯甲酸獲得標題化合物。淺黃色固體。MS(ESI)：320.1([{37Cl}M+H]+)、318.1([{35Cl}M+H]+)。 The title compound was obtained in a similar manner to Example 7 using 3-chlorobenzoic acid (CAS: 535-80-8) instead of 4-chlorobenzoic acid in step (c). Light yellow solid. MS (ESI): 320.1 ([ {37 Cl} M + H] +), 318.1 ([{35 Cl} M + H] +).

實例13 Example 13

(RS)-4-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-4-ethoxy-N-(6-morpholin-2-yl-3-pyridyl)benzamide

以類似實例7之方式在步驟(c)中使用4-乙氧基苯甲酸(CAS：619-86-3)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：328.2([M+H]+)。 The title compound was obtained in a similar manner to Example 7 using 4-ethoxybenzoic acid (CAS: 619-86-3) instead of 4-chlorobenzoic acid. White solid. MS (ESI): 328.2 ([M+H] + ).

實例14 Example 14

(RS)-4-氟-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺 (RS)-4-fluoro-N-(6-morpholin-2-yl-3-pyridyl)benzamide

以類似實例7之方式在步驟(c)中使用4-氟苯甲酸(CAS：456-22-4)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：302.1([M+H]+)。 The title compound was obtained in a similar manner to Example 7 using 4-fluorobenzoic acid (CAS: 456-22-4) instead of 4-chlorobenzoic acid in step (c). White solid. MS (ESI): 302.1 ([M+H] + ).

實例15 Example 15

(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(c)中使用4-氯-5-丙基-1H-吡唑-3-羧酸(CAS：1340578-20-2)代替4-氯苯甲酸獲得標題化合物。白色固體。 MS(ESI)：352.1([{37Cl}M+H]+)、350.1([{35Cl}M+H]+)。 The title compound was obtained in the same manner as in Example 7 using 4-chloro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 1340578-20-2) instead of 4-chlorobenzoic acid. White solid. MS (ESI): 352.1 ([ {37 Cl} M + H] +), 350.1 ([{35 Cl} M + H] +).

實例16 Example 16

(RS)-N-(6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

以類似實例7之方式在步驟(c)中使用2-(三氟甲基)吡啶-4-羧酸(CAS：131747-41-6)代替4-氯苯甲酸獲得標題化合物。淺黃色固體。MS(ESI)：353.0([M+H]+)。 The title compound was obtained in the same manner as in Example 7 using 2-(trifluoromethyl)pyridine-4-carboxylic acid (CAS: 131747-41-6). Light yellow solid. MS (ESI): 353.0 ([M+H] + ).

實例17 Example 17

(RS)-N-(6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)嘧啶-4-胺 (RS)-N-(6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyrimidine-4-amine

以類似實例1之方式在步驟(g)中使用2-(三氟甲基)嘧啶-4-胺(CAS：672-42-4)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：326.2([M+H]+)。 The title compound was obtained in a similar manner to Example 1 using 2-(trifluoromethyl)pyrimidin-4-amine (CAS: 672-42-4) instead of 4-chloroaniline in step (g). White solid. MS (ESI): 326.2 ([M+H] + ).

實例18 Example 18

N-(4-氯苯基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺 N-(4-chlorophenyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

a)(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯及(2S)-2-(5-溴-2-a) (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and (2S)-2-(5-bromo-2- 吡啶基)嗎啉-4-羧酸第三丁酯Pyridyl)morpholine-4-carboxylic acid tert-butyl ester

藉由SFC使用下列條件分離(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯：Chiralpak AD-3管柱(100×4.6mmI.D.：3um)；乙醇(0.05%DEA)於CO2中，從5%至40%作為流動相；3mL/min流速；波長：220nm。作為第一餾分獲得(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯(1.6g，滯留時間：1.421min)。作為第二餾分獲得(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯(1.6g，滯留時間：1.571min)。 Separation of (RS)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester by SFC using the following conditions: Chiralpak AD-3 column (100 x 4.6 mm I.D.: 3 um); ethanol (0.05% DEA) in CO 2 , from 5% to 40% as mobile phase; 3 mL/min flow rate; wavelength: 220 nm. As a first fraction, (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (1.6 g, residence time: 1.421 min) was obtained. As a second fraction, (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (1.6 g, residence time: 1.571 min) was obtained.

b)N-(4-氯苯基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺b) N-(4-chlorophenyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

以類似實例1之方式在步驟(g)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯與4-氯苯胺(CAS：106-47-8)反應獲得N-(4-氯苯基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺。蠟狀固體。MS(ESI)：292.1([{37Cl}M+H]+)、290.2([{35Cl}M+H]+)。 In the same manner as in Example 1, in the step (g), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Reaction of bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester with 4-chloroaniline (CAS: 106-47-8) to obtain N-(4-chlorophenyl)-6-[(2S) -morpholin-2-yl]pyridin-3-amine. Waxy solid. MS (ESI): 292.1 ([ {37 Cl} M + H] +), 290.2 ([{35 Cl} M + H] +).

實例19 Example 19

6-[(2S)-嗎啉-2-基]-N-[4-(三氟甲基)苯基]吡啶-3-胺 6-[(2S)-morpholin-2-yl]-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine

以類似實例18之方式在步驟(b)中使用4-(三氟甲基)苯胺(CAS：455-14-1)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：324.0([M+H]+)。 The title compound was obtained in a similar manner to Example 18 using 4-(trifluoromethyl)aniline (CAS: 455-14-1) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 324.0 ([M+H] + ).

實例20 Example 20

N-(5-氯-2-吡啶基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺 N-(5-chloro-2-pyridyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

以類似實例18之方式在步驟(b)中使用2-胺基-5-氯吡啶(CAS：1072-98-6)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：293.0([{37Cl}M+H]+)、291.0([{35Cl}M+H]+)。 The title compound was obtained in a similar manner to Example 18 using 2-amino-5-chloropyridine (CAS: 1072-98-6) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 293.0 ([ {37 Cl} M + H] +), 291.0 ([{35 Cl} M + H] +).

實例21 Example 21

N-(5-溴-2-吡啶基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺 N-(5-bromo-2-pyridyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine

以類似實例18之方式在步驟(b)中使用2-胺基-5-溴吡啶(CAS：1072-97-5)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：337.0([{81Br}M+H]+)、335.0([{79Br}M+H]+)。 The title compound was obtained in a similar manner to Example 18 using 2-amino-5-bromopyridine (CAS: 1072-97-5) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 337.0 ([{ 81 Br}M+H] + ), 335.0 ([{ 79 Br}M+H] + ).

實例22 Example 22

6-[(2S)-嗎啉-2-基]-N-[6-(三氟甲基)-3-吡啶基]吡啶-3-胺 6-[(2S)-morpholin-2-yl]-N-[6-(trifluoromethyl)-3-pyridyl]pyridin-3-amine

以類似實例18之方式在步驟(b)中使用5-胺基-2-(三氟甲基)吡啶(CAS：106877-33-2)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.1([M+H]+)。 The title compound was obtained in the same manner as in Example 18, using 5-amino-2-(trifluoromethyl)pyridine (CAS: 106877-33-2) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 325.1 ([M+H] + ).

實例23 Example 23

6-[(2S)-嗎啉-2-基]-N-[4-(三氟甲基)-2-吡啶基]吡啶-3-胺 6-[(2S)-morpholin-2-yl]-N-[4-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

以類似實例18之方式在步驟(b)中使用2-胺基-4-(三氟甲基)吡啶(CAS：106447-97-6)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.1([M+H]+)。 The title compound was obtained in a similar manner to Example 18 using 2-amino-4-(trifluoromethyl)pyridine (CAS: 106447-97-6) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 325.1 ([M+H] + ).

實例24 Example 24

N-(4-氯苯基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺 N-(4-chlorophenyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine

以類似實例1之方式在步驟(g)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯與4-氯苯胺(CAS：106-47-8)反應獲得標題化合物。蠟狀固體。MS(ESI)：292.1([{37Cl}M+H]+)、290.1([{35Cl}M+H]+)。 In the same manner as in Example 1, in the step (g), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Reaction of bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester with 4-chloroaniline (CAS: 106-47-8) gave the title compound. Waxy solid. MS (ESI): 292.1 ([ {37 Cl} M + H] +), 290.1 ([{35 Cl} M + H] +).

實例25 Example 25

6-[(2R)-嗎啉-2-基]-N-[4-(三氟甲基)苯基]吡啶-3-胺 6-[(2R)-morpholin-2-yl]-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine

以類似實例24之方式使用4-(三氟甲基)苯胺(CAS：455-14-1)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：324.0([M+H]+)。 The title compound was obtained in a similar manner to Example 24 using 4-(trifluoromethyl)aniline (CAS: 455-14-1) instead of 4-chloroaniline. White solid. MS (ESI): 324.0 ([M+H] + ).

實例26 Example 26

N-(5-氯-2-吡啶基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺 N-(5-chloro-2-pyridyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine

以類似實例24之方式使用2-胺基-5-氯吡啶(CAS：1072-98-6)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：293.1([{37Cl}M+H]+)、291.1([{35Cl}M+H]+)。 The title compound was obtained in a similar manner to Example 24 using 2-amino-5-chloropyridine (CAS: 1072-98-6) instead of 4-chloroaniline. White solid. MS (ESI): 293.1 ([ {37 Cl} M + H] +), 291.1 ([{35 Cl} M + H] +).

實例27 Example 27

6-[(2R)-嗎啉-2-基]-N-[6-(三氟甲基)-3-吡啶基]吡啶-3-胺 6-[(2R)-morpholin-2-yl]-N-[6-(trifluoromethyl)-3-pyridyl]pyridin-3-amine

以類似實例24之方式使用5-胺基-2-(三氟甲基)吡啶(CAS：106877-33-2)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.0([M+H]+)。 The title compound was obtained in a similar manner to Example 24 using 5-amino-2-(trifluoromethyl)pyridine (CAS: 106877-33-2) instead of 4-chloroaniline. White solid. MS (ESI): 325.0 ([M+H] + ).

實例28 Example 28

6-[(2R)-嗎啉-2-基]-N-[4-(三氟甲基)-2-吡啶基]吡啶-3-胺 6-[(2R)-morpholin-2-yl]-N-[4-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

以類似實例24之方式使用2-胺基-4-(三氟甲基)吡啶(CAS：106447-97-6)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.0([M+H]+)。 The title compound was obtained in a similar manner to Example 24 using 2-amino-4-(trifluoromethyl)pyridine (CAS: 106447-97-6) instead of 4-chloroaniline. White solid. MS (ESI): 325.0 ([M+H] + ).

實例29 Example 29

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(三氟甲基)吡啶-2-胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(trifluoromethyl)pyridin-2-amine

以類似實例18之方式在步驟(b)中使用2-胺基-5-(三氟甲基)吡啶(CAS：74784-70-6)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.1([M+H]+)。 The title compound was obtained in a similar manner to Example 18 using 2-amino-5-(trifluoromethyl)pyridine (CAS: 74784-70-6) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 325.1 ([M+H] + ).

實例30 Example 30

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-6-(三氟甲基)吡啶-2-胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-6-(trifluoromethyl)pyridin-2-amine

以類似實例18之方式在步驟(b)中使用2-胺基-6-(三氟甲基)吡啶(CAS：34486-24-3)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.0([M+H]+)。 The title compound was obtained in a similar manner to Example 18 using 2-amino-6-(trifluoromethyl)pyridine (CAS: 34486-24-3) instead of 4-chloroaniline in step (b). White solid. MS (ESI): 325.0 ([M+H] + ).

實例31 Example 31

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]benzamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯獲得標題化合物。白色固體。MS(ESI)：319.9([{37Cl}M+H]+)、317.9 ([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- The butyl bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester gave the title compound. White solid. MS (ESI): 319.9 ([ {37 Cl} M + H] +), 317.9 ([{35 Cl} M + H] +).

實例32 Example 32

3-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 3-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]benzamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-氯苯甲酸(CAS：535-80-8)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：319.9([{37Cl}M+H]+)、317.9([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and the title compound was obtained in the step (c) using 3-chlorobenzoic acid (CAS: 535-80-8) instead of 4-chlorobenzoic acid. White solid. MS (ESI): 319.9 ([ {37 Cl} M + H] +), 317.9 ([{35 Cl} M + H] +).

實例33 Example 33

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-4-(三氟甲基)苯甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-4-(trifluoromethyl)benzamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-(三氟甲基)苯甲酸(CAS：455-24-3)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.0([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 4-(trifluoromethyl)benzoic acid (CAS: 455-24-3) instead of 4-chlorobenzene in step (c) The title compound was obtained from formic acid. White solid. MS (ESI): 352.0 ([M+H] + ).

實例34 Example 34

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(三氟甲基)吡啶-4-甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(trifluoromethyl)pyridine-4-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用2-(三氟甲基)吡啶-4-羧酸(CAS：131747-41-6)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.9([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) using 2-(trifluoromethyl)pyridine-4-carboxylic acid (CAS: 131747-41-6) 4-Chlorobenzoic acid gave the title compound. White solid. MS (ESI): 352.9 ([M+H] + ).

實例35 Example 35

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)苯甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)benzamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-(三氟甲基)苯甲酸(CAS：454-92-2)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.0([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 3-(trifluoromethyl)benzoic acid (CAS: 454-92-2) instead of 4-chlorobenzene in step (c) The title compound was obtained from formic acid. White solid. MS (ESI): 352.0 ([M+H] + ).

實例36 Example 36

N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-6-(2,2,2-三氟乙氧基)吡啶-3-甲醯胺 N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用6-(2,2,2-三氟乙氧基)菸鹼酸(CAS：175204-90-7)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：382.9([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 6-(2,2,2-trifluoroethoxy)nicotinic acid in step (c) (CAS: 175204-90 -7) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 382.9 ([M+H] + ).

實例37 Example 37

2-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]嘧啶-5-甲醯胺 2-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]pyrimidine-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用2-乙基嘧啶-5-羧酸(CAS：72790-16-0)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：314.0([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 2-ethylpyrimidine-5-carboxylic acid (CAS:72790-16-0) instead of 4-chlorobenzene The title compound was obtained from formic acid. White solid. MS (ESI): 314.0 ([M+H] + ).

實例38 Example 38

3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-異丙基吡唑-5-羧酸(CAS：92933-47-6)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：316.0([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 3-isopropylpyrazole-5-carboxylic acid (CAS: 92933-47-6) in place of 4- in step (c) Chlorobenzoic acid gave the title compound. White solid. MS (ESI): 316.0 ([M+H] + ).

實例39 Example 39

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-5-丙基-1H-吡唑-3-羧酸(CAS：1340578-20-2)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.1([{37Cl}M+H]+)、350.1([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 1340578-20) -2) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 352.1 ([ {37 Cl} M + H] +), 350.1 ([{35 Cl} M + H] +).

實例40 Example 40

4-氯-3-環丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-Chloro-3-cyclopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-3-環丙基-1H-吡唑-5-羧酸(CAS：1291275-83-6)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：349.9([{37Cl}M+H]+)、347.9([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-3-cyclopropyl-1H-pyrazole-5-carboxylic acid (CAS: 1129275- 83-6) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 349.9 ([ {37 Cl} M + H] +), 347.9 ([{35 Cl} M + H] +).

實例41 Example 41

1-(3-氯苯基)-3-[6-[(2S)-嗎啉-2-基]-3-吡啶基]脲 1-(3-chlorophenyl)-3-[6-[(2S)-morpholin-2-yl]-3-pyridyl]urea

以類似實例8之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯獲得標題化合物。白色固體。MS(ESI)：335.0([{37Cl}M+H]+)、333.0([{35Cl}M+H]+)。 In the same manner as in Example 8, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- The butyl bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester gave the title compound. White solid. MS (ESI): 335.0 ([ {37 Cl} M + H] +), 333.0 ([{35 Cl} M + H] +).

實例42 Example 42

1-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-[3-(三氟甲基)苯基]脲 1-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-[3-(trifluoromethyl)phenyl]urea

以類似實例8之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(a)中使用異氰酸3-(三氟甲基)苯酯(CAS：329-01-1)代替異氰酸3-氯苯酯獲得標題化合物。白色固體。MS(ESI)：367.0([M+H]+)。 In the same manner as in Example 8, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (a) using 3-(trifluoromethyl)phenyl isocyanate (CAS: 329-01-1) instead of 3-Chlorophenyl cyanate gave the title compound. White solid. MS (ESI): 367.0 ([M+H] + ).

實例43 Example 43

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-5-(三氟甲基)-2H-吡唑-3-羧酸(CAS：934758-95-9)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：377.9([{37Cl}M+H]+)、375.9([{35Cl}M+H]+)。 Using (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tributyl instead of (RS)-2-(5-bromo) in step (a) in a similar manner to Example 7. 2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-5-(trifluoromethyl)-2H-pyrazole-3-carboxylic acid (CAS: 934758-95-9) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 377.9 ([ {37 Cl} M + H] +), 375.9 ([{35 Cl} M + H] +).

實例44 Example 44

4-氯-3-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-3-甲基-1H-吡唑-5-羧酸(CAS：29400-84-8)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：324.1([{37Cl}M+H]+)、322.2([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-3-methyl-1H-pyrazole-5-carboxylic acid (CAS: 29400-84) -8) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 324.1 ([ {37 Cl} M + H] +), 322.2 ([{35 Cl} M + H] +).

實例45 Example 45

4-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-甲基-1H-吡唑-3-羧酸(CAS：82231-51-4)代替4-氯苯 甲酸獲得標題化合物。白色固體。MS(ESI)：288.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and replaced in step (c) with 4-methyl-1H-pyrazole-3-carboxylic acid (CAS: 82231-51-4) 4-Chlorobenzoic acid gave the title compound. White solid. MS (ESI): 288.2 ([M+H] + ).

實例46 Example 46

4-氯-1-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-丙基-吡唑-3-甲醯胺 4-chloro-1-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-propyl-pyrazole-3-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-1-甲基-5-丙基-1H-吡唑-3-羧酸(CAS：1248078-41-2)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：366.0([{37Cl}M+H]+)、364.0([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-1-methyl-5-propyl-1H-pyrazole-3-carboxylic acid ( CAS: 1248078-41-2) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 366.0 ([ {37 Cl} M + H] +), 364.0 ([{35 Cl} M + H] +).

實例47 Example 47

N-(5-溴-2-吡啶基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺 N-(5-bromo-2-pyridyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine

以類似實例1之方式在步驟(g)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並使用2-胺基-5-溴吡啶(CAS：1072-97-5)代替4-氯苯胺(CAS：106-47-8)獲得標題化合物。蠟狀固體。MS(ESI)：337.0([{81Br}M+H]+)、335.1([{79Br}M+H]+)。 In the same manner as in Example 1, in the step (g), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 2-amino-5-bromopyridine (CAS: 1072-97-5) instead of 4-chloroaniline (CAS: 106-47- 8) Obtain the title compound. Waxy solid. MS (ESI): 337.0 ([{ 81 Br}M+H] + ), 335.1 ([{ 79 Br}M+H] + ).

實例48 Example 48

4-氯-1-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-丙基-吡唑-3-甲醯胺 4-chloro-1-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-propyl-pyrazole-3-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-1-甲基-5-丙基-1H-吡唑-3-羧酸(CAS：1248078-41-2)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：366.2([{37Cl}M+H]+)、364.2([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-1-methyl-5-propyl-1H-pyrazole-3-carboxylic acid ( CAS: 1248078-41-2) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 366.2 ([ {37 Cl} M + H] +), 364.2 ([{35 Cl} M + H] +).

實例49 Example 49

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-(三氟甲基)吡啶-2-胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-(trifluoromethyl)pyridin-2-amine

以類似實例1之方式在步驟(g)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並使用2-胺基-5-(三氟甲基)吡啶(CAS：74784-70-6)代替4-氯苯胺(CAS：106-47-8)獲得標題化合物。白色固體。MS(ESI)：325.2([M+H]+)。 In the same manner as in Example 1, in the step (g), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 2-amino-5-(trifluoromethyl)pyridine (CAS: 74784-70-6) instead of 4-chloroaniline (CAS :106-47-8) The title compound was obtained. White solid. MS (ESI): 325.2 ([M+H] + ).

實例50 Example 50

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-6-(三氟甲基)吡啶-2-胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-6-(trifluoromethyl)pyridin-2-amine

以類似實例1之方式在步驟(g)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並使用2-胺基-6-(三氟甲基)吡啶(CAS：34486-24-3)代替4-氯苯胺(CAS：106-47-8)獲得標題化合物。白色固體。MS(ESI)：325.2([M+H]+)。 In the same manner as in Example 1, in the step (g), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 2-amino-6-(trifluoromethyl)pyridine (CAS: 34486-24-3) instead of 4-chloroaniline (CAS :106-47-8) The title compound was obtained. White solid. MS (ESI): 325.2 ([M+H] + ).

實例51 Example 51

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]benzamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯獲得標題化合物。白色固體。MS(ESI)：320.1([{37Cl}M+H]+)、318.1([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- The butyl bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester gave the title compound. White solid. MS (ESI): 320.1 ([ {37 Cl} M + H] +), 318.1 ([{35 Cl} M + H] +).

實例52 Example 52

3-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]苯甲醯胺 3-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]benzamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉- 4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-氯苯甲酸(CAS：535-80-8)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：320.1([{37Cl}M+H]+)、318.1([{35Cl}M+H]+)。 In the same manner as in Example 7, (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- in step (a). Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and the title compound was obtained in the step (c) using 3-chlorobenzoic acid (CAS: 535-80-8) instead of 4-chlorobenzoic acid. White solid. MS (ESI): 320.1 ([ {37 Cl} M + H] +), 318.1 ([{35 Cl} M + H] +).

實例53 Example 53

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-4-(三氟甲基)苯甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-4-(trifluoromethyl)benzamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-(三氟甲基)苯甲酸(CAS：455-24-3)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 4-(trifluoromethyl)benzoic acid (CAS: 455-24-3) instead of 4-chlorobenzene in step (c) The title compound was obtained from formic acid. White solid. MS (ESI): 352.2 ([M+H] + ).

實例54 Example 54

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-2-(三氟甲基)吡啶-4-甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-2-(trifluoromethyl)pyridine-4-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用2-(三氟甲基)吡啶-4-羧酸(CAS：131747-41-6)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：353.1([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) using 2-(trifluoromethyl)pyridine-4-carboxylic acid (CAS: 131747-41-6) 4-Chlorobenzoic acid gave the title compound. White solid. MS (ESI): 353.1 ([M+H] + ).

實例55 Example 55

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)苯甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)benzamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-(三氟甲基)苯甲酸(CAS：454-92-2)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.1([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 3-(trifluoromethyl)benzoic acid (CAS: 454-92-2) instead of 4-chlorobenzene in step (c) The title compound was obtained from formic acid. White solid. MS (ESI): 352.1 ([M+H] + ).

實例56 Example 56

N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-6-(2,2,2-三氟乙氧基)吡啶-3-甲醯胺 N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用6-(2,2,2-三氟乙氧基)菸鹼酸(CAS：175204-90-7)代替4-氯苯甲酸獲得標題化合物。蠟狀固體。MS(ESI)：383.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 6-(2,2,2-trifluoroethoxy)nicotinic acid in step (c) (CAS: 175204-90 -7) The title compound was obtained in place of 4-chlorobenzoic acid. Waxy solid. MS (ESI): 383.2 ([M+H] + ).

實例57 Example 57

2-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]嘧啶-5-甲醯胺 2-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]pyrimidine-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用2-乙基嘧啶-5-羧酸(CAS：72790-16-0)代替4-氯苯甲酸獲得標題化合物。蠟狀固體。MS(ESI)：314.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 2-ethylpyrimidine-5-carboxylic acid (CAS:72790-16-0) instead of 4-chlorobenzene The title compound was obtained from formic acid. Waxy solid. MS (ESI): 314.2 ([M+H] + ).

實例58 Example 58

3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-異丙基吡唑-5-羧酸(CAS：92933-47-6)代替4-氯苯甲酸獲得標題化合物。蠟狀固體。MS(ESI)：316.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 3-isopropylpyrazole-5-carboxylic acid (CAS: 92933-47-6) in place of 4- in step (c) Chlorobenzoic acid gave the title compound. Waxy solid. MS (ESI): 316.2 ([M+H] + ).

實例59 Example 59

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-5-丙基-1H-吡唑-3-羧酸(CAS：1340578-20-2)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：352.2([{37Cl}M+H]+)、350.2([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 1340578-20) -2) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 352.2 ([ {37 Cl} M + H] +), 350.2 ([{35 Cl} M + H] +).

實例60 Example 60

4-氯-3-環丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-cyclopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-3-環丙基-1H-吡唑-5-羧酸(CAS：1291275-83-6)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：350.2([{37Cl}M+H]+)、348.2([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-3-cyclopropyl-1H-pyrazole-5-carboxylic acid (CAS: 1129275- 83-6) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 350.2 ([ {37 Cl} M + H] +), 348.2 ([{35 Cl} M + H] +).

實例61 Example 61

1-(3-氯苯基)-3-[6-[(2R)-嗎啉-2-基]-3-吡啶基]脲 1-(3-chlorophenyl)-3-[6-[(2R)-morpholin-2-yl]-3-pyridyl]urea

以類似實例8之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯獲得標題化合物。白色固體。MS(ESI)：335.1([{37Cl}M+H]+)、333.2([{35Cl}M+H]+)。 In the same manner as in Example 8, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- The butyl bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester gave the title compound. White solid. MS (ESI): 335.1 ([ {37 Cl} M + H] +), 333.2 ([{35 Cl} M + H] +).

實例62 Example 62

1-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-[3-(三氟甲基)苯基]脲 1-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-[3-(trifluoromethyl)phenyl]urea

以類似實例8之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並使用異氰酸3-(三氟甲基)苯酯(CAS：329-01-1)代替異氰酸3-氯苯酯獲得標題化合物。白色固體。MS(ESI)：367.1([M+H]+)。 In the same manner as in Example 8, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and using 3-(trifluoromethyl)phenyl isocyanate (CAS: 329-01-1) instead of 3-chlorobenzene isocyanate The ester obtained the title compound. White solid. MS (ESI): 367.1 ([M+H] + ).

實例63 Example 63

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-5-(三氟甲基)-2H-吡唑-3-羧酸(CAS：934758-95-9)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：378.1([{37Cl}M+H]+)、376.1([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-5-(trifluoromethyl)-2H-pyrazole-3-carboxylic acid (CAS :934758-95-9) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 378.1 ([ {37 Cl} M + H] +), 376.1 ([{35 Cl} M + H] +).

實例64 Example 64

4-氯-3-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-氯-3-甲基-1H-吡唑-5-羧酸(CAS：29400-84-8)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：324.1([{37Cl}M+H]+)、322.1([{35Cl}M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 4-chloro-3-methyl-1H-pyrazole-5-carboxylic acid (CAS: 29400-84) -8) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 324.1 ([ {37 Cl} M + H] +), 322.1 ([{35 Cl} M + H] +).

實例65 Example 65

4-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用4-甲基-1H-吡唑-3-羧酸(CAS：82231-51-4)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：288.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and replaced in step (c) with 4-methyl-1H-pyrazole-3-carboxylic acid (CAS: 82231-51-4) 4-Chlorobenzoic acid gave the title compound. White solid. MS (ESI): 288.2 ([M+H] + ).

實例66 Example 66

(R)-3-乙基-4-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-1H-吡唑-5-甲醯胺 (R)-3-Ethyl-4-methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-乙基-4-甲基-1H-吡唑-5-羧酸(CAS：957129-38-3)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：316.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid (CAS: 957129- 38-3) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 316.2 ([M+H] + ).

實例67 Example 67

(S)-3-乙基-4-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-1H-吡唑-5-甲醯胺 (S)-3-Ethyl-4-methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用3-乙基-4-甲基-1H-吡唑-5-羧酸(CAS：957129-38-3)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：316.2([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid (CAS: 957129- 38-3) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 316.2 ([M+H] + ).

實例68 Example 68

(R)-6-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-2-(三氟甲基)嘧啶-4-甲醯胺 (R)-6-Methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-2-(trifluoromethyl)pyrimidine-4-carboxamide

以類似實例7之方式在步驟(a)中使用(2R)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用6-甲基-2-(三氟甲基)嘧啶-4-羧酸(CAS：945717-59-9)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：368.1([M+H]+)。 In the same manner as in Example 7, in the step (a), (2R)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 6-methyl-2-(trifluoromethyl)pyrimidine-4-carboxylic acid (CAS: 945717- 59-9) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 368.1 ([M+H] + ).

實例69 Example 69

(S)-6-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-2-(三氟甲基)嘧啶-4-甲醯胺 (S)-6-Methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-2-(trifluoromethyl)pyrimidine-4-carboxamide

以類似實例7之方式在步驟(a)中使用(2S)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯代替(RS)-2-(5-溴-2-吡啶基)嗎啉-4-羧酸第三丁酯並在步驟(c)中使用6-甲基-2-(三氟甲基)嘧啶-4-羧酸(CAS：945717-59-9)代替4-氯苯甲酸獲得標題化合物。白色固體。MS(ESI)：368.1([M+H]+)。 In the same manner as in Example 7, in the step (a), (2S)-2-(5-bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was used instead of (RS)-2-(5- Bromo-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester and in step (c) 6-methyl-2-(trifluoromethyl)pyrimidine-4-carboxylic acid (CAS: 945717- 59-9) The title compound was obtained in place of 4-chlorobenzoic acid. White solid. MS (ESI): 368.1 ([M+H] + ).

實例70 Example 70

(RS)-N-(4-氯苯基)-2-嗎啉-2-基-嘧啶-5-胺 (RS)-N-(4-chlorophenyl)-2-morpholin-2-yl-pyrimidine-5-amine

a)5-溴嘧啶-2-羰基氯a) 5-bromopyrimidine-2-carbonyl chloride

在室溫下，向5-溴嘧啶-2-羧酸(10.0g，CAS：37131-87-6)在CH2Cl2(100mL)中之溶液中添加草醯氯(6.4g)。添加DMF(0.5mL)。該反應在室溫下持續5小時。過濾該混合物。於減壓下濃縮濾液並在高真空下進一步乾燥，以產生呈灰色固體之粗5-溴嘧啶-2-羰基氯(10.9g，產率：100%)，其無需純化即可用於下一步驟中。 To a solution of 5-bromopyrimidine-2-carboxylic acid (10.0 g, CAS: 37131-87-6) in CH 2 Cl 2 (100 mL) was added EtOAc (EtOAc). DMF (0.5 mL) was added. The reaction was continued at room temperature for 5 hours. The mixture was filtered. The filtrate was concentrated under reduced pressure and dried with EtOAc EtOAcjjjjjjjjj in.

b)2-溴-1-(5-溴嘧啶-2-基)乙酮b) 2-bromo-1-(5-bromopyrimidin-2-yl)ethanone

在0℃下於N2氣氛下，向來自於步驟(a)之5-溴嘧啶-2-羰基氯(10.9g，49.5mmol)在CH3CN(200mL)中之溶液中滴加在己烷中之 TMSCHN2(2M，74.3mL)。在室溫下將該溶液攪拌16小時。然後在0℃下添加HBr在AcOH(48%，20mL)中之溶液。在室溫下將該溶液攪拌3小時。添加EtOAc(500ml)及水(100ml)。用鹽水清洗有機層，經Na2SO4乾燥並於減壓下濃縮。藉由急驟層析法(矽膠，以體積計石油醚：EtOAc=30/1~10/1)純化粗產物，以產生呈黃色油之2-溴-1-(5-溴嘧啶-2-基)乙酮(13.8g，產率：100%)。 Under an atmosphere of N 2, a solution of 5-bromo-pyrimidine from step (a) of the 2-carbonyl chloride (10.9g, 49.5mmol) in hexane was added dropwise at 0 ℃ in the 3 CN (200mL) solution in CH Medium in TMSCHN 2 (2M, 74.3 mL). The solution was stirred at room temperature for 16 hours. A solution of HBr in AcOH (48%, 20 mL) was then added at 0 °C. The solution was stirred at room temperature for 3 hours. Add EtOAc (500 ml) and water (100 ml). The organic layer was washed with brine, dried over Na 2 CH 4 The crude product was purified by flash chromatography (EtOAc:EtOAc:EtOAc:EtOAc Ethyl ketone (13.8 g, yield: 100%).

MS(ESI)：282.8({81Br+81Br}M+H)+、280.8({79Br+81Br}M+H)+、278.8({79Br+79Br}M+H)+。 MS (ESI): 282.8 ({ 81 Br + 81 Br} M + H) +, 280.8 ({79 Br + 81 Br} M + H) +, 278.8 ({79 Br + 79 Br} M + H) +.

c)2-[苄基(2-羥乙基)胺基]-1-(5-溴嘧啶-2-基)乙酮c) 2-[Benzyl(2-hydroxyethyl)amino]-1-(5-bromopyrimidin-2-yl)ethanone

向來自於步驟(b)之2-溴-1-(5-溴嘧啶-2-基)乙酮(13.8g，49.5mmol)在CH3CN(200mL)中之溶液中添加N-苄基乙醇胺(7.5g，CAS：104-63-2)及K2CO3(13.7g)。在室溫下將該混合物攪拌整夜。將該反應溶液倒入水中並用CH2Cl2(3 x 200mL)萃取。經Na2SO4乾燥合併之有機層並於減壓下濃縮。藉由急驟層析法(矽膠，以體積計CH2Cl2：MeOH=200/1~50/1)純化粗產物，以產生呈黃色油之2-[苄基(2-羥乙基)胺基]-1-(5-溴嘧啶-2-基)乙酮(3.3g，18.7%總計以三個步驟產自步驟(a))。 L- (5-bromo-2-yl) ethanone (13.8g, 49.5mmol) was added N- benzylethanolamine in the 3 CN (200mL) in a solution of 2-bromo-CH from step (b) of (7.5 g, CAS: 104-63-2) and K 2 CO 3 (13.7 g). The mixture was stirred overnight at room temperature. The reaction solution was poured into water and extracted with CH 2 Cl 2 (3×200 mL). Over Na 2 SO 4 the combined organic layers were dried and concentrated under reduced pressure. By flash chromatography (silica gel, by volume of CH 2 Cl 2: MeOH = 200 /1 ~ 50/1) The crude product was purified to yield a yellow oil of 2- [benzyl (2-hydroxyethyl) amine 1-[5-Bromopyrimidin-2-yl)ethanone (3.3 g, 18.7% in total from step (a) in three steps).

MS(ESI)：349.9({79Br}M+H)+、351.9({81Br}M+H)+。 MS (ESI): 349.9 ({ 79 Br} M + H) +, 351.9 ({81 Br} M + H) +.

d)(RS)-2-[苄基(2-羥乙基)胺基]-1-(5-溴嘧啶-2-基)乙醇d) (RS)-2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromopyrimidin-2-yl)ethanol

在0℃下，向2-[苄基(2-羥乙基)胺基]-1-(5-溴嘧啶-2-基)乙酮(3.3g)在MeOH(70mL)中之溶液中添加NaBH4(394mg)。在室溫下將該溶液攪拌一小時直至TLC分析顯示初始材料之消耗。將反應溶液倒入水中並用CH2Cl2(2 x 200ml)萃取。經Na2SO4乾燥合併之有機層並於減壓下濃縮，以產生粗(RS)-2-[苄基(2-羥乙基)胺基]-1-(5-溴嘧啶-2-基)乙醇(3.5g，產率：100%)，其無需純化即可用於下一步驟中。 Add to a solution of 2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromopyrimidin-2-yl)ethanone (3.3 g) in MeOH (70 mL) NaBH 4 (394 mg). The solution was stirred at room temperature for one hour until TLC analysis showed consumption of the starting material. The reaction solution was poured into water and extracted with CH 2 Cl 2 (2×200 ml). The organic layer was dried over SO 4 Na 2 merger and concentrated under reduced pressure to give crude (the RS) -2- [benzyl (2-hydroxyethyl) amino] -1- (5-bromo-2- Ethyl alcohol (3.5 g, yield: 100%) which was used in the next step without purification.

e)(RS)-4-苄基-2-(5-溴嘧啶-2-基)嗎啉e) (RS)-4-benzyl-2-(5-bromopyrimidin-2-yl)morpholine

在0℃下，向(RS)-2-[苄基(2-羥乙基)胺基]-1-(5-溴嘧啶-2-基)乙醇(3.5g，9.93mmol，直接來自於步驟d)在THF(80mL)中之溶液中添加Et3N(1.5g)及甲磺醯氯(1.14g)。在室溫下將該混合物攪拌2小時及然後過濾。在0℃下向濾液中添加第三戊醇鉀(1.5g)在THF(20mL)中之溶液。在室溫下將該混合物攪拌一小時。將該反應溶液倒入EtOAc(500mL)中，用鹽水(50mL)清洗並於減壓下濃縮。藉由急驟層析法(矽膠，以體積計CH2Cl2/MeOH=200/1~50/1)純化粗產物，以產生(RS)-4-苄基-2-(5-溴嘧啶-2-基)嗎啉(0.5g，16%以兩個步驟產自步驟d)。 To (RS)-2-[benzyl(2-hydroxyethyl)amino]-1-(5-bromopyrimidin-2-yl)ethanol (3.5 g, 9.93 mmol, directly from step at 0 ° C d) Et 3 N (1.5 g) and methanesulfonyl chloride (1.14 g) were added to a solution in THF (80 mL). The mixture was stirred at room temperature for 2 hours and then filtered. A solution of potassium third pentoxide (1.5 g) in THF (20 mL) was added to the filtrate at 0 °C. The mixture was stirred at room temperature for one hour. The reaction solution was poured into EtOAc (EtOAc) By flash chromatography (silica gel, to 2 Cl 2 / MeOH = 200/ 1 ~ 50/1 by volume CH) The crude product was purified to yield (RS) -4- benzyl-2- (5-bromo-pyrimidin - 2-yl)morpholine (0.5 g, 16% from step d) in two steps.

MS(ESI)：333.9({79Br}M+H)+,335.9({81Br}M+H)+。 MS (ESI): 333.9 ({ 79 Br} M + H) +, 335.9 ({81 Br} M + H) +.

f)(RS)-2-(5-溴嘧啶-2-基)嗎啉f) (RS)-2-(5-bromopyrimidin-2-yl)morpholine

向(RS)-4-苄基-2-(5-溴嘧啶-2-基)嗎啉(0.5g)在CH2Cl2(10mL)中之溶液中添加氯甲酸2-氯乙酯(643mg，CAS：627-11-2)。然後在回流溫度下將該溶液攪拌4小時直至TLC顯示初始材料之消耗。於減壓下移除揮發物。將殘餘物溶解於甲醇(10mL)中並在回流溫度下攪拌一小時。於減壓下濃縮反應溶液。於高真空下之進一步乾燥產生粗(RS)-2-(5-溴嘧啶-2-基)嗎啉(365mg，產率：100%)，其無需純化即可用於下一步驟中。 Add 2-chloroethyl chloroformate (643 mg) to a solution of (RS)-4-benzyl-2-(5-bromopyrimidin-2-yl)morpholine (0.5 g) in CH 2 Cl 2 (10 mL) , CAS: 627-11-2). The solution was then stirred at reflux temperature for 4 hours until TLC showed consumption of the starting material. The volatiles were removed under reduced pressure. The residue was dissolved in methanol (10 mL) and stirred at reflux temperature for one hour. The reaction solution was concentrated under reduced pressure. Further drying under high vacuum gave crude (RS)-2-(5-bromopyrimidin-2-yl)morpholine (365 mg, yield: 100%) which was used in the next step without purification.

g)(RS)-2-(5-溴嘧啶-2-基)嗎啉-4-羧酸第三丁酯g) (RS)-2-(5-bromopyrimidin-2-yl)morpholine-4-carboxylic acid tert-butyl ester

在室溫下，向來自於步驟(f)之(RS)-2-(5-溴嘧啶-2-基)嗎啉(365mg，1.5mmol)及K2CO3(414mg)在THF(10mL)及水(5mL)之混合物中之溶液中添加二碳酸二第三丁酯(486mg，CAS：24424-99-5)。該反應持續整夜。用CH2Cl2(2 x 50mL)萃取混合物。用鹽水(20mL)清洗合併之有機層，經Na2SO4乾燥並於減壓下濃縮。藉由急驟層析法(矽膠，以體積計CH2Cl2/MeOH=200/1~50/1)之純化產生呈黃色油之(RS)-2-(5-溴嘧啶-2-基)嗎啉-4-羧酸第三丁酯(300mg，產率：58%)。 To (RS)-2-(5-bromopyrimidin-2-yl)morpholine (365 mg, 1.5 mmol) and K 2 CO 3 (414 mg) from step (f) in THF (10 mL) Di-tert-butyl dicarbonate (486 mg, CAS: 24424-99-5) was added to the solution in a mixture with water (5 mL). The reaction continued overnight. The mixture was extracted with CH 2 Cl 2 (2 x 50mL ). Combined organic layers were washed with brine (20mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Purification by flash chromatography (chromic acid, CH 2 Cl 2 /MeOH = 200/1~50/1) affords (RS)-2-(5-bromopyrimidin-2-yl) as a yellow oil. Morpholine-4-carboxylic acid tert-butyl ester (300 mg, yield: 58%).

MS(ESI)：366.0({79Br}M+Na)+、368.0({81Br}M+Na)+、287.8({79Br}M-C4H8+H)+、289.8({81Br}M-C4H8+H)+。 MS (ESI): 366.0 ({ 79 Br}M+Na) + , 368.0 ({ 81 Br}M+Na) + , 287.8 ({ 79 Br}MC 4 H 8 +H) + , 289.8 ({ 81 Br} MC 4 H 8 +H) + .

h)(RS)-N-(4-氯苯基)-2-嗎啉-2-基-嘧啶-5-胺h)(RS)-N-(4-chlorophenyl)-2-morpholin-2-yl-pyrimidine-5-amine

向(RS)-2-(5-溴嘧啶-2-基)嗎啉-4-羧酸第三丁酯(30mg)及4-氯苯胺(11mg，CAS：106-47-8)在二噁烷(1mL)中之溶液中添加4,5-雙(二苯基膦基)-9,9-二甲基呫噸(Xantphos，15mg，CAS：161265-03-8)、Cs2CO3(85mg，CAS：534-17-8)及叁(二亞苄基丙酮)二鈀(0)(8mg，CAS：51364-51-3)。該反應在90℃下於N2氣氛下進行整夜。用CH2Cl2(10mL)稀釋該溶液，用鹽水(20mL)清洗，經Na2SO4乾燥並於減壓下濃縮。將殘餘物溶解於CH2Cl2(1mL)及TFA(1mL)之混合物中。在室溫下將該溶液攪拌3小時。於減壓下移除揮發物。藉由製備型HPLC(流動相A：H2O，B：含有0.1%TFA之CH3CN，C18管柱)純化殘餘物，以產生呈白色固體之(RS)-N-(4-氯苯基)-2-嗎啉-2-基-嘧啶-5-胺(10mg，以兩個步驟產出40%)。 To (RS)-2-(5-bromopyrimidin-2-yl)morpholine-4-carboxylic acid tert-butyl ester (30 mg) and 4-chloroaniline (11 mg, CAS: 106-47-8) in dioxins 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 15 mg, CAS: 161265-03-8), Cs 2 CO 3 (Cs 2 CO 3 ) was added to the solution in the alkane (1 mL). 85 mg, CAS: 534-17-8) and hydrazine (dibenzylideneacetone) dipalladium (0) (8 mg, CAS: 51364-51-3). The reaction was carried out overnight at 90 ° C under a N 2 atmosphere. The solution was diluted with CH 2 Cl 2 (10mL), washed with brine (20mL), dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was dissolved in a mixture CH 2 Cl 2 (1mL) and TFA (1mL) in the. The solution was stirred at room temperature for 3 hours. The volatiles were removed under reduced pressure. By preparative HPLC (mobile phase A: H 2 O, B: 0.1% TFA containing of CH 3 CN, C18 column) to give the residue, to yield a white solid of (RS) -N- (4- chlorophenyl Bis-2-morpholin-2-yl-pyrimidine-5-amine (10 mg, 40% in two steps).

1H NMR(400MHz，甲醇-d4)：δ 8.54(2H)、7.33(2H)、7.17(2H)、4.9(1H)、4.1(1H)、3.97(1H)、3.63(1H)、3.51(1H)、3.35~3.23(2H)。 1 H NMR (400MHz, methanol -d 4): δ 8.54 (2H ), 7.33 (2H), 7.17 (2H), 4.9 (1H), 4.1 (1H), 3.97 (1H), 3.63 (1H), 3.51 ( 1H), 3.35~3.23 (2H).

MS(ESI)：290.9({35Cl}M+H)+、292.9({37Cl}M+H)+。 MS (ESI): 290.9 ({ 35 Cl} M + H) +, 292.9 ({37 Cl} M + H) +.

實例71 Example 71

(RS)-2-嗎啉-2-基-N-[4-(三氟甲基)苯基]嘧啶-5-胺 (RS)-2-morpholin-2-yl-N-[4-(trifluoromethyl)phenyl]pyrimidin-5-amine

以類似實例70之方式在步驟(h)中使用4-(三氟甲基)苯胺(CAS：455-14-1)代替4-氯苯胺獲得標題化合物。白色固體。MS(ESI)：325.0 ([M+H]+)。 The title compound was obtained in a similar manner to Example 70 using 4-(trifluoromethyl)aniline (CAS: 455-14-1) instead of 4-chloroaniline in step (h). White solid. MS (ESI): 325.0 ([M+H] + ).

實例72 Example 72

(RS)-4-氯-N-(2-嗎啉-2-基嘧啶-5-基)苯甲醯胺 (RS)-4-chloro-N-(2-morpholin-2-ylpyrimidin-5-yl)benzamide

a)(RS)-2-[5-(二苯亞甲基胺基)嘧啶-2-基]嗎啉-4-羧酸第三丁酯a) (RS)-2-[5-(diphenylmethyleneamino)pyrimidin-2-yl]morpholine-4-carboxylic acid tert-butyl ester

向(RS)-2-(5-溴嘧啶-2-基)嗎啉-4-羧酸第三丁酯(230mg)及二苯甲酮亞胺(127mg，CAS：1013-88-3)在二噁烷(10mL)中之溶液中添加4,5-雙(二苯基膦基)-9,9-二甲基呫噸(Xantphos，116mg，CAS：161265-03-8)、叁(二亞苄基丙酮)二鈀(0)(61.3mg，CAS：51364-51-3)及Cs2CO3(653mg，CAS：534-17-8)。該反應在90℃下於N2氣氛下進行整夜。將該溶液倒入水(100mL)中並用CH2Cl2(2 x 150mL)萃取。經Na2SO4乾燥合併之有機層並於減壓下濃縮，以產生粗(RS)-2-[5-(二苯亞甲基胺基)嘧啶-2-基]嗎啉-4-羧酸第三丁酯(297mg，產率：100%)，其無需純化即可用於下一步驟中。 To (RS)-2-(5-bromopyrimidin-2-yl)morpholine-4-carboxylic acid tert-butyl ester (230 mg) and benzophenone imine (127 mg, CAS: 1013-88-3) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 116 mg, CAS: 161265-03-8), bismuth (two) was added to the solution in dioxane (10 mL). Benzylideneacetone) dipalladium (0) (61.3 mg, CAS: 51364-51-3) and Cs 2 CO 3 (653 mg, CAS: 534-17-8). The reaction was carried out overnight at 90 ° C under a N 2 atmosphere. The solution was poured into water (100 mL) and extracted with CH 2 Cl 2 (2 x 150mL ). Over 2 SO 4 organic layers were dried Na and the concentrated under reduced pressure to give the crude (RS) -2- [5- (diphenylmethylene amino) pyrimidin-2-yl] morpholin-4-carboxamide Tributyl acrylate (297 mg, yield: 100%) was used in the next step without purification.

b)(RS)-2-(5-胺基嘧啶-2-基)嗎啉-4-羧酸第三丁酯b) (RS)-2-(5-Aminopyrimidin-2-yl)morpholine-4-carboxylic acid tert-butyl ester

向(RS)-2-[5-(二苯亞甲基胺基)嘧啶-2-基]嗎啉-4-羧酸第三丁酯(297mg，0.668mmol)在MeOH(10mL)中之溶液中添加乙酸鈉(274mg，CAS：127-09-3)及羥胺鹽酸鹽(69.6mg，CAS：5470-11-1)。在室溫下將該混合物攪拌2小時直至TLC分析顯示初始材料消耗完全。將該溶液倒入水(50mL)中，用CH2Cl2(2 x 100mL)萃取。合併之有機層經Na2SO4乾燥，於減壓下濃縮並藉由急驟層析法(矽膠，以體積計CH2Cl2/MeOH=100/1~50/1)純化，以產生呈黃色固體之(RS)-2-(5-胺 基嘧啶-2-基)嗎啉-4-羧酸第三丁酯(100mg，產率：55.6%)。 a solution of (RS)-2-[5-(diphenylmethyleneamino)pyrimidin-2-yl]morpholine-4-carboxylic acid tert-butyl ester (297 mg, 0.668 mmol) in MeOH (10 mL) Sodium acetate (274 mg, CAS: 127-09-3) and hydroxylamine hydrochloride (69.6 mg, CAS: 5470-11-1) were added. The mixture was stirred for 2 hours at room temperature until TLC analysis showed complete material consumption. The solution was poured into water (50mL), extracted with CH 2 Cl 2 (2 x 100mL ). The combined organic layer was dried over Na 2 SO 4, concentrated under reduced pressure and purified by flash chromatography (silica gel, by volume of CH 2 Cl 2 / MeOH 100/ 1 ~ 50/1 =) was purified to yield a yellow Solid (RS)-2-(5-aminopyrimidin-2-yl)morpholine-4-carboxylic acid tert-butyl ester (100 mg, yield: 55.6%).

MS(ESI)：281.2(M+H)+。 MS (ESI): 281.2 (M+H) + .

c)(RS)-4-氯-N-(2-嗎啉-2-基嘧啶-5-基)苯甲醯胺c) (RS)-4-chloro-N-(2-morpholin-2-ylpyrimidin-5-yl)benzamide

向4-氯苯甲酸(16.7mg，CAS：74-11-3)在DMF(1mL)中之溶液中添加HATU(40.3mg，CAS：CAS：148893-10-1)及DIPEA(37.2mg，CAS：7087-68-5)。在室溫下將該混合物攪拌30分鐘。添加(RS)-2-(5-胺基嘧啶-2-基)嗎啉-4-羧酸第三丁酯(27mg)。該反應在室溫下持續整夜。然後用CH2Cl2(10mL)稀釋該溶液，用鹽水(20mL)清洗，經Na2SO4乾燥並於減壓下濃縮。將殘餘物溶解於CH2Cl2(1mL)及三氟乙酸(TFA，1mL，CAS：76-05-1)之混合物中。在室溫下將該溶液攪拌2小時。於減壓下移除揮發物。藉由製備型HPLC(流動相A：H2O，B：含有0.1%TFA之CH3CN，C18管柱)純化殘餘物，以產生呈白色固體之(RS)-4-氯-N-(2-嗎啉-2-基嘧啶-5-基)苯甲醯胺(8mg，以兩個步驟產出26%)。 Add HATU (40.3 mg, CAS: CAS: 148893-10-1) and DIPEA (37.2 mg, CAS) to a solution of 4-chlorobenzoic acid (16.7 mg, CAS: 74-11-3) in DMF (1 mL). :7087-68-5). The mixture was stirred at room temperature for 30 minutes. (RS)-2-(5-Aminopyrimidin-2-yl)morpholine-4-carboxylic acid tert-butyl ester (27 mg) was added. The reaction was continued overnight at room temperature. The solution was then diluted with CH 2 Cl 2 (10mL), washed with brine (20mL), dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was dissolved in CH 2 Cl 2 (1mL) and trifluoroacetic acid (TFA, 1mL, CAS: 76-05-1 ) in the mixtures. The solution was stirred at room temperature for 2 hours. The volatiles were removed under reduced pressure. By preparative HPLC (mobile phase A: H 2 O, B: 0.1% TFA containing of CH 3 CN, C18 column) to give the residue, to yield a white solid of (RS) -4- chloro -N- ( 2-morpholin-2-ylpyrimidin-5-yl)benzamide (8 mg, 26% yield in two steps).

1H NMR(400MHz，甲醇-d4)：δ 9.24(2H)、7.98(2H)、7.57(2H)、4.97(1H)、4.21(1H)、4.02(1H)、3.73(1H)、3.54(1H)、3.73~3.30(2H)。 1 H NMR (400MHz, methanol -d 4): δ 9.24 (2H ), 7.98 (2H), 7.57 (2H), 4.97 (1H), 4.21 (1H), 4.02 (1H), 3.73 (1H), 3.54 ( 1H), 3.73~3.30 (2H).

MS(ESI)：319.0({35Cl}M+H)+、321.0({37Cl}M+H)+。 MS (ESI): 319.0 ({ 35 Cl} M + H) +, 321.0 ({37 Cl} M + H) +.

實例73 Example 73

(RS)-1-(3-氯苯基)-3-(2-嗎啉-2-基嘧啶-5-基)脲 (RS)-1-(3-chlorophenyl)-3-(2-morpholin-2-ylpyrimidin-5-yl)urea

向(RS)-2-(5-胺基嘧啶-2-基)嗎啉-4-羧酸第三丁酯(27mg)在CH2Cl2(1mL)中之溶液中添加Et3N(19.4mg，CAS：121-44-8)及異氰 酸3-氯苯酯(14.7mg，CAS：2909-38-8)。該反應在室溫下進行整夜。用CH2Cl2(10mL)稀釋該溶液，用檸檬酸水性溶液(2 x 20mL)及鹽水(20mL)清洗，經Na2SO4乾燥並於減壓下濃縮。將殘餘物溶解於CH2Cl2(1mL)及三氟乙酸(TFA，1mL，CAS：76-05-1)之混合物中。在室溫下將該溶液攪拌2小時。於減壓下移除揮發物。藉由製備型HPLC(流動相A：H2O，B：含有0.1%TFA之CH3CN，C18管柱)純化殘餘物，以產生呈白色固體之標題化合物(7mg，以兩個步驟產出22%)。 To (RS) -2- (5- amino-2-yl) morpholine-4-carboxylic acid tert-butyl ester (27 mg of) in Et 3 N was added a solution of CH 2 Cl 2 (1mL) in (19.4 Mg, CAS: 121-44-8) and 3-chlorophenyl isocyanate (14.7 mg, CAS: 2909-38-8). The reaction was carried out overnight at room temperature. The solution was diluted with CH 2 Cl 2 (10mL), washed with aqueous citric acid solution (2 x 20mL) and brine (20mL), dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was dissolved in CH 2 Cl 2 (1mL) and trifluoroacetic acid (TFA, 1mL, CAS: 76-05-1 ) in the mixtures. The solution was stirred at room temperature for 2 hours. The volatiles were removed under reduced pressure. By preparative HPLC (mobile phase A: H 2 O, B: 0.1% TFA containing of CH 3 CN, C18 column) to give the residue, to yield the title compound as a white solid (7 mg of, yield in two steps twenty two%).

1H NMR(400MHz，甲醇-d4)：δ 9.00(2H)、7.67(1H)、7.32~7.26(2H)、7.05(1H)、4.95(1H)、4.18(1H)、4.01(1H)、3.67(1H)、3.53(1H)、3.36~3.30(2H)。 1 H NMR (400 MHz, methanol-d 4 ): δ 9.00 (2H), 7.67 (1H), 7.32 to 7.26 (2H), 7.05 (1H), 4.95 (1H), 4.18 (1H), 4.01 (1H), 3.67 (1H), 3.53 (1H), 3.36~3.30 (2H).

MS(ESI)：334.1({35Cl}M+H)+、336.1({37Cl}M+H)+。 MS (ESI): 334.1 ({ 35 Cl} M + H) +, 336.1 ({37 Cl} M + H) +.

實例74 Example 74

(RS)-4-氯-3-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)-1H-吡唑-5-甲醯胺 (RS)-4-chloro-3-ethoxy-N-(6-morpholin-2-yl-3-pyridyl)-1H-pyrazole-5-carboxamide

a)5-羥基-1H-吡唑-3-羧酸甲酯a) Methyl 5-hydroxy-1H-pyrazole-3-carboxylate

向一水合肼(3.85g，0.077mol，CAS：7803-57-8)在甲苯(30mL)中之溶液中添加乙酸(15mL)及丁炔二酸二甲酯(10g，0.07mol，CAS：762-42-5)。在室溫下將該溶液攪拌3小時。然後將該混合物倒入冰水中。藉由過濾收集沉澱物並用冷水清洗。在高真空下之進一步乾燥產生呈白色固體之5-羥基-1H-吡唑-3-羧酸甲酯(7.5g，產率：75%)。 To a solution of hydrazine monohydrate (3.85 g, 0.077 mol, CAS: 7803-57-8) in toluene (30 mL) was added acetic acid (15 mL) and dimethyl succinimide (10 g, 0.07 mol, CAS: 762 -42-5). The solution was stirred at room temperature for 3 hours. The mixture was then poured into ice water. The precipitate was collected by filtration and washed with cold water. Further drying under high vacuum gave methyl 5-hydroxy-1H-pyrazole-3-carboxylate (7.5 g, yield: 75%) as a white solid.

1H NMR(400MHz,DMSO-d6)：δ 12.81(s,1H)、10.04(br,1H)、5.96(br,1H)、3.77(s,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 12.81 (s, 1H), 10.04 (br, 1H), 5.96 (br, 1H), 3.77 (s, 3H).

b)5-乙氧基-1H-吡唑-3-羧酸甲酯b) Methyl 5-ethoxy-1H-pyrazole-3-carboxylate

向5-羥基-1H-吡唑-3-羧酸甲酯(4g，28.17mmol)在DMF(25mL)中之溶液中添加K2CO3(5.83g，42.2mmol)及碘乙烷(4.8g，31mmol)。在室溫下將該溶液攪拌15h。然後將該混合物倒入冰水中。用乙酸乙酯(100mL)萃取該混合物。用鹽水(30mL)清洗有機層，經Na2SO4乾燥並於減壓下濃縮。自二氯甲烷(10ml)中再結晶產生呈白色固體之5-乙氧基-1H-吡唑-3-羧酸甲酯(2.2g，產率：46%)。 K 2 CO 3 (5.83 g, 42.2 mmol) and ethyl iodide (4.8 g) were added to a solution of methyl 5-hydroxy-1H-pyrazole-3-carboxylate (4 g, 28.17 mmol) in DMF (25 mL) , 31mmol). The solution was stirred at room temperature for 15 h. The mixture was then poured into ice water. The mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with brine (30mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Recrystallization from dichloromethane (10 ml) gave methyl 5-ethoxy-1H-pyrazole-3-carboxylate (2.2 g, yield: 46%).

1H NMR(400MHz,DMSO-d6)：δ 13.13(s,1H)、6.23(s,1H)、4.11(d,2H)、3.81(s,3H)、1.28(m,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 13.13 (s, 1H), 6.23 (s, 1H), 4.11 (d, 2H), 3.81 (s, 3H), 1.28 (m, 3H).

c)4-氯-5-乙氧基-1H-吡唑-3-羧酸甲酯c) methyl 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylate

在0℃下，向5-乙氧基-1H-吡唑-3-羧酸甲酯(2.2g，12.94mmol)在DMF(40mL)中之溶液中添加N-氯代丁二醯亞胺(2.06g，15.53mmol，CAS：128-09-6)。然後將該混合物加熱至50℃。持續攪拌15小時。於減壓下濃縮該反應溶液以移除約50%量之DMF。然後將該溶液倒入冰水中。藉由過濾收集沉澱物並藉由冷水清洗。在高真空下之進一步乾燥產生呈白色固體之甲基4-氯-5-乙氧基-1H-吡唑-3-羧酸鹽(1.65g，產率：63%)。 To a solution of methyl 5-ethoxy-1H-pyrazole-3-carboxylate (2.2 g, 12.94 mmol) in DMF (40 mL) was added N-chlorobutaneimide ( 2.06g, 15.53mmol, CAS: 128-09-6). The mixture was then heated to 50 °C. Stirring was continued for 15 hours. The reaction solution was concentrated under reduced pressure to remove about 50% of DMF. The solution was then poured into ice water. The precipitate was collected by filtration and washed with cold water. Further drying under high vacuum gave methyl 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylate as a white solid (1.65 g, yield: 63%).

1H NMR(400MHz,DMSO-d6)：δ 13.44(br,1H)、4.24(d,2H)、3.85(s,3H)、1.32(t,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 13.44 (br, 1H), 4.24 (d, 2H), 3.85 (s, 3H), 1.32 (t, 3H).

d)4-氯-5-乙氧基-1H-吡唑-3-羧酸d) 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylic acid

在0℃下，向4-氯-5-乙氧基-1H-吡唑-3-羧酸甲酯(1.65g，8.06mmol)在THF(30mL)中之溶液中添加1M水性NaOH溶液(16.1mL，16.1mmol)。然後將該溶液回流3小時。使該反應混合物冷卻至室溫並倒入水中。用濃縮HCl將pH調整至~1。藉由過濾收集沉澱物並用冷 水清洗。在高真空下之進一步乾燥產生呈白色固體之4-氯-5-乙氧基-1H-吡唑-3-羧酸(1.4g，產率：91.5%)。 Add 1 M aqueous NaOH solution (16.1) to a solution of methyl 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylate (1.65 g, 8.06 mmol) in THF (30 mL). mL, 16.1 mmol). The solution was then refluxed for 3 hours. The reaction mixture was allowed to cool to room temperature and poured into water. The pH was adjusted to ~1 with concentrated HCl. Collecting sediment by filtration and using cold Water cleaning. Further drying under high vacuum gave 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylic acid (1.4 g, yield: 91.5%) as a white solid.

1H NMR(400MHz,DMSO-d6)：δ 13.25(s,1H)、4.23(d,2H)、1.32(t,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 13.25 (s, 1H), 4.23 (d, 2H), 1.32 (t, 3H).

e)(RS)-4-氯-3-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)-1H-吡唑-5-甲醯胺e) (RS)-4-chloro-3-ethoxy-N-(6-morpholin-2-yl-3-pyridyl)-1H-pyrazole-5-carboxamide

以類似實例7之方式在步驟(c)中使用4-氯-5-乙氧基-1H-吡唑-3-羧酸代替4-氯苯甲酸獲得標題化合物。白色固體。 The title compound was obtained in a similar manner to Example 7 using 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylic acid instead of 4-chlorobenzoic acid in step (c). White solid.

1H NMR(400MHz，甲醇-d4)：δ 8.91(d,1H)、8.26(dd,1H)、7.62(d,1H)、4.90(s,1H)、4.33(m,2H)、4.25(m,1H)、4.04(m,1H)、3.70(d,1H)、3.36(d,1H)、3.29(m,2H)、1.43(t,3H)。 1 H NMR (400MHz, methanol -d 4): δ 8.91 (d , 1H), 8.26 (dd, 1H), 7.62 (d, 1H), 4.90 (s, 1H), 4.33 (m, 2H), 4.25 ( m, 1H), 4.04 (m, 1H), 3.70 (d, 1H), 3.36 (d, 1H), 3.29 (m, 2H), 1.43 (t, 3H).

MS(ESI)：352.1({35Cl}M+H)+、354.1({37Cl}M+H)+。 MS (ESI): 352.1 ({ 35 Cl} M + H) +, 354.1 ({37 Cl} M + H) +.

實例75 Example 75

(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazole-5- Guanamine

a)5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯a) methyl 5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate

向5-羥基-1H-吡唑-3-羧酸甲酯(10g，70.4mmol)、Cs2CO3(25g，77.5mmol)在DMF(100ml)中之溶液中分批添加三氟甲磺酸2,2,2-三氟乙酯(16.3g，70.4mmol，CAS：6226-25-1)。在室溫下將該溶液攪拌整夜。將該反應混合物小心地倒入500ml冰水中。藉由過濾收集沉澱物並用冷水清洗。在高真空下之進一步乾燥產生呈白色固體之5- (2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯(12g，產率：76%)。 Addition of trifluoromethanesulfonic acid in portions to a solution of methyl 5-hydroxy-1H-pyrazole-3-carboxylate (10 g, 70.4 mmol), Cs 2 CO 3 (25 g, 77.5 mmol) in DMF (100 mL) 2,2,2-Trifluoroethyl ester (16.3 g, 70.4 mmol, CAS: 6226-25-1). The solution was stirred overnight at room temperature. The reaction mixture was carefully poured into 500 ml of ice water. The precipitate was collected by filtration and washed with cold water. Further drying under high vacuum gave methyl 5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate as a white solid (12 g, yield: 76%).

1H NMR(400MHz,DMSO-d6)：δ 13.41(s,1H)、6.43(s,1H)、4.86(m,2H)、3.84(s,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 13.41 (s, 1H), 6.43 (s, 1H), 4.86 (m, 2H), 3.84 (s, 3H).

MS(ESI)：225.1([M+H]+)。 MS (ESI): 225.1 ([M+H] + ).

b)4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯b) methyl 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate

在0℃下，向5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯(1.9g，8.47mmol)在DMF(30mL)中之溶液中添加N-氯代丁二醯亞胺(1.35g，10.17mmol)。然後在50℃下將該溶液攪拌15小時。於真空下濃縮反應溶液以移除50%之DMF。然後將該溶液倒入水中。藉由過濾收集沉澱物，用水清洗並在高真空下乾燥，以產生呈白色固體之4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯(1.9g，產率：87%)。 Add to a solution of methyl 5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate (1.9 g, 8.47 mmol) in DMF (30 mL) N-chlorobutanediamine (1.35 g, 10.17 mmol). The solution was then stirred at 50 ° C for 15 hours. The reaction solution was concentrated under vacuum to remove 50% of DMF. The solution was then poured into water. The precipitate was collected by filtration, washed with water and dried under high vacuum to give 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxyl as a white solid. Methyl ester (1.9 g, yield: 87%).

c)4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸c) 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylic acid

在0℃下，向4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯(1.9g，7.35mmol)在THF(15mL)及MeOH(15mL)之混合物中之溶液中添加1M水性NaOH(14.7mL,14.7mmol)。然後在回流溫度下將該溶液攪拌3小時。將該反應溶液倒入水中。用濃縮HCl溶液將pH調整至約1。藉由過濾收集沉澱物，用水清洗並在高真空下乾燥，以產生呈白色固體之4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸(1.5g，產率：83%)。 Methyl 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate (1.9 g, 7.35 mmol) in THF (15 mL) 1 M aqueous NaOH (14.7 mL, 14.7 mmol) was added to a solution of MeOH (15 mL). The solution was then stirred at reflux temperature for 3 hours. The reaction solution was poured into water. The pH was adjusted to about 1 with a concentrated HCl solution. The precipitate was collected by filtration, washed with water and dried under high vacuum to give 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxyl as a white solid. Acid (1.5 g, yield: 83%).

1H NMR(400MHz,DMSO-d6)：δ 13.91(br,1H)、13.56(s,1H)、4.91(m,2H)。 1 H NMR (400MHz, DMSO- d 6): δ 13.91 (br, 1H), 13.56 (s, 1H), 4.91 (m, 2H).

MS(ESI)：245.0({35Cl}M+H)+、247.0({37Cl}M+H)+。 MS (ESI): 245.0 ({ 35 Cl} M + H) +, 247.0 ({37 Cl} M + H) +.

d)(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺d) (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)-3-(2,2,2-trifluoroethoxy)-1H-pyrazole-5 -Procarbamide

以類似實例7之方式在步驟(c)中使用4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸代替4-氯苯甲酸獲得標題化合物。白色固體。 The title was obtained in the same manner as in Example 7 using 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylic acid instead of 4-chlorobenzoic acid in step (c). Compound. White solid.

1H NMR(400MHz，甲醇-d4)：δ 8.90(d,1H)、8.26(dd,1H)、7.63(d,1H)、4.91(s,1H)、4.81(m,2H)、4.25(d,1H)、4.03(m,1H)、3.70(d,1H)、3.36(d,1H)、3.29(m,2H)。 1 H NMR (400MHz, methanol -d 4): δ 8.90 (d , 1H), 8.26 (dd, 1H), 7.63 (d, 1H), 4.91 (s, 1H), 4.81 (m, 2H), 4.25 ( d, 1H), 4.03 (m, 1H), 3.70 (d, 1H), 3.36 (d, 1H), 3.29 (m, 2H).

MS(ESI)：406.1({35Cl}M+H)+、408.1({37Cl}M+H)+。 MS (ESI): 406.1 ({ 35 Cl} M + H) +, 408.1 ({37 Cl} M + H) +.

實例76 Example 76

4-氯-3-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-氯-3-乙基-1H-吡唑-5-羧酸(CAS：158668-22-5)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 4-chloro-3-ethyl-1H-pyrazole-5-carboxylic acid (CAS: 158668-22-5) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：336.0({35Cl}M+H)+、338.0({37Cl}M+H)+。 MS (ESI): 336.0 ({ 35 Cl} M + H) +, 338.0 ({37 Cl} M + H) +.

實例77 Example 77

3-乙基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-ethyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用5-乙基-4-氟-1H-吡唑-3-羧酸(CAS：681034-63-9)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 5-ethyl-4-fluoro-1H-pyrazole-3-carboxylic acid (CAS: 681034-63-9) was used instead of 3-ethyl-4-methyl-1H-pyrazole- The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：320.0(M+H)+。 MS (ESI): 320.0 (M + H) + .

實例78 Example 78

4-溴-3-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-溴-5-乙基-1H-吡唑-3-羧酸(CAS：1291177-22-4)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。 蠟狀固體。 In a similar manner to Example 67, 4-bromo-5-ethyl-1H-pyrazole-3-carboxylic acid (CAS: 1291177-22-4) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The 5-carboxylic acid gave the title compound. Waxy solid.

MS(ESI)：381.9([{81Br}M+H]+)、379.9([{79Br}M+H]+)。 MS (ESI): 381.9 ([{ 81 Br}M+H] + ), 379.9 ([{ 79 Br}M+H] + ).

實例79 Example 79

4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-氟-5-丙基-1H-吡唑-3-羧酸(CAS：681034-64-0)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 4-fluoro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 681034-64-0) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：334.0(M+H)+。 MS (ESI): 334.0 (M+H) + .

實例80 Example 80

3-環丙基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-cyclopropyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用5-環丙基-4-氟-1H-吡唑-3-羧酸(CAS：681034-74-2)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 In a similar manner to Example 67, 5-cyclopropyl-4-fluoro-1H-pyrazole-3-carboxylic acid (CAS: 681034-74-2) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The -5-carboxylic acid gave the title compound. Waxy solid.

MS(ESI)：332.0(M+H)+。 MS (ESI): 332.0 (M+H) + .

實例81 Example 81

4-溴-3-環丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-cyclopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-溴-5-環丙基-2H-吡唑-3-羧酸(CAS：1290764-98-5)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 4-bromo-5-cyclopropyl-2H-pyrazole-3-carboxylic acid (CAS:1290764-98-5) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The -5-carboxylic acid gave the title compound. White solid.

MS(ESI)：394.0([{81Br}M+H]+)、392.0([{79Br}M+H]+)。 MS (ESI): 394.0 ([{ 81 Br}M+H] + ), 392.0 ([{ 79 Br}M+H] + ).

實例82 Example 82

4-氯-3-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-氯-3-乙基-1H-吡唑-5-羧酸(CAS：158668-22-5)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 4-chloro-3-ethyl-1H-pyrazole-5-carboxylic acid (CAS: 158668-22-5) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：336.1({35Cl}M+H)+、338.1({37Cl}M+H)+。 MS (ESI): 336.1 ({ 35 Cl} M + H) +, 338.1 ({37 Cl} M + H) +.

實例83 Example 83

3-乙基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-ethyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用5-乙基-4-氟-1H-吡唑-3-羧酸(CAS：681034-63-9)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 5-Ethyl-4-fluoro-1H-pyrazole-3-carboxylic acid (CAS: 681034-63-9) was used in a similar manner to Example 66 instead of 3-ethyl-4-methyl-1H-pyrazole- The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：320.2(M+H)+。 MS (ESI): 320.2 (M+H) + .

實例84 Example 84

4-溴-3-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-溴-5-乙基-1H-吡唑-3-羧酸(CAS：1291177-22-4)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 4-bromo-5-ethyl-1H-pyrazole-3-carboxylic acid (CAS: 1291177-22-4) was used instead of 3-ethyl-4-methyl-1H-pyrazole- The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：382.1([{81Br}M+H]+)、380.1([{79Br}M+H]+)。 MS (ESI): 382.1 ([{ 81 Br}M+H] + ), 380.1 ([{ 79 Br}M+H] + ).

實例85 Example 85

4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺 4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-氟-5-丙基-1H-吡唑-3-羧酸(CAS：681034-64-0)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 4-fluoro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 681034-64-0) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：334.2(M+H)+。 MS (ESI): 334.2 (M+H) + .

實例86 Example 86

3-環丙基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-cyclopropyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用5-環丙基-4-氟-1H-吡唑-3-羧酸(CAS：681034-74-2)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 In a similar manner to Example 66, 5-cyclopropyl-4-fluoro-1H-pyrazole-3-carboxylic acid (CAS: 681034-74-2) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The -5-carboxylic acid gave the title compound. Waxy solid.

MS(ESI)：332.2(M+H)+。 MS (ESI): 332.2 (M+H) + .

實例87 Example 87

4-溴-3-環丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-bromo-3-cyclopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-溴-5-環丙基-2H-吡唑-3-羧酸(CAS：1290764-98-5)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 4-bromo-5-cyclopropyl-2H-pyrazole-3-carboxylic acid (CAS:1290764-98-5) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The -5-carboxylic acid gave the title compound. White solid.

MS(ESI)：394.0([{81Br}M+H]+)、392.0([{79Br}M+H]+)。 MS (ESI): 394.0 ([{ 81 Br}M+H] + ), 392.0 ([{ 79 Br}M+H] + ).

實例88 Example 88

3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isobutyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用3-異丁基-1H-吡唑-5-羧酸(CAS：92933-49-8)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 3-isobutyl-1H-pyrazole-5-carboxylic acid (CAS: 92933-49-8) was used instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylate. The title compound was obtained from the acid. White solid.

MS(ESI)：330.2(M+H)+。 MS (ESI): 330.2 (M+H) + .

實例89 Example 89

4-氟-3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isobutyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

a)6-甲基-2,4-二側氧基-庚酸乙酯a) 6-Methyl-2,4-dioxy-heptanoate

在0℃下，向乙醇鈉(7g，0.1mol)在無水乙醇(150mL)中之溶液中添加草酸二乙酯(15g，0.1mol，CAS：95-92-1)。然後分批添加4-甲基-2-戊酮(10g，0.1mol，CAS：108-10-1)。在50℃下將該混合物攪拌20小時。將該溶液冷卻至室溫並直接用於下一步驟中。 To a solution of sodium ethoxide (7 g, 0.1 mol) in absolute ethanol (150 mL) was added diethyl oxalate (15 g, 0.1 mol, CAS: 95-92-1) at 0 °C. Then 4-methyl-2-pentanone (10 g, 0.1 mol, CAS: 108-10-1) was added in portions. The mixture was stirred at 50 ° C for 20 hours. The solution was cooled to room temperature and used directly in the next step.

b)5-異丁基-1H-吡唑-3-羧酸乙酯b) ethyl 5-isobutyl-1H-pyrazole-3-carboxylate

向來自於步驟(a)之6-甲基-2,4-二側氧基-庚酸乙酯(0.1mol)在乙醇(150mL)中之溶液中添加乙酸(9g，0.15mol)及一水合肼(8.1g，0.15mol，CAS：7803-57-8)。將該反應混合物攪拌12小時。然後於減壓下濃縮該反應溶液，用水稀釋並用乙酸乙酯(2 x 300mL)萃取兩次。用鹽水(50mL)清洗合併之有機層，經Na2SO4乾燥，濾過薄二氧化矽墊並於減壓下濃縮。藉由矽膠層析法純化粗產物，以產生呈白色固體之5-異丁基-1H-吡唑-3-羧酸乙酯(13g，產率：68%)。 Add acetic acid (9 g, 0.15 mol) and monohydrate to a solution of 6-methyl-2,4-dioxy-heptanoic acid ethyl ester (0.1 mol) from ethanol (150 mL) from step (a)肼 (8.1 g, 0.15 mol, CAS: 7803-57-8). The reaction mixture was stirred for 12 hours. The reaction solution was then concentrated under reduced pressure, diluted with water and EtOAc EtOAc. Combined organic layers were washed with brine (50mL), dried over Na 2 SO 4, filtered through a thin pad of silicon dioxide and concentrated under reduced pressure. The crude product was purified by silica gel chromatography to afford ethyl 5--butyl-1H-pyrazole-3-carboxylate as a white solid (13 g, yield: 68%).

MS(ESI)：197.2(M+H)+。 MS (ESI): 197.2 (M+H) + .

c)4-氟-5-異丁基-1H-吡唑-3-羧酸乙酯c) ethyl 4-fluoro-5-isobutyl-1H-pyrazole-3-carboxylate

在0℃下，向5-異丁基-1H-吡唑-3-羧酸乙酯(5.0g，25.5mmol)在CH3CN(300mL)中之溶液中添加Selectfluor®(18.0g，51.0mmol，CAS：140681-55-6)。然後將該溶液加熱至70℃。持續攪拌15小時。使該反應溶液冷卻至室溫並於減壓下濃縮。用水性HCl(3N，200mL)稀釋殘餘物並用二氯甲烷(100mL x 2)萃取。用鹽水(20mL)清洗合併之有機層，經Na2SO4乾燥並於減壓下濃縮。透過矽膠管柱層析法(以 體積計二氯甲烷/MeOH=200/1~100/1)之純化產生呈黃色油之4-氟-5-異丁基-1H-吡唑-3-羧酸乙酯(1.4g，產率：26%)。 At 0 ℃, to -1H- pyrazole-5-isobutyl-3-carboxylate (5.0g, 25.5mmol) was added Selectfluor® (18.0g in the CH 3 CN (300mL) solution, 51.0mmol , CAS: 140681-55-6). The solution was then heated to 70 °C. Stirring was continued for 15 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with aqueous HCl (3N,EtOAc) Combined organic layers were washed with brine (20mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Purification by gel column chromatography (dichloromethane/MeOH = 200/1~100/1) afforded 4-fluoro-5-isobutyl-1H-pyrazole-3-carboxylate as a yellow oil. Ethyl acetate (1.4 g, yield: 26%).

1H NMR(400MHz,DMSO-d6)：δ 4.42(q,2H)、2.55(d,2H)、2.00(m,1H)、1.40(t,3H)、0.96(d,6H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 4.42 (q, 2H), 2.55 (d, 2H), 2.00 (m, 1H), 1.40 (t, 3H), 0.96 (d, 6H).

MS(ESI)：215.1(M+H)+。 MS (ESI): 215.1 (M+H) + .

d)4-氟-5-異丁基-1H-吡唑-3-羧酸d) 4-fluoro-5-isobutyl-1H-pyrazole-3-carboxylic acid

在0℃下，向4-氟-5-異丁基-1H-吡唑-3-羧酸(1.4g，6.54mmol)在THF/MeOH(V/V=1：1，20mL)中之溶液中添加1M aq NaOH(13.1mL，13.1mmol)。然後將該溶液回流3小時。將該反應溶液倒入水中。用濃縮HCl將pH調整至約1。用乙酸乙酯(100mL x 2)萃取該混合物。用鹽水(20mL)清洗合併之有機層，於減壓下濃縮並再結晶自乙酸乙酯(30mL)中，以產生呈黃色固體之4-氟-5-異丁基-1H-吡唑-3-羧酸(1.2g，產率：99%)。 To a solution of 4-fluoro-5-isobutyl-1H-pyrazole-3-carboxylic acid (1.4 g, 6.54 mmol) in THF / MeOH (V/V = 1:1, 20 mL) 1 M aq NaOH (13.1 mL, 13.1 mmol) was added. The solution was then refluxed for 3 hours. The reaction solution was poured into water. The pH was adjusted to about 1 with concentrated HCl. The mixture was extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with EtOAc EtOAc (EtOAc m. -carboxylic acid (1.2 g, yield: 99%).

1H NMR(400MHz,DMSO-d6)：δ 2.44(d,2H)、1.90(m,1H)、0.87(d,6H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 2.44 (d, 2H), 1.90 (m, 1H), 0.87 (d, 6H).

MS(ESI)：187.1(M+H)+。 MS (ESI): 187.1 (M + H) + .

e)4-氟-3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺e) 4-Fluoro-3-isobutyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-氟-5-異丁基-1H-吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 The title compound was obtained in a similar manner to Example 67 using 4-fluoro-5-isobutyl-1H-pyrazole-3-carboxylic acid instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. Waxy solid.

MS(ESI)：348.2(M+H)+。 MS (ESI): 348.2 (M+H) + .

實例90 Example 90

3-丁基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用5-丁基-4-氟-1H-吡唑-3-羧酸(CAS：681034-65-1)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 Instead of 3-ethyl-4-methyl-1H-pyrazole, 5-butyl-4-fluoro-1H-pyrazole-3-carboxylic acid (CAS: 681034-65-1) was used in a similar manner to Example 67. The 5-carboxylic acid gave the title compound. Waxy solid.

MS(ESI)：348.2(M+H)+。 MS (ESI): 348.2 (M+H) + .

實例91 Example 91

3-丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用5-丁基-1H-吡唑-3-羧酸(CAS：92933-48-7)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 In a similar manner to Example 67, 5-butyl-1H-pyrazole-3-carboxylic acid (CAS: 92933-48-7) was used instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. The title compound was obtained. Waxy solid.

MS(ESI)：330.2(M+H)+。 MS (ESI): 330.2 (M+H) + .

實例92 Example 92

5-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺 5-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3-methyl Guanamine

a)5-異丙基-1H-吡唑-3-羧酸乙酯a) 5-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester

向4-甲基-3-側氧基戊酸乙酯(4g，21.6mmol，CAS：7152-15-0)在乙醇(100mL)中之溶液中添加乙酸(1.9g，32.4mmol)及一水合肼(1.7g，0.032mol，CAS：7803-57-8)。將該反應混合物攪拌12小時直至LCMS分析顯示該反應完成。於減壓下濃縮該反應溶液並用水稀釋。用二氯甲烷(2 x 100mL)萃取該混合物兩次。用鹽水(40mL)清洗合併之有機層，經Na2SO4乾燥，濾過薄二氧化矽墊並於真空下濃縮，以產生呈黃色油之5-異丙基-1H-吡唑-3-羧酸乙酯(2.1g，產率：54%)。 Add acetic acid (1.9 g, 32.4 mmol) and monohydrate to a solution of 4-methyl-3-oxoethoxyvalerate (4 g, 21.6 mmol, CAS: 7152-15-0) in ethanol (100 mL)肼 (1.7 g, 0.032 mol, CAS: 7803-57-8). The reaction mixture was stirred for 12 hours until LCMS analysis indicated the reaction was completed. The reaction solution was concentrated under reduced pressure and diluted with water. The mixture was extracted twice with dichloromethane (2 x 100 mL). Combined organic layers were washed with brine (40 mL), dried over Na 2 SO 4, filtered through a thin pad of silicon dioxide and concentrated in vacuo to yield as a yellow oil of isopropyl 5- -1H- pyrazole-3-carboxamide Ethyl acetate (2.1 g, yield: 54%).

MS(ESI)：183.2(M+H)+。 MS (ESI): 183.2 (M+H) + .

b)5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸乙酯b) ethyl 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylate

向5-異丙基-1H-吡唑-3-羧酸乙酯(1g，5.5mmol)在DMF(10mL)中之溶液中添加2,2,2-三氟碘乙烷(1.7g，8.3mmol，CAS：353-83-3)及Cs2CO3(2.1g，11mmol)。在50℃下將該反應混合物攪拌12小時。然後於減壓下濃縮該反應溶液並用水稀釋。用乙酸乙酯(2 x 100mL)萃取該混合物。用鹽水(50mL)清洗合併之有機層，經Na2SO4乾燥，濾過薄二氧化矽墊並於真空下乾燥。藉由矽膠層析法純化粗產物，以產生呈白色固體之5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸乙酯(500mg，產率：36%)。 Add 2,2,2-trifluoroiodoethane (1.7 g, 8.3) to a solution of ethyl 5-isopropyl-1H-pyrazole-3-carboxylate (1 g, 5.5 mmol) in DMF (10 mL) M, CAS: 353-83-3) and Cs 2 CO 3 (2.1 g, 11 mmol). The reaction mixture was stirred at 50 ° C for 12 hours. The reaction solution was then concentrated under reduced pressure and diluted with water. The mixture was extracted with ethyl acetate (2 x 100 mL). Combined organic layers were washed with brine (50mL), dried over Na 2 SO 4, filtered through a thin pad of silicon dioxide and dried under vacuum. The crude product was purified by silica gel chromatography to give ethyl 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylate as a white solid (500 mg, yield :36%).

MS(ESI)：265.2(M+H)+。 MS (ESI): 265.2 (M+H) + .

c)5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸c) 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylic acid

向5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸乙酯(2g，7.6mmol)在MeOH/H2O(V/V=3：1，12mL)中之溶液中添加NaOH(1.2g，30.3mmol)。在30℃下將該反應混合物攪拌2小時。於減壓下濃縮該反應溶液並用水稀釋。用2N HCl(30mL)將該混合物酸化至約pH=2。用乙酸乙酯(2 x 100mL)萃取混合物。用鹽水(100mL)清洗合併之有機層，經Na2SO4乾燥，濾過薄二氧化矽墊並於減壓下濃縮。在高真空下之進一步乾燥產生呈白色固體之5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸(1.6g，產率：89%)。 To ethyl 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylate (2 g, 7.6 mmol) in MeOH / H 2 O (V/V = 3:1 NaOH (1.2 g, 30.3 mmol) was added to the solution in 12 mL). The reaction mixture was stirred at 30 ° C for 2 hours. The reaction solution was concentrated under reduced pressure and diluted with water. The mixture was acidified to about pH = 2 with 2N HCl (30 mL). The mixture was extracted with ethyl acetate (2 x 100 mL). Combined organic layers were washed with brine (100mL), dried over Na 2 SO 4, filtered through a thin pad of silicon dioxide and concentrated under reduced pressure. Further drying under high vacuum gave 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylic acid (1.6 g, yield: 89%) as a white solid.

1H NMR(CDCl3,400MHz)：δ 6.91(s,1H)、5.25(q,2H)、3.04(m,1H)、1.29(d,6H)。 1 H NMR (CDCl 3 , 400 MHz): δ 6.91 (s, 1H), 5.25 (q, 2H), 3.04 (m, 1H), 1.29 (d, 6H).

MS(ESI)：237.2(M+H)+。 MS (ESI): 237.2 (M+H) + .

d)5-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺d) 5-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3 -Procarbamide

以類似實例67之方式使用5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylic acid was used instead of 3-ethyl-4-methyl-1H-pyrazole- The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：398.2(M+H)+。 MS (ESI): 398.2 (M+H) + .

實例93 Example 93

2-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺 2-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole-3- Formamide

a)5-羥基-1H-吡唑-3-羧酸甲酯a) Methyl 5-hydroxy-1H-pyrazole-3-carboxylate

向一水合肼(44.8g，0.894mol，CAS：7803-57-8)在甲苯(300mL)中之溶液中添加乙酸(180mL)及丁炔二酸二甲酯(100mL，0.813mol，CAS：762-42-5)。在室溫下將該溶液攪拌3小時。將該混合物倒入冰水中。藉由過濾收集沉澱物，用冷水清洗並在高真空下乾燥以產生呈白色固體之5-羥基-1H-吡唑-3-羧酸甲酯(67.5g，產率：59%)。 To a solution of hydrazine monohydrate (44.8 g, 0.894 mol, CAS: 7803-57-8) in toluene (300 mL) was added acetic acid (180 mL) and dimethyl succinimide (100 mL, 0.813 mol, CAS: 762 -42-5). The solution was stirred at room temperature for 3 hours. The mixture was poured into ice water. The precipitate was collected by filtration, washed with cold water and dried under high vacuum to afford methyl 5-hydroxy-1H-pyrazole-3-carboxylate (67.5 g, yield: 59%) as a white solid.

1H NMR(400MHz,DMSO-d6)：δ 12.81(bra,1H)、10.03(br,1H)、5.91(s,1H)、3.78(s,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 12.81 (bra, 1H), 10.03 (br, 1H), 5.91 (s, 1H), 3.78 (s, 3H).

b)5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯b) methyl 5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate

向5-羥基-1H-吡唑-3-羧酸甲酯(10g，70.4mmol)、Cs2CO3(25g，77.5mmol)在DMF(100ml)中之溶液中分批添加三氟甲磺酸2,2,2-三氟乙酯(16.3g，70.4mmol)。在室溫下將該溶液攪拌整夜。然後將該反應混合物倒入500ml冰水中。藉由過濾收集沉澱物，用冷水清洗並在高真空下乾燥，以產生呈白色固體之5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯(12g，產率：76%)。 Addition of trifluoromethanesulfonic acid in portions to a solution of methyl 5-hydroxy-1H-pyrazole-3-carboxylate (10 g, 70.4 mmol), Cs 2 CO 3 (25 g, 77.5 mmol) in DMF (100 mL) 2,2,2-Trifluoroethyl ester (16.3 g, 70.4 mmol). The solution was stirred overnight at room temperature. The reaction mixture was then poured into 500 ml of ice water. The precipitate was collected by filtration, washed with cold water and dried under high vacuum to give methyl 5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate as a white solid. (12 g, yield: 76%).

1H NMR(400MHz,DMSO-d6)：δ 13.41(s,1H)、6.43(s,1H)、4.86(m,2H)、3.84(s,3H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 13.41 (s, 1H), 6.43 (s, 1H), 4.86 (m, 2H), 3.84 (s, 3H).

MS(ESI)：225.1(M+H)+。 MS (ESI): 225.1 (M+H) + .

c)2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸甲酯c) Methyl 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxylate

向5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸甲酯(12.0g，53.4mmol)及Cs2CO3(52.0g，161mmol)在DMF(100.0ml)中之溶液中分批添加2-溴丙烷(7.2g，56.0mmol)。在室溫下將該溶液攪拌整夜。然後於真空中濃縮該反應溶液以移除至少50%之DMF。將剩餘混合物倒入水中。藉由過濾收集沉澱物，用冷水清洗，在高真空下乾燥，以產生呈白色固體之2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸甲酯(10.3g， 產率：74%)。 Methyl 5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylate (12.0 g, 53.4 mmol) and Cs 2 CO 3 (52.0 g, 161 mmol) in DMF (100.0) 2-Bromopropane (7.2 g, 56.0 mmol) was added portionwise to a solution in ml. The solution was stirred overnight at room temperature. The reaction solution was then concentrated in vacuo to remove at least 50% of DMF. Pour the remaining mixture into the water. The precipitate was collected by filtration, washed with cold water and dried under high vacuum to give 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxyl as a white solid. Methyl ester (10.3 g, yield: 74%).

1H NMR(400MHz,DMSO-d6)：δ 6.45(s,1H)、5.35(m,1H)、4.82(q,2H)、3.83(s,3H)、1.371(d,6H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 6.45 (s, 1H), 5.35 (m, 1H), 4.82 (q, 2H), 3.83 (s, 3H), 1.371 (d, 6H).

MS(ESI)：267.0(M+H)+。 MS (ESI): 267.0 (M+H) + .

d)2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸d) 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxylic acid

在室溫下，將2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸甲酯(4.3g，16.2mmol)及NaOH(1.9g，48.5mmol)在MeOH/H2O(V/V=3：1，50.0ml)中之溶液攪拌整夜。藉由在0℃下添加濃縮HCl(約5ml)將該反應混合物酸化至pH=4~5。將該溶液倒入500ml冰水中。藉由過濾收集沉澱物，用冷水清洗並在高真空下乾燥，以產生呈白色固體之2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸(3.86g，產率：95%)。 Methyl 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxylate (4.3 g, 16.2 mmol) and NaOH (1.9 g, 48.5) Methyl) The solution in MeOH/H2O (V/V = 3:1, 50.0 mL) was stirred overnight. The reaction mixture was acidified to pH = 4-5 by the addition of concentrated HCl (~5 mL) at 0 °C. The solution was poured into 500 ml of ice water. The precipitate was collected by filtration, washed with cold water and dried under high vacuum to give 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxyl as a white solid. Acid (3.86 g, yield: 95%).

1H NMR(400MHz,DMSO-d6)：δ 6.37(s,1H)、5.38(m,1H)、4.79(q,2H)、1.34(d,6H)。 1 H NMR (400 MHz, DMSO-d 6 ): δ 6.37 (s, 1H), 5.38 (m, 1H), 4.79 (q, 2H), 1.34 (d, 6H).

MS(ESI)：252.9(M+H)+。 MS (ESI): 252.9 (M+H) + .

e)2-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺e) 2-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole- 3-methylamine

以類似實例67之方式使用2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxylic acid was used in place of 3-ethyl-4-methyl-1H-pyrazole. The -5-carboxylic acid gave the title compound. White solid.

MS(ESI)：414.2(M+H)+。 MS (ESI): 414.2 (M+H) + .

實例94 Example 94

3-異丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-isobutyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用3-異丁基-1H-吡唑-5-羧酸(CAS：92933-49-8)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 3-isobutyl-1H-pyrazole-5-carboxylic acid (CAS: 92933-49-8) was used instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylate. The title compound was obtained from the acid. White solid.

MS(ESI)：330.2(M+H)+。 MS (ESI): 330.2 (M+H) + .

實例95 Example 95

4-氟-3-異丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isobutyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-氟-5-異丁基-1H-吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 The title compound was obtained in a similar manner to Example 66 using 4-fluoro-5-isobutyl-1H-pyrazole-3-carboxylic acid instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. Waxy solid.

MS(ESI)：348.2(M+H)+。 MS (ESI): 348.2 (M+H) + .

實例96 Example 96

3-丁基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用5-丁基-4-氟-1H-吡唑-3-羧酸(CAS：681034-65-1)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。蠟狀固體。 In a similar manner to Example 66, 5-butyl-4-fluoro-1H-pyrazole-3-carboxylic acid (CAS: 681034-65-1) was used instead of 3-ethyl-4-methyl-1H-pyrazole. The 5-carboxylic acid gave the title compound. Waxy solid.

MS(ESI)：348.2(M+H)+。 MS (ESI): 348.2 (M+H) + .

實例97 Example 97

3-丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 3-butyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用5-丁基-1H-吡唑-3-羧酸(CAS：92933-48-7)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 5-butyl-1H-pyrazole-3-carboxylic acid (CAS: 92933-48-7) was used instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. The title compound was obtained. White solid.

MS(ESI)：330.2(M+H)+。 MS (ESI): 330.2 (M+H) + .

實例98 Example 98

5-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺 5-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3-methyl Guanamine

以類似實例66之方式使用5-異丙基-2-(2,2,2-三氟乙基)吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 Instead of 3-ethyl-4-methyl-1H-pyrazole, 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylic acid was used in a similar manner to Example 66. The 5-carboxylic acid gave the title compound. White solid.

MS(ESI)：398.1(M+H)+。 MS (ESI): 398.1 (M+H) + .

實例99 Example 99

2-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺 2-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole-3- Formamide

以類似實例66之方式使用2-異丙基-5-(2,2,2-三氟乙氧基)吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 2-isopropyl-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxylic acid was used instead of 3-ethyl-4-methyl-1H-pyrazole. The -5-carboxylic acid gave the title compound. White solid.

MS(ESI)：414.2(M+H)+。 MS (ESI): 414.2 (M+H) + .

實例100 Example 100

4-氯-3-乙氧基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethoxy-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-氯-5-乙氧基-1H-吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 The title compound was obtained in a similar manner to Example 66 using 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylic acid instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. White solid.

MS(ESI)：352.1({35Cl}M+H)+、354.1({37Cl}M+H)+。 MS (ESI): 352.1 ({ 35 Cl} M + H) +, 354.1 ({37 Cl} M + H) +.

實例101 Example 101

4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(2,2,2-三氟乙氧基)-1H- 吡唑-5-甲醯胺 4-Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-(2,2,2-trifluoroethoxy)-1H- Pyrazole-5-formamide

以類似實例66之方式使用4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 4-chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3-carboxylic acid was used instead of 3-ethyl-4-methyl-1H-pyridin. The title compound was obtained from the azole-5-carboxylic acid. White solid.

MS(ESI)：406.1({35Cl}M+H)+、408.0({37Cl}M+H)+。 MS (ESI): 406.1 ({ 35 Cl} M + H) +, 408.0 ({37 Cl} M + H) +.

實例102 Example 102

(RS)-5-氯-N-(5-氯-2-吡啶基)-6-嗎啉-2-基-吡啶-3-胺 (RS)-5-chloro-N-(5-chloro-2-pyridyl)-6-morpholin-2-yl-pyridin-3-amine

a)5-溴-3-氯-吡啶-2-羰基氯a) 5-bromo-3-chloro-pyridine-2-carbonyl chloride

在室溫下，向5-溴-3-氯吡啶-2-羧酸(5.0g，21.06mmol，CAS：1189513-51-6)在二氯甲烷(50mL)中之懸浮液中添加草醯氯(3.38g，31.6mmol，CAS：79-37-8)及DMF(0.1mL)。該反應持續5小時。於減壓下濃縮該溶液並在高真空下乾燥，以產生呈黃色固體之粗5-溴-3-氯-吡啶-2-羰基氯(5.4g，產率：100%)，其直接用於下一步驟中。 To a suspension of 5-bromo-3-chloropyridine-2-carboxylic acid (5.0 g, 21.06 mmol, CAS: 1189513-51-6) in dichloromethane (50 mL) at room temperature (3.38 g, 31.6 mmol, CAS: 79-37-8) and DMF (0.1 mL). The reaction lasted for 5 hours. The solution was concentrated under reduced pressure and dried <RTI ID=0.0></RTI></RTI> to dry</RTI></RTI> to <RTI ID=0.0> In the next step.

b)2-溴-1-(5-溴-3-氯-2-吡啶基)乙酮b) 2-bromo-1-(5-bromo-3-chloro-2-pyridyl)ethanone

在0~5℃下，向粗5-溴-3-氯-吡啶-2-羰基氯(5.4g，21.06mmol)在CH3CN(100mL)中之溶液中滴加(三甲基甲矽烷基)重氮甲烷溶液(2M之己烷溶液，31.6mL，63.2mmol，CAS：18107-18-1)。在室溫下將 該混合物攪拌整夜。在0~5℃下添加HBr(48%在水中，10mL)。將該溶液攪拌一小時。將該反應溶液倒入水(200mL)中。用EtOAc(200mL)萃取該混合物。用鹽水(100mL)清洗有機層，經Na2SO4乾燥並於減壓下濃縮。通過管柱層析法(以體積計石油醚/乙酸乙酯=100/1)純化殘餘物，以產生呈黃色固體之5-溴-3-氯-吡啶-2-羰基氯(5.17g，產率：78.3%)。 To a solution of crude 5-bromo-3-chloro-pyridine-2-carbonyl chloride (5.4 g, 21.06 mmol) in CH3CN (100 mL) ( 3 M. Diazomethane solution (2M in hexanes, 31.6 mL, 63.2 mmol, CAS: 18107-18-1). The mixture was stirred overnight at room temperature. HBr (48% in water, 10 mL) was added at 0-5 °C. The solution was stirred for one hour. The reaction solution was poured into water (200 mL). The mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine (100mL), dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography EtOAc (EtOAc:EtOAc) Rate: 78.3%).

MS(ESI)：315.8([{81Br+81Br}M+H]+)、313.8([{81Br+79Br}M+H]+)、311.8([{79Br+79Br}M+H]+)。 MS (ESI): 315.8 ([{ 81 Br + 81 Br}M+H] + ), 313.8 ([{ 81 Br+ 79 Br}M+H] + ), 311.8 ([{ 79 Br+ 79 Br}M+H] + ).

c)5-溴-3-氯-2-(環氧乙烷-2-基)吡啶c) 5-bromo-3-chloro-2-(oxiran-2-yl)pyridine

在0-5℃下，向5-溴-3-氯-吡啶-2-羰基氯(5.17g，16.5mmol)在乙醇(100mL)中之溶液中添加NaBH4(752.4mg，19.8mmol)。在室溫下將該溶液攪拌一小時。添加K2CO3(2.3g，16.5mmol)。該反應持續整夜。將該反應混合物倒入水(200mL)中並用乙酸乙酯(200mL)萃取。用鹽水(100mL)清洗有機層，經Na2SO4乾燥並於減壓下濃縮。在高真空下之進一步乾燥產生呈黃色油之5-溴-3-氯-2-(環氧乙烷-2-基)吡啶(3.86g，產率：100%)，其直接用於下一步驟中。 At 0-5 ℃, 5-bromo-3-chloro - Add NaBH 4 (752.4mg, 19.8mmol) pyridine-2-carbonyl chloride (5.17g, 16.5mmol) in solution (100 mL) of the ethanol. The solution was stirred at room temperature for one hour. K 2 CO 3 (2.3 g, 16.5 mmol) was added. The reaction continued overnight. The reaction mixture was poured into water (200 mL) The organic layer was washed with brine (100mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Further drying under high vacuum gave 5-bromo-3-chloro-2-(oxiran-2-yl)pyridine as a yellow oil (3.86 g, yield: 100%). In the steps.

MS(ESI)：235.9([{81Br}M+H]+)、233.9([{79Br}M+H]+)。 MS (ESI): 235.9 ([{ 81 Br}M+H] + ), 233.9 ([{ 79 Br}M+H] + ).

d)1-(5-溴-3-氯-2-吡啶基)-2-(2-羥乙基胺基)乙醇d) 1-(5-bromo-3-chloro-2-pyridyl)-2-(2-hydroxyethylamino)ethanol

向5-溴-3-氯-2-(環氧乙烷-2-基)吡啶(3.86g，16.5mmol)在THF(20mL)中之溶液中添加乙醇胺(10mL，CAS：141-43-5)。在室溫下將該溶液攪拌整夜。然後用乙酸乙酯(200mL)稀釋該溶液。用鹽水(100mL)清洗有機層，經Na2SO4乾燥並於減壓下濃縮。在高真空下之進一步乾燥產生呈黃色油之粗1-(5-溴-3-氯-2-吡啶基)-2-(2-羥乙基胺基)乙醇(3.0g，產率：61.6%)。其直接用於下一步驟中。 Add ethanolamine (10 mL, CAS: 141-43-5) to a solution of 5-bromo-3-chloro-2-(oxiran-2-yl)pyridine (3.86 g, 16.5 mmol) in THF (20 mL) ). The solution was stirred overnight at room temperature. The solution was then diluted with ethyl acetate (200 mL). The organic layer was washed with brine (100mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Further drying under high vacuum gave crude 1-(5-bromo-3-chloro-2-pyridyl)-2-(2-hydroxyethylamino)ethanol as a yellow oil (3.0 g, yield: 61.6 %). It is used directly in the next step.

e)N-[2-(5-溴-3-氯-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯e) N-[2-(5-bromo-3-chloro-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylic acid tert-butyl ester

向1-(5-溴-3-氯-2-吡啶基)-2-(2-羥乙基胺基)乙醇(3.0g，16.5mmol)在THF(30mL)及水(20mL)之混合物中之溶液中添加二碳酸二第三丁酯(3.29g，15.22mmol，CAS：24424-99-5)及K2CO3(2.8g，20.3mmol)。在室溫下將該溶液攪拌整夜。用水(50mL)稀釋該反應溶液。用乙酸乙酯(200mL)萃取該混合物。用鹽水(100mL)清洗有機層，經Na2SO4乾燥並於減壓下濃縮。透過管柱層析法(以體積計CH2Cl2/MeOH=100/1~50/1)純化殘餘物，以產生呈黃色油之N-[2-(5-溴-3-氯-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯(1.5g，產率：37.5%)。 To a mixture of 1-(5-bromo-3-chloro-2-pyridinyl)-2-(2-hydroxyethylamino)ethanol (3.0 g, 16.5 mmol) in THF (30 mL) and water (20 mL) Di-tert-butyl dicarbonate (3.29 g, 15.22 mmol, CAS: 24424-99-5) and K 2 CO 3 (2.8 g, 20.3 mmol) were added to the solution. The solution was stirred overnight at room temperature. The reaction solution was diluted with water (50 mL). The mixture was extracted with ethyl acetate (200 mL). The organic layer was washed with brine (100mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Through column chromatography (by volume of CH 2 Cl 2 / MeOH = 100 /1 ~ 50/1) the residue was purified to yield a yellow oil of N- [2- (5- bromo-3-chloro-2 -Tridecyl pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylate (1.5 g, yield: 37.5%).

MS(ESI)：295.0([{79Br}M-Boc+H]+)、296.9([{81Br}M-Boc+H]+)、338.9([{79Br}M-56+H]+)、340.9([{81Br}M-56+H]+)。 MS (ESI): 295.0 ([{ 79 Br}M-Boc+H] + ), 296.9 ([{ 81 Br}M-Boc+H] + ), 338.9 ([{ 79 Br}M-56+H] + ), 340.9 ([{ 81 Br}M-56+H] + ).

f)2-(5-溴-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯f) 2-(5-bromo-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

在室溫下，向N-[2-(5-溴-3-氯-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯(1.5g，3.79mmol)在甲苯(20mL)中之溶液中添加PPh3(1.19g，4.55mmol)及Et3N(957mg，9.47mmol)。然後在0~5℃下添加偶氮羧酸二異丙酯(0.92g，4.55mmol，CAS：2446-83-5)在甲苯(10mL)中之溶液。在室溫下將該溶液攪拌整夜。然後用乙酸乙酯(200mL)稀釋該反應溶液。用水性NaHCO3(100mL×3)及鹽水(100mL×2)清洗該混合物，經Na2SO4乾燥並於減壓下濃縮。透過管柱層析法(以體積計石油醚/乙酸乙酯=20/1~5/1)純化殘餘物，以產生呈白色固體之2-(5-溴-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯(1.0g，產率：70%)。 To the tert-butyl N-[2-(5-bromo-3-chloro-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylate at room temperature ( 1.5 g, 3.79 mmol) PPh 3 (1.19 g, 4.55 mmol) and Et 3 N (957 mg, 9.47 mmol) were added to a solution in toluene (20 mL). A solution of diisopropyl azocarboxylate (0.92 g, 4.55 mmol, CAS: 2446-83-5) in toluene (10 mL) was then added at 0~5 °C. The solution was stirred overnight at room temperature. The reaction solution was then diluted with ethyl acetate (200 mL). Aqueous NaHCO 3 (100mL × 3) and brine (100mL × 2) and the mixture was washed, dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by column chromatography eluting EtOAc (EtOAc:EtOAc: ) morpholine-4-carboxylic acid tert-butyl ester (1.0 g, yield: 70%).

1H NMR(400MHz，甲醇-d4)：δ 8.62(d,J=2Hz,1H)、7.89(d,J=2Hz,1H)、4.89(d,J=10Hz,1H)、4.30~3.8(m,3H)、3.76(m,1H)、3.13(br,2H)、1.49(s,9H)。 1 H NMR (400 MHz, methanol-d 4 ): δ 8.62 (d, J = 2 Hz, 1H), 7.89 (d, J = 2 Hz, 1H), 4.89 (d, J = 10 Hz, 1H), 4.30 to 3.8 ( m, 3H), 3.76 (m, 1H), 3.13 (br, 2H), 1.49 (s, 9H).

g)(RS)-5-氯-N-(5-氯-2-吡啶基)-6-嗎啉-2-基-吡啶-3-胺g)(RS)-5-chloro-N-(5-chloro-2-pyridyl)-6-morpholin-2-yl-pyridin-3-amine

在N2氣氛下，向2-(5-溴-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯(80mg，0.211mmol)及2-胺基-5-氯吡啶(27mg，0.211mmol，CAS：1072-98-6)在二噁烷(1mL)中之溶液中添加Xantphos(4,5-雙(二苯基膦基)-9,9-二甲基呫噸，36.7mg，0.063mmol，CAS：161265-03-8)、Cs2CO3(206.2mg，0.633mmol)及叁(二亞苄基丙酮)二鈀(0)(19.3mg，0.021mmol，CAS：51364-51-3)。在80℃下將該混合物攪拌整夜。然後將該溶液倒入水(100mL)中。用CH2Cl2(150mL×2)萃取該混合物。經Na2SO4乾燥合併之有機層並於減壓下濃縮。將殘餘物溶解於CH2Cl2(1mL)中。然後添加三氟乙酸(1mL)。在室溫下將該溶液攪拌3小時。於減壓下濃縮該反應溶液。透過製備型HPLC(0.5%TFA之CH3CN溶液)純化殘餘物，以產生呈白色固體之(RS)-5-氯-N-(5-氯-2-吡啶基)-6-嗎啉-2-基-吡啶-3-胺(5omg)。 To a solution of 2-(5-bromo-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (80 mg, 0.211 mmol) and 2-amino-5-chloropyridine under N 2 atmosphere (27 mg, 0.211 mmol, CAS: 1072-98-6) Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene was added to a solution in dioxane (1 mL) , 36.7 mg, 0.063 mmol, CAS: 161265-03-8), Cs 2 CO 3 (206.2 mg, 0.633 mmol) and hydrazine (dibenzylideneacetone) dipalladium (0) (19.3 mg, 0.021 mmol, CAS: 51364-51-3). The mixture was stirred overnight at 80 °C. The solution was then poured into water (100 mL). The mixture was extracted with CH 2 Cl 2 (150 mL×2). Over Na 2 SO 4 the combined organic layers were dried and concentrated under reduced pressure. The residue was dissolved in CH 2 Cl 2 (1mL). Then trifluoroacetic acid (1 mL) was added. The solution was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure. Via preparative HPLC (0.5% TFA solution of CH 3 CN) to give the residue, to yield a white solid of (RS) -5- chloro -N- (5- chloropyridin-2-yl) -6-morpholin - 2-yl-pyridin-3-amine (5omg).

1H NMR(400MHz，甲醇-d4)：δ 8.62(dd,2H)、8.21(s,1H)、7.64(dd,1H)、6.87(d,1H)、5.23(dd,1H)、4.11(m,1H)、3.98(m,1H)、3.67(m,1H)、3.49(m,1H)、3.35~3.30(m,2H)。 1 H NMR (400MHz, methanol -d 4): δ 8.62 (dd , 2H), 8.21 (s, 1H), 7.64 (dd, 1H), 6.87 (d, 1H), 5.23 (dd, 1H), 4.11 ( m, 1H), 3.98 (m, 1H), 3.67 (m, 1H), 3.49 (m, 1H), 3.35 to 3.30 (m, 2H).

MS(ESI)：325.1({35Cl}M+H)+、327.0({37Cl}M+H)+。 MS (ESI): 325.1 ({ 35 Cl} M + H) +, 327.0 ({37 Cl} M + H) +.

實例103 Example 103

(RS)-5-氯-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺 (RS)-5-chloro-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

以類似實例102之方式在步驟(g)中使用2-胺基-5-三氟甲基吡啶(CAS：74784-70-6)代替2-胺基-5-氯吡啶獲得標題化合物。白色固體。MS(ESI)：361.0([{37Cl}M+H]+)、359.1([{35Cl}M+H]+)。 The title compound was obtained by substituting 2-amino-5-trifluoromethylpyridine (CAS: 74784-70-6) for 2-amino-5-chloropyridine in step (g). White solid. MS (ESI): 361.0 ([ {37 Cl} M + H] +), 359.1 ([{35 Cl} M + H] +).

實例104 Example 104

(RS)-5-甲基-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺 (RS)-5-methyl-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

a)2-溴-1-(5-溴-3-甲基-2-吡啶基)乙酮a) 2-bromo-1-(5-bromo-3-methyl-2-pyridyl)ethanone

在0℃下，攪拌5-溴-3-甲基吡啶-2-羰基氯(4g，17mmol，CAS：1114809-24-3)在CH3CN(60mL)中之溶液。添加(三甲基甲矽烷基)重氮甲烷(2M之己烷溶液，21mL，42mmol，CAS：18107-18-1)。在室溫下將該混合物攪拌整夜，直至TLC分析顯示初始材料消耗完全。添加HBr(12mL，48%水性溶液)。所得溶液在室溫下攪拌整夜。以飽和水性NaHCO3處理該混合物以將pH調整至約7。分層。用乙酸乙酯(200mL x 2)萃取水性層。用鹽水(200mL)清洗合併之有機層，經硫酸鈉乾燥並於減壓下濃縮。殘餘物(4.5g)無需純化即可用於下一步驟中。 At 0 ℃, stirred for 5-bromo-3-methyl-2-carbonyl chloride (4g, 17mmol, CAS: 1114809-24-3 ) in CH 3 CN (60mL) of solution. (Trimethylmethanealkyl)diazomethane (2M in hexanes, 21 mL, 42 mmol, EtOAc: 18107-18-1). The mixture was stirred overnight at room temperature until TLC analysis showed complete material consumption. HBr (12 mL, 48% aqueous solution) was added. The resulting solution was stirred at room temperature overnight. Treated with saturated aqueous NaHCO 3 the mixture to adjust the pH to about 7. Layered. The aqueous layer was extracted with ethyl acetate (200 mL x 2). The combined organic layers were washed with EtOAc EtOAc m. The residue (4.5 g) was used in the next step without purification.

b)5-溴-3-甲基-2-(環氧乙烷-2-基)吡啶b) 5-bromo-3-methyl-2-(oxiran-2-yl)pyridine

在0℃下，攪拌2-溴-1-(5-溴-3-甲基-2-吡啶基)乙酮(4g，13.7mmol)在EtOH(80mL)中之溶液。添加NaBH4(623mg，16.4mmol)。在室溫下將該混合物攪拌4小時。添加K2CO3(945mg，6.9mmol)。所得溶液在室溫下攪拌整夜。用水(300ml)稀釋該混合物。分層。用EtOAc(300mL x 2)萃取水性層。用鹽水(300mL)清洗合併之有機層，經硫酸鈉乾燥並於減壓下濃縮。該殘餘物無需純化即可用於下一步驟中。 A solution of 2-bromo-1-(5-bromo-3-methyl-2-pyridyl)ethanone (4 g, 13.7 mmol) in EtOAc (EtOAc) NaBH 4 (623 mg, 16.4 mmol) was added. The mixture was stirred at room temperature for 4 hours. K 2 CO 3 (945 mg, 6.9 mmol) was added. The resulting solution was stirred at room temperature overnight. The mixture was diluted with water (300 ml). Layered. The aqueous layer was extracted with EtOAc (300 mL×2). The combined organic layers were washed with EtOAc EtOAc m. This residue was used in the next step without purification.

c)1-(5-溴-3-甲基-2-吡啶基)-2-(2-羥乙基胺基)乙醇c) 1-(5-bromo-3-methyl-2-pyridyl)-2-(2-hydroxyethylamino)ethanol

向5-溴-3-甲基-2-(環氧乙烷-2-基)吡啶(3.5g，16.4mmol)在THF(15mL)中之攪拌溶液中添加2-胺基乙醇(15mL，CAS：41-43-5)。該混合物在室溫下攪拌整夜。然後將該反應混合物倒入THF/EtOAc (1：1，200mL)中並用鹽水(100mL)清洗。經Na2SO4乾燥有機層並濃縮，以產生呈油之粗1-(5-溴-3-甲基-2-吡啶基)-2-(2-羥乙基胺基)乙醇(2.6g，產率：58%)，其無需純化即可用於下一步驟中。 Add 2-aminoethanol (15 mL, CAS) to a stirred solution of 5-bromo-3-methyl-2-(oxiran-2-yl)pyridine (3.5 g, 16.4 mmol) in THF (15 mL) :41-43-5). The mixture was stirred overnight at room temperature. The reaction mixture was then poured into EtOAc / EtOAc (EtOAc,EtOAc) The organic layer was dried over Na 2 SO 4 and concentrated to give an oil of crude 1- (5-bromo-3-methyl-2-pyridyl) -2- (2-hydroxyethyl amino) ethanol (2.6g Yield: 58%) which was used in the next step without purification.

MS(ESI)：277.0([{81Br}M+H]+)、275.0([{79Br}M+H]+)。 MS (ESI): 277.0 ([{ 81 Br}M+H] + ), 275.0 ([{ 79 Br}M+H] + ).

d)N-[2-(5-溴-3-甲基-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯d) N-[2-(5-bromo-3-methyl-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylic acid tert-butyl ester

在室溫下，將1-(5-溴-3-甲基-2-吡啶基)-2-(2-羥乙基胺基)乙醇(2.6g，9.5mmol，粗)、K2CO3(3.0g，22mmol)及(Boc)2O(1.9g，7.3mmol，CAS：24424-99-5)在THF(30mL)中之混合物攪拌12小時。然後用水(200mL)稀釋該混合物並用乙酸乙酯(200mL x 2)萃取。用水(100mL)及鹽水(100mL)清洗合併之有機層並於減壓下濃縮。藉由矽膠層析法之純化產生呈淺黃色油之N-[2-(5-溴-3-甲基-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯(1.31g，產率：37%)。 1-(5-Bromo-3-methyl-2-pyridyl)-2-(2-hydroxyethylamino)ethanol (2.6 g, 9.5 mmol, crude), K 2 CO 3 at room temperature A mixture of (3.0 g, 22 mmol) and (Boc) 2 O (1.9 g, 7.3 mmol, EtOAc: 2424-99-5) The mixture was then diluted with water (200 mL) and extracted with EtOAc EtOAc. The combined organic layers were washed with EtOAcq. Purification by gelatin chromatography to give N-[2-(5-bromo-3-methyl-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl) as a pale yellow oil Third butyl carbamate (1.31 g, yield: 37%).

e)2-(5-溴-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯e) 2-(5-bromo-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

在0℃下，將N-[2-(5-溴-3-甲基-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯(1.3g，3.5mmol)、PPh3(1.02g，4.2mmol)及Et3N(900mg，9mmol)之混合物攪拌10分鐘。滴加偶氮羧酸二異丙酯(848mg，4.2mmol，CAS：2446-83-5)。該反應持續整夜。於減壓下濃縮該混合物。藉由在矽膠上之急驟層析法之純化產生呈灰白色固體之2-(5-溴-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯(600mg，產率：48%)。 N-[2-(5-Bromo-3-methyl-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylic acid tert-butyl ester at 0 ° C A mixture of (1.3 g, 3.5 mmol), PPh 3 (1.02 g, 4.2 mmol) and Et 3 N (900 mg, 9 mmol) was stirred for 10 min. Diisopropyl azocarboxylate (848 mg, 4.2 mmol, CAS: 2446-83-5) was added dropwise. The reaction continued overnight. The mixture was concentrated under reduced pressure. Purification by flash chromatography on silica gel to give 2-(5-bromo-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester as an off-white solid (600 mg, yield :48%).

1H NMR(400MHz，甲醇-d4)：δ 8.46(d,1H)、7.87(d,1H)、4.65(m,1H)、4.11(m,1H)、3.98(m,2H)、3.72(t,1H)、3.32(m,2H)、2.43(s,3H)、1.52(s,9H)。 1 H NMR (400MHz, methanol -d 4): δ 8.46 (d , 1H), 7.87 (d, 1H), 4.65 (m, 1H), 4.11 (m, 1H), 3.98 (m, 2H), 3.72 ( t, 1H), 3.32 (m, 2H), 2.43 (s, 3H), 1.52 (s, 9H).

MS(ESI)：359.0([{81Br}M+H]+)、357.0([{79Br}M+H]+)。 MS (ESI): 359.0 ([{ 81 Br}M+H] + ), 357.0 ([{ 79 Br}M+H] + ).

f)(RS)-5-甲基-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺f) (RS)-5-Methyl-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

在90℃下於N2氣氛下，將2-(5-溴-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯(60mg，0.17mmol)、2-胺基-5-三氟甲基吡啶(26mg，CAS：74784-70-6)、Xantphos(20mg，0.034mmol，CAS：161265-03-8)、Pd2(dba)3(16mg，0.017mmol，CAS：51364-51-3)及Cs2CO3(166mg，0.51mmol)在二噁烷(5mL)中之混合物攪拌12小時。然後用水(100mL)稀釋該混合物並用乙酸乙酯(100mL x 2)萃取。用水(100mL)清洗合併之有機層並於減壓下濃縮。在高真空下進一步乾燥殘餘物。 2-(5-Bromo-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (60 mg, 0.17 mmol), 2-amino group at 90 ° C under N 2 atmosphere 5-5-trifluoromethylpyridine (26 mg, CAS: 74784-70-6), Xantphos (20 mg, 0.034 mmol, CAS: 161265-03-8), Pd 2 (dba) 3 (16 mg, 0.017 mmol, CAS: A mixture of 51364-51-3) and Cs 2 CO 3 (166 mg, 0.51 mmol) in dioxane (5 mL) was stirred for 12 hr. The mixture was then diluted with water (100 mL) and extracted with EtOAc EtOAc. The combined organic layers were washed with water (100 mL) The residue was further dried under high vacuum.

然後將殘餘物溶解於二氯甲烷(2mL)中。添加三乙胺(0.5ml)。所得混合物在室溫下攪拌一小時。於減壓下移除揮發物。矽膠層析法純化產生呈白色固體之(RS)-5-甲基-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺(15mg)。 The residue was then dissolved in dichloromethane (2 mL). Triethylamine (0.5 ml) was added. The resulting mixture was stirred at room temperature for one hour. The volatiles were removed under reduced pressure. Purification by gelatin chromatography gave (RS)-5-methyl-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine as a white solid (15mg).

1H NMR(400MHz，甲醇-d4)：δ 9.05(d,1H)、8.54(s,1H)、8.24(d,1H)、7.89(dd,1H)、7.01(d,1H)、5.21(dd,1H)、4.17(m,1H)、4.04(m,1H)、3.60(m,2H)、3.41(m,1H)、3.34(m,1H)、2.50(s,3H)。 1 H NMR (400MHz, methanol -d 4): δ 9.05 (d , 1H), 8.54 (s, 1H), 8.24 (d, 1H), 7.89 (dd, 1H), 7.01 (d, 1H), 5.21 ( Dd, 1H), 4.17 (m, 1H), 4.04 (m, 1H), 3.60 (m, 2H), 3.41 (m, 1H), 3.34 (m, 1H), 2.50 (s, 3H).

MS(ESI)：339.1(M+H)+。 MS (ESI): 339.1 (M+H) + .

實例105 Example 105

4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺 4-Chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(2,2,2-trifluoroethoxy)-1H-pyrazole-5 -Procarbamide

以類似實例67之方式使用4-氯-5-(2,2,2-三氟乙氧基)-1H-吡唑-3- 羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 4-Chloro-5-(2,2,2-trifluoroethoxy)-1H-pyrazole-3- was used in a similar manner to Example 67. The title compound was obtained by substituting carboxylic acid for 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. White solid.

MS(ESI)：406.1({35Cl}M+H)+、408.1({37Cl}M+H)+。 MS (ESI): 406.1 ({ 35 Cl} M + H) +, 408.1 ({37 Cl} M + H) +.

實例106 Example 106

4-氯-3-乙氧基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-ethoxy-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-氯-5-乙氧基-1H-吡唑-3-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 The title compound was obtained in a similar manner to Example 67 using 4-chloro-5-ethoxy-1H-pyrazole-3-carboxylic acid instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. White solid.

MS(ESI)：352.1({35Cl}M+H)+、354.1({37Cl}M+H)+。 MS (ESI): 352.1 ({ 35 Cl} M + H) +, 354.1 ({37 Cl} M + H) +.

實例107 Example 107

(RS)-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(5-chloro-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

a)2-[5-(二苯亞甲基胺基)-3-氯-2-吡啶基]嗎啉-4-羧酸第三丁酯a) 2-[5-(diphenylmethyleneamino)-3-chloro-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

在N2氣氛下，向2-(5-溴-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯(0.4g，1.057mmol)及二苯甲酮亞胺(191.3mg，1.057mmol，CAS：1013-88-3)在二噁烷(15mL)中之溶液中添加Xantphos(4,5-雙(二苯基膦基)-9,9-二甲基呫噸，183.5mg，0.317mmol，CAS：161265-03-8)、Cs2CO3(1.03g，3.17mmol)及叁(二亞苄基丙酮)二鈀(0)(96.8mg， 0.1mmol，CAS：51364-51-3)。在85℃下將該混合物攪拌整夜。然後過濾該反應混合物。於真空中濃縮濾液，以產生呈黃色油之粗2-[5-(二苯亞甲基胺基)-3-氯-2-吡啶基]嗎啉-4-羧酸第三丁酯(505mg，產率：100%)，其直接用於下一步驟中。 To a solution of 2-(5-bromo-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (0.4 g, 1.057 mmol) and benzophenone imine (191.3) under N 2 atmosphere Mg, 1.057 mmol, CAS: 1013-88-3) Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene was added to a solution in dioxane (15 mL). 183.5 mg, 0.317 mmol, CAS: 161265-03-8), Cs 2 CO 3 (1.03 g, 3.17 mmol) and hydrazine (dibenzylideneacetone) dipalladium (0) (96.8 mg, 0.1 mmol, CAS: 51364) -51-3). The mixture was stirred overnight at 85 °C. The reaction mixture was then filtered. The filtrate was concentrated in vacuo to give crude 2-[5-(diphenylmethyleneamino)-3-chloro-2-pyridinyl]morpholine-4-carboxylic acid tert-butyl ester (505 mg). Yield: 100%) which was used directly in the next step.

b)2-(5-胺基-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯b) 2-(5-Amino-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

向2-[5-(二苯亞甲基胺基)-3-氯-2-吡啶基]嗎啉-4-羧酸第三丁酯(505mg，1.057mmol)在甲醇(10mL)中之溶液中添加乙酸鈉(433.4mg，5.28mmol)及羥胺鹽酸鹽(110.2mg，1.58mmol)。在室溫下將該混合物攪拌2小時。將該溶液倒入水(50mL)中並用CH2Cl2(100mL×2)萃取。經Na2SO4乾燥合併之有機層，於真空中濃縮並透過管柱層析法(以體積計CH2Cl2/甲醇=100/1~50/1)純化，以產生呈黃色固體之2-(5-胺基-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯(270mg，產率：81%)。 To a solution of 2-[5-(diphenylmethyleneamino)-3-chloro-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester (505 mg, 1.057 mmol) in methanol (10 mL) Sodium acetate (433.4 mg, 5.28 mmol) and hydroxylamine hydrochloride (110.2 mg, 1.58 mmol) were added. The mixture was stirred at room temperature for 2 hours. The solution was poured into water (50mL) and extracted with CH 2 Cl 2 (100mL × 2 ). The organic layer was dried over SO 4 merger of Na 2, concentrated and purified through column chromatography (by volume of CH 2 Cl 2 / methanol = 100 / 1-50 / 1) in vacuo to yield a yellow solid of 2 -(5-Amino-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (270 mg, yield: 81%).

MS(ESI)：258.0([{35Cl}M-56+H]+)、314.0([{35Cl}M+H]+)、316.0([{37Cl}M+H]+)、336.0([{35Cl}M+Na]+)。 MS (ESI): 258.0 ([{ 35 Cl}M-56+H] + ), 314.0 ([{ 35 Cl}M+H] + ), 316.0 ([{ 37 Cl}M+H] + ), 336.0 ([{ 35 Cl}M+Na] + ).

c)(RS)-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺c) (RS)-N-(5-chloro-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

向2-(三氟甲基)吡啶-4-羧酸(40mg，0.21mmol，CAS：131747-41-6)在DMF(1mL)中之溶液中添加HATU(79.7mg，0.21mmol，CAS：148893-10-1)、二異丙基乙基胺(73.7mg，0.57mmol)及2-(5-胺基-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯(60mg，0.19mmol)。在室溫下將該溶液攪拌整夜。然後用CH2Cl2(50mL)稀釋該反應混合物。用鹽水(50mL×2)清洗該溶液，經Na2SO4乾燥並在真空下濃縮。將殘餘物溶解於CH2Cl2(1mL)及三氟乙酸(1mL)中。在室溫下將該溶液攪拌2小時。在真空下濃縮該反應溶液。透過製備型HPLC(0.5%三氟乙酸之CH3CN溶液)純化殘餘物，以產生呈白色固體之(RS)-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺(11mg)。 Add HATU (79.7 mg, 0.21 mmol, CAS: 148893) to a solution of 2-(trifluoromethyl)pyridine-4-carboxylic acid (40 mg, 0.21 mmol, CAS: 131747-41-6) in DMF (1 mL) -10-1), diisopropylethylamine (73.7 mg, 0.57 mmol) and 2-(5-amino-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester ( 60 mg, 0.19 mmol). The solution was stirred overnight at room temperature. The reaction mixture was then diluted with CH 2 Cl 2 (50mL). The solution was washed with brine (50mL × 2), concentrated in vacuo and dried over Na 2 SO 4. The residue was dissolved in CH 2 Cl 2 (1mL) and trifluoroacetic acid (1 mL) in. The solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under vacuum. Via preparative HPLC (0.5% trifluoroacetic acid solution of CH 3 CN) to give the residue, to yield a white solid of (RS) -N- (5- chloro-6-morpholin-2-yl-3-pyridyl -2-(Trifluoromethyl)pyridine-4-carboxamide (11 mg).

1H NMR(400MHz，甲醇-d4)：δ 8.95(d,1H)、8.90(d,1H)、8.50(d,1H)、8.34(s,1H)、8.15(m,1H)、5.28(dd,1H)、4.07(m,1H)、4.01(m,1H)、3.72(m,1H)、3.56(m,1H)、3.36~3.30(m,2H)。 1 H NMR (400MHz, methanol -d 4): δ 8.95 (d , 1H), 8.90 (d, 1H), 8.50 (d, 1H), 8.34 (s, 1H), 8.15 (m, 1H), 5.28 ( Dd, 1H), 4.07 (m, 1H), 4.01 (m, 1H), 3.72 (m, 1H), 3.56 (m, 1H), 3.36 to 3.30 (m, 2H).

MS(ESI)：387.1([{35Cl}M+H]+)、389.1([{37Cl}M+H]+)。 MS (ESI): 387.1 ([{ 35 Cl}M+H] + ), 389.1 ([{ 37 Cl}M+H] + ).

實例108 Example 108

(RS)-4-氯-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(5-chloro-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

以類似實例107之方式在步驟(c)中使用4-氯-5-丙基-1H-吡唑-3-羧酸(CAS：1340578-20-2)代替2-(三氟甲基)吡啶-4-羧酸獲得標題化合物。白色固體。MS(ESI)：386.1([{37Cl}M+H]+)、384.1([{35Cl}M+H]+)。 In a similar manner to Example 107, in the step (c), 4-chloro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 1340578-20-2) was used instead of 2-(trifluoromethyl)pyridine. The 4-carboxylic acid gave the title compound. White solid. MS (ESI): 386.1 ([ {37 Cl} M + H] +), 384.1 ([{35 Cl} M + H] +).

實例109 Example 109

(RS)-1-(5-氯-6-嗎啉-2-基-3-吡啶基)-3-(3-氯苯基)脲 (RS)-1-(5-chloro-6-morpholin-2-yl-3-pyridyl)-3-(3-chlorophenyl)urea

向2-(5-胺基-3-氯-2-吡啶基)嗎啉-4-羧酸第三丁酯(60mg，0.19mmol)在CH2Cl2(1mL)中之溶液中添加三乙胺(38.4mg，0.38mmol)及異氰酸3-氯苯酯(29.2mg，0.19mmol，CAS：2909-38-8)。在室溫下將該溶液攪拌整夜。用CH2Cl2(50mL)稀釋該反應溶液，用鹽水(50 mL×2)清洗，經Na2SO4乾燥並在真空下乾燥。將殘餘物溶解於CH2Cl2(1mL)及三氟乙酸(1mL)之混合物中。在室溫下將該溶液攪拌2小時。於減壓下移除揮發物。透過製備型HPLC(0.5%三氟乙酸之CH3CN溶液)純化殘餘物，以產生呈白色固體之標題化合物(20mg)。 Add to the solution of 2-(5-amino-3-chloro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (60 mg, 0.19 mmol) in CH 2 Cl 2 (1 mL) Amine (38.4 mg, 0.38 mmol) and 3-chlorophenyl isocyanate (29.2 mg, 0.19 mmol, CAS: 2909-38-8). The solution was stirred overnight at room temperature. The reaction solution was diluted with CH 2 Cl 2 (50mL), washed with brine (50 mL × 2), dried over Na 2 SO 4 and dried under vacuum. The residue was dissolved in a mixture of CH 2 Cl 2 (1 mL) and trifluoroacetic acid (1 mL) of the. The solution was stirred at room temperature for 2 hours. The volatiles were removed under reduced pressure. Via preparative HPLC (0.5% trifluoroacetic acid solution of CH 3 CN) to give the residue, to give the title compound (20mg) as a white solids.

1H NMR(400MHz，甲醇-d4)：δ 8.58(s,1H)、8.25(s,1H)、7.67(s,1H)、7.31~7.27(m,2H)、7.08~7.06(m,1H)、5.27~5.24(dd,J=12Hz,1H)、4.10~4.00(m,1H)、4.99~3.98(m,1H)、3.71~3.68(m,1H)、3.55~3.54(m,1H)、3.36~3.30(m,2H)。 1 H NMR (400 MHz, methanol-d 4 ): δ 8.58 (s, 1H), 8.25 (s, 1H), 7.67 (s, 1H), 7.31 to 7.27 (m, 2H), 7.08 to 7.06 (m, 1H) ), 5.27~5.24 (dd, J=12Hz, 1H), 4.10~4.00(m,1H), 4.99~3.98(m,1H), 3.71~3.68(m,1H), 3.55~3.54(m,1H) , 3.36~3.30 (m, 2H).

用於化合物RW-04-035-05之LCMS：MS(ESI)：367.1({35Cl}M+H)+、369.0({37Cl}M+H)+。 LCMS for the compound RW-04-035-05: MS (ESI): 367.1 ({35CI}M+H)+, 369.0 ({37Cl}M+H)+.

實例110 Example 110

(RS)-N-(5-氯-2-吡啶基)-5-氟-6-嗎啉-2-基-吡啶-3-胺 (RS)-N-(5-chloro-2-pyridinyl)-5-fluoro-6-morpholin-2-yl-pyridin-3-amine

a)2-溴-1-(5-溴-3-氟-2-吡啶基)乙酮a) 2-bromo-1-(5-bromo-3-fluoro-2-pyridyl)ethanone

在室溫下，向1-(5-溴-3-氟吡啶-2-基)乙酮(5.5g，25.2mmol，CAS：1160936-52-6)在乙酸(30mL)中之溶液中添加氫溴酸溶液(33重量%之乙酸溶液，30mL)及吡咯啶酮氫三溴化物(8.4g，26.4mmol，CAS：22580-55-8)。在室溫下將該溶液攪拌整夜。於減壓下濃縮該溶液。用乙酸乙酯(800mL)稀釋殘餘物。藉由過濾收集沉澱物並在高真空下乾燥，以產生呈HBr鹽之2-溴-1-(5-溴-3-氟-2-吡啶基)乙酮(7.52g，產率：79%)。 Adding hydrogen to a solution of 1-(5-bromo-3-fluoropyridin-2-yl)ethanone (5.5 g, 25.2 mmol, CAS: 1160936-52-6) in acetic acid (30 mL) at room temperature Bromic acid solution (33% by weight acetic acid solution, 30 mL) and pyrrolidone hydrogen tribromide (8.4 g, 26.4 mmol, CAS: 22580-55-8). The solution was stirred overnight at room temperature. The solution was concentrated under reduced pressure. The residue was diluted with ethyl acetate (800 mL). The precipitate was collected by filtration and dried under high vacuum to give 2-bromo-1-(5-bromo-3-fluoro-2-pyridyl)ethanone as a HBr salt (7.52 g, yield: 79%) ).

b)5-溴-3-氟-2-(環氧乙烷-2-基)吡啶b) 5-bromo-3-fluoro-2-(oxiran-2-yl)pyridine

在0~5℃下，向2-溴-1-(5-溴-3-氟-2-吡啶基)乙酮(7.52g，20 mmol，HBr鹽)在乙醇(140mL)中之溶液中添加NaBH4(910mg，24mmol)。然後在室溫下將該溶液攪拌一小時。添加乙醇鈉(660mg，10mmol)。在室溫下將該溶液攪拌整夜。將該反應溶液倒入水(100mL)中並用乙酸乙酯(100mL x 3)萃取。用鹽水(200mL)清洗合併之有機層，經Na2SO4乾燥並在真空中濃縮，以產生呈黃色油之5-溴-3-氟-2-(環氧乙烷-2-基)吡啶(4.4g，產率：100%)。其直接用於下一步驟中。 Add to a solution of 2-bromo-1-(5-bromo-3-fluoro-2-pyridyl)ethanone (7.52 g, 20 mmol, HBr salt) in ethanol (140 mL) at 0~5 °C NaBH 4 (910 mg, 24 mmol). The solution was then stirred at room temperature for one hour. Sodium ethoxide (660 mg, 10 mmol) was added. The solution was stirred overnight at room temperature. The reaction solution was poured into water (100 mL) and extracted with ethyl acetate (100 mL×3). Combined organic layers were washed with brine (200 mL), dried over Na 2 SO 4 and concentrated in vacuo to yield as a yellow oil of 5- bromo-3-fluoro-2- (oxiran-2-yl) pyridine (4.4 g, yield: 100%). It is used directly in the next step.

MS(ESI)：219.9([{81Br}M+H]+)、217.9([{79Br}M+H]+)。 MS (ESI): 219.9 ([{ 81 Br}M+H] + ), 217.9 ([{ 79 Br}M+H] + ).

c)1-(5-溴-3-氟-2-吡啶基)-2-(2-羥乙基胺基)乙醇c) 1-(5-bromo-3-fluoro-2-pyridyl)-2-(2-hydroxyethylamino)ethanol

向5-溴-3-氟-2-(環氧乙烷-2-基)吡啶(4.8g，22.12mmol)在THF(20mL)中之溶液中添加2-胺基乙醇(10mL，CAS：41-43-5)。在室溫下將該溶液攪拌整夜。用乙酸乙酯(200mL)稀釋該反應溶液。用鹽水(100mL)清洗有機層，經Na2SO4乾燥並在真空中濃縮，以產生呈黃色固體之粗1-(5-溴-3-氟-2-吡啶基)-2-(2-羥乙基胺基)乙醇(5.0g，產率：81%)，其直接用於下一步驟中。 Add 2-aminoethanol (10 mL, CAS: 41) to a solution of 5-bromo-3-fluoro-2-(oxiran-2-yl)pyridine (4.8 g, 22.12 mmol) in THF (20 mL) -43-5). The solution was stirred overnight at room temperature. The reaction solution was diluted with ethyl acetate (200 mL). The organic layer was washed with brine (100 mL), dried over Na 2 SO 4 and concentrated in vacuo to yield a yellow solid of crude 1- (5-bromo-3-fluoro-2-pyridyl) -2- (2- Hydroxyethylamino)ethanol (5.0 g, yield: 81%) which was used directly in the next step.

d)N-[2-(5-溴-3-氟-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯d) N-[2-(5-bromo-3-fluoro-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylic acid tert-butyl ester

向1-(5-溴-3-氟-2-吡啶基)-2-(2-羥乙基胺基)乙醇(5.0g，17.9mmol)在THF(50mL)及H2O(30mL)之混合物中之溶液中添加二碳酸二第三丁酯(5.8g，26.9mmol，CAS：24424-99-5)及K2CO3(4.9g，36mmol)。在室溫下將該溶液攪拌整夜。用水(50mL)稀釋該反應溶液。用乙酸乙酯(100mL x 2)萃取該混合物。用鹽水(100mL)清洗合併之有機層，經Na2SO4乾燥並於減壓下濃縮。透過矽膠管柱層析法(以體積計CH2Cl2/MeOH=100/1~50/1)純化殘餘物，以產生呈黃色油之N-[2-(5-溴-3-氟-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯(5.2g，產率：77%)。 1- (5-bromo-3-fluoro-2-pyridyl) -2- (2-hydroxyethyl amino) ethanol (5.0g, 17.9mmol) in THF (50mL) and H 2 O (30mL) of Di-tert-butyl dicarbonate (5.8 g, 26.9 mmol, CAS: 24424-99-5) and K 2 CO 3 (4.9 g, 36 mmol) were added to the solution in the mixture. The solution was stirred overnight at room temperature. The reaction solution was diluted with water (50 mL). The mixture was extracted with ethyl acetate (100 mL x 2). Combined organic layers were washed with brine (100mL), dried over Na 2 SO 4 and concentrated under reduced pressure. As a yellow oil ratio through silica gel column chromatography (by volume of CH 2 Cl 2 / MeOH = 100 /1 ~ 50/1) the residue was purified to yield N- [2- (5- bromo-3-fluoro - T-butyl 2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylate (5.2 g, yield: 77%).

MS(ESI)：278.9([{79Br}M-Boc+H]+)、280.9([{81Br}M- Boc+H]+)。 MS (ESI): 278.9 ([{ 79 Br}M-Boc+H] + ), 280.9 ([{ 81 Br}M- Boc+H] + ).

e)2-(5-溴-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯e) 2-(5-bromo-3-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

在室溫下，向N-[2-(5-溴-3-氟-2-吡啶基)-2-羥基-乙基]-N-(2-羥乙基)胺甲酸第三丁酯(5.2g，13.7mmol)在甲苯(100mL)中之溶液中添加PPh3(4.3g，16.4mmol)及Et3N(3.46g，34.25mmol)。然後在0~5℃下添加DIAD(3.32g，16.4mmol)在甲苯(30mL)中之溶液。在室溫下將該溶液攪拌整夜。用水(100mL)稀釋該反應溶液並用乙酸乙酯(100mL x 2)萃取。用水性NaHCO3(100mL x 3)及鹽水(100mL x 2)清洗合併之有機層，經Na2SO4乾燥並於減壓下濃縮。透過矽膠管柱層析法(以體積計石油醚/乙酸乙酯=20/1~5/1)純化殘餘物，以產生呈白色固體之2-(5-溴-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯(3.2g，產率：65%)。 To the tert-butyl N-[2-(5-bromo-3-fluoro-2-pyridyl)-2-hydroxy-ethyl]-N-(2-hydroxyethyl)aminecarboxylate at room temperature ( 5.2g, 13.7mmol) was added PPh in toluene (100 mL) in a solution of 3 (4.3g, 16.4mmol) and Et 3 N (3.46g, 34.25mmol) . A solution of DIAD (3.32 g, 16.4 mmol) in toluene (30 mL) was then added at 0~5 °C. The solution was stirred overnight at room temperature. The reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (100 mL). Aqueous NaHCO 3 (100mL x 3) and brine (100mL x 2) The combined organic layer was washed, dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by EtOAc EtOAc (EtOAc:EtOAc:EtOAc Tert-butyl morpholine-4-carboxylic acid (3.2 g, yield: 65%).

MS(ESI)：361.0([{79Br}M+H]+)、363.0([{81Br}M+H]+)。 MS (ESI): 361.0 ([{ 79 Br}M+H] + ), 363.0 ([{ 81 Br}M+H] + ).

f)(RS)-N-(5-氯-2-吡啶基)-5-氟-6-嗎啉-2-基-吡啶-3-胺f) (RS)-N-(5-chloro-2-pyridinyl)-5-fluoro-6-morpholin-2-yl-pyridin-3-amine

在N2氣氛下，向2-(5-溴-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯(80mg，0.221mmol)及2-胺基-5-氯吡啶(28.4mg，0.221mmol，CAS：1072-98-6)在二噁烷(1mL)中之溶液中添加Xantphos(4,5-雙(二苯基膦基)-9,9-二甲基呫噸，38.4mg，0.066mmol，CAS：161265-03-8)、Cs2CO3(216mg，0.663mmol)及叁(二亞苄基丙酮)二鈀(0)(20mg，0.022mmol，CAS：51364-51-3)。在80℃下將該混合物攪拌整夜。然後將該溶液倒入水(100mL)中。用CH2Cl2(150mL×2)萃取該混合物。經Na.2SO4乾燥合併之有機層並於減壓下濃縮。將殘餘物溶解於CH2Cl2(1mL)中。然後添加三氟乙酸(1mL)。在室溫下將該溶液攪拌3小時。於減壓下濃縮該反應溶液。透過製備型HPLC(0.5%TFA之CH3CN溶液)純化殘餘物，以產生呈白色固體之(RS)-N-(5-氯-2-吡啶基)-5-氟-6-嗎啉-2-基-吡啶-3-胺(44mg)。 To a solution of 2-(5-bromo-3-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (80 mg, 0.221 mmol) and 2-amino-5-chloropyridine under N 2 atmosphere (28.4 mg, 0.221 mmol, CAS: 1072-98-6) Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylhydrazine) was added to a solution in dioxane (1 mL). Tons, 38.4 mg, 0.066 mmol, CAS: 161265-03-8), Cs 2 CO 3 (216 mg, 0.663 mmol) and hydrazine (dibenzylideneacetone) dipalladium (0) (20 mg, 0.022 mmol, CAS: 51364) -51-3). The mixture was stirred overnight at 80 °C. The solution was then poured into water (100 mL). The mixture was extracted with CH 2 Cl 2 (150 mL×2). Over Na. 2 SO 4 organic layers were dried and concentrated under reduced pressure, and the. The residue was dissolved in CH 2 Cl 2 (1mL). Then trifluoroacetic acid (1 mL) was added. The solution was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure. Via preparative HPLC (0.5% TFA solution of CH 3 CN) to give the residue, to yield a white solid of (RS) -N- (5- chloropyridin-2-yl) -5-fluoro-6-morpholino - 2-Base-pyridin-3-amine (44 mg).

1H NMR(400MHz，甲醇-d4)：δ 8.45(m,2H)、8.22(d,1H)、7.64(dd,1H)、6.88(d,1H)、5.12(m,1H)、4.12(m,1H)、3.98(m,1H)、3.67(m,1H)、3.48(m,1H)、3.33(m,1H)、3.31(m,1H)。 1 H NMR (400MHz, methanol -d 4): δ 8.45 (m , 2H), 8.22 (d, 1H), 7.64 (dd, 1H), 6.88 (d, 1H), 5.12 (m, 1H), 4.12 ( m, 1H), 3.98 (m, 1H), 3.67 (m, 1H), 3.48 (m, 1H), 3.33 (m, 1H), 3.31 (m, 1H).

MS(ESI)：308.9([{35Cl}M+H]+)、310.9([{37Cl}M+H]+)。 MS (ESI): 308.9 ([{ 35 Cl}M+H] + ), 310.9 ([{ 37 Cl}M+H] + ).

實例111 Example 111

(RS)-5-氟-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺 (RS)-5-fluoro-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine

以類似實例110之方式在步驟(f)中使用2-胺基-5-三氟甲基吡啶(CAS：74784-70-6)代替2-胺基-5-氯吡啶獲得標題化合物。白色固體。 The title compound was obtained by substituting 2-amino-5-trifluoromethylpyridine (CAS: 74784-70-6) for 2-amino-5-chloropyridine in step (f). White solid.

MS(ESI)：343.0(M+H)+。 MS (ESI): 343.0 (M+H) + .

實例112 Example 112

(RS)-1-(3-氯苯基)-3-(5-氟-6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(3-chlorophenyl)-3-(5-fluoro-6-morpholin-2-yl-3-pyridyl)urea

a)2-[5-(二苯亞甲基胺基)-3-氟-2-吡啶基]嗎啉-4-羧酸第三丁酯a) 2-[5-(diphenylmethyleneamino)-3-fluoro-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

在N2氣氛下，向2-(5-溴-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯(0.6g，1.66mmol)及二苯甲酮亞胺(300mg，1.66mmol，CAS：1013-88-3)在二噁烷(30mL)中之溶液中添加Xantphos(4,5-雙(二苯基膦基)-9,9-二甲基呫噸，288mg，0.5mmol，CAS：161265-03-8)、Cs2CO3(1.62g，4.98mmol)及叁(二亞苄基丙酮)二鈀(0)(152mg，0.166mmol， CAS：51364-51-3)。在85℃下將該混合物攪拌整夜。然後過濾該反應混合物。於真空下濃縮濾液以產生呈黃色油之粗2-[5-(二苯亞甲基胺基)-3-氟-2-吡啶基]嗎啉-4-羧酸第三丁酯(766mg，產率：100%)，其直接用於下一步驟中。 To a solution of 2-(5-bromo-3-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (0.6 g, 1.66 mmol) and benzophenone imine (300 mg under N 2 atmosphere) , 1.66 mmol, CAS: 1013-88-3) Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 288 mg) in dioxane (30 mL) , 0.5 mmol, CAS: 161265-03-8), Cs 2 CO 3 (1.62 g, 4.98 mmol) and hydrazine (dibenzylideneacetone) dipalladium (0) (152 mg, 0.166 mmol, CAS: 51364-51- 3). The mixture was stirred overnight at 85 °C. The reaction mixture was then filtered. The filtrate was concentrated in vacuo to give crude <RTIgt; 2-[5-(diphenylmethyleneamino)-3-fluoro-2-pyridinyl]morpholine-4-carboxylic acid tert-butyl ester (766 mg, Yield: 100%) which was used directly in the next step.

b)2-(5-胺基-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯b) 2-(5-Amino-3-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

向2-[5-(二苯亞甲基胺基)-3-氟-2-吡啶基]嗎啉-4-羧酸第三丁酯(766mg，1.66mmol)在甲醇(20mL)中之溶液中添加乙酸鈉(681mg，8.3mmol)及羥胺鹽酸鹽(173mg，2.5mmol)。在室溫下將該混合物攪拌2小時。將該溶液倒入水(50mL)中並用CH2Cl2(100mL×2)萃取。經Na2SO4乾燥合併之有機層，於真空下濃縮並透過管柱層析法(以體積計CH2Cl2/甲醇=100/1~50/1)純化以產生呈黃色固體之2-(5-胺基-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯(350mg，產率：71%)。 To a solution of 2-[5-(diphenylmethyleneamino)-3-fluoro-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester (766 mg, 1.66 mmol) in methanol (20 mL) Sodium acetate (681 mg, 8.3 mmol) and hydroxylamine hydrochloride (173 mg, 2.5 mmol) were added. The mixture was stirred at room temperature for 2 hours. The solution was poured into water (50mL) and extracted with CH 2 Cl 2 (100mL × 2 ). SO 4 by the combined organic layers were dried Na 2, concentrated in vacuo and purified via column chromatography (volume of CH 2 Cl 2 / methanol = 100/1 ~ 50/1) to give a yellow solid of 2- (5-Amino-3-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (350 mg, yield: 71%).

MS(ESI)：242.0(M-56+H)+、298.0(M+H)+。 MS (ESI): 242.0 (M -56 + H) +, 298.0 (M + H) +.

c)(RS)-1-(3-氯苯基)-3-(5-氟-6-嗎啉-2-基-3-吡啶基)脲c) (RS)-1-(3-chlorophenyl)-3-(5-fluoro-6-morpholin-2-yl-3-pyridyl)urea

向2-(5-胺基-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯(70mg，0.235mmol)在二氯甲烷(1mL)中之溶液中添加Et3N(48mg，0.47mmol)及異氰酸3-氯苯酯(36mg，0.24mmol，CAS：2909-38-8)。在室溫下將該溶液攪拌整夜。用二氯甲烷(50mL)稀釋該反應溶液。然後用鹽水(50mL×2)清洗該溶液，經Na2SO4乾燥，於減壓下濃縮，並在高真空下乾燥。將殘餘物溶解於二氯甲烷(1mL)及三氟乙酸(1mL)中。在室溫下將該溶液攪拌2小時。於減壓下濃縮該反應溶液。透過製備型HPLC(0.5%TFA之CH3CN溶液)純化殘餘物，以產生呈白色固體之(RS)-1-(3-氯苯基)-3-(5-氟-6-嗎啉-2-基-3-吡啶基)脲(52mg)。 Add Et 3 N to a solution of 2-(5-amino-3-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (70 mg, 0.235 mmol) in dichloromethane (1 mL) (48 mg, 0.47 mmol) and 3-chlorophenyl isocyanate (36 mg, 0.24 mmol, CAS: 2909-38-8). The solution was stirred overnight at room temperature. The reaction solution was diluted with dichloromethane (50 mL). Then washed with brine (50mL × 2) The solution, dried over Na 2 SO 4, concentrated under reduced pressure, and dried under high vacuum. The residue was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (1 mL). The solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. Via preparative HPLC (0.5% TFA solution of CH 3 CN) to give the residue, to yield a white solid of (RS) -1- (3- chlorophenyl) -3- (5-fluoro-6-morpholino - 2-yl-3-pyridyl)urea (52 mg).

1H NMR(400MHZ，甲醇-d4)：δ 8.41(s,1H)、8.06(dd,1H)、7.67(s,1H)、7.29(m,2H)、7.05(m,1H)、5.13(dd,1H)、4.12(m,1H)、3.98(m,1H)、3.69(m,1H)、3.51(dd,1H)、3.35~3.30(m, 2H)。 1 H NMR (400 MHZ, methanol-d 4 ): δ 8.41 (s, 1H), 8.06 (dd, 1H), 7.67 (s, 1H), 7.29 (m, 2H), 7.05 (m, 1H), 5.13 ( Dd, 1H), 4.12 (m, 1H), 3.98 (m, 1H), 3.69 (m, 1H), 3.51 (dd, 1H), 3.35 to 3.30 (m, 2H).

MS(ESI)：351.1([{35Cl}M+H]+)、353.1([{37Cl}M+H]+)。 MS (ESI): 351.1 ([{ 35 Cl}M+H] + ), 353.1 ([{ 37 Cl}M+H] + ).

實例113 Example 113

(RS)-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(5-fluoro-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

向2-(三氟甲基)吡啶-4-羧酸(57mg，0.30mmol，CAS：131747-41-6)在DMF(1mL)中之溶液中添加HATU(112.2mg，0.295mmol，CAS：148893-10-1)、N,N-二異丙基乙胺(104mg，0.804mmol，CAS：7087-68-5)及2-(5-胺基-3-氟-2-吡啶基)嗎啉-4-羧酸第三丁酯(80mg，0.27mmol)。在室溫下將該溶液攪拌整夜。用二氯甲烷(50mL)稀釋該反應混合物。然後用水(50mL)及鹽水(50mL)清洗該溶液，經Na2SO4乾燥，於減壓下濃縮並在高真空下乾燥。將殘餘物溶解於二氯甲烷(1mL)及三氟乙酸(1mL)中。在室溫下將該溶液攪拌2小時。於減壓下濃縮該反應溶液。透過製備型HPLC(0.5%TFA之CH3CN溶液)純化殘餘物，以產生呈白色固體之(RS)-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺(10mg)。 Add HATU (112.2 mg, 0.295 mmol, CAS: 148893) to a solution of 2-(trifluoromethyl)pyridine-4-carboxylic acid (57 mg, 0.30 mmol, CAS: 131747-41-6) in DMF (1 mL) -10-1), N,N-diisopropylethylamine (104 mg, 0.804 mmol, CAS: 7807-68-5) and 2-(5-amino-3-fluoro-2-pyridyl)morpholine 4-carboxylic acid tert-butyl ester (80 mg, 0.27 mmol). The solution was stirred overnight at room temperature. The reaction mixture was diluted with dichloromethane (50 mL). Then washed with water (50mL) and brine (50mL) and the solution washed, dried over Na 2 SO 4, concentrated under reduced pressure and dried under high vacuum. The residue was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (1 mL). The solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. Via preparative HPLC (0.5% TFA solution of CH 3 CN) to give the residue, to yield a white solid of (RS) -N- (5- fluoro-6-morpholin-2-yl-3-pyridyl) - 2-(Trifluoromethyl)pyridine-4-carboxamide (10 mg).

1H NMR(400MHz，甲醇-d4)：δ 8.94(d,1H)、8.77(d,1H)、8.34~8.30(m,2H)、8.15(d,1H)、5.19(dd,1H)、4.14(m,1H)、4.06(m,1H)、3.71(m,1H)、3.55(m,1H)、3.36~3.30(m,2H)。 1 H NMR (400 MHz, methanol-d 4 ): δ 8.94 (d, 1H), 8.77 (d, 1H), 8.34 to 8.30 (m, 2H), 8.15 (d, 1H), 5.19 (dd, 1H), 4.14 (m, 1H), 4.06 (m, 1H), 3.71 (m, 1H), 3.55 (m, 1H), 3.36 to 3.30 (m, 2H).

MS(ESI)：393.0(M+Na)+、371.0(M+H)+。 MS (ESI): 393.0 (M + Na) +, 371.0 (M + H) +.

實例114 Example 114

(RS)-4-氯-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲 醯胺 (RS)-4-chloro-N-(5-fluoro-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5- Guanamine

以類似實例113之方式使用4-氯-5-丙基-1H-吡唑-3-羧酸(CAS：1340578-20-2)代替2-(三氟甲基)吡啶-4-羧酸獲得標題化合物。白色固體。MS(ESI)：370.0([{37Cl}M+H]+)、368.0([{35Cl}M+H]+)。 In a similar manner to Example 113, 4-chloro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 1340578-20-2) was used instead of 2-(trifluoromethyl)pyridine-4-carboxylic acid. Title compound. White solid. MS (ESI): 370.0 ([ {37 Cl} M + H] +), 368.0 ([{35 Cl} M + H] +).

實例115 Example 115

4-氯-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-氯-5-丙烷-2-基-2H-吡唑-3-羧酸(CAS：1291271-55-0)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 66, 4-chloro-5-propan-2-yl-2H-pyrazole-3-carboxylic acid (CAS: 1291271-55-0) was used instead of 3-ethyl-4-methyl-1H- The title compound was obtained as the pyrazole-5-carboxylic acid. White solid.

MS(ESI)：350.0({35Cl}M+H)+、352.0({37Cl}M+H)+。 MS (ESI): 350.0 ({ 35 Cl} M + H) +, 352.0 ({37 Cl} M + H) +.

實例116 Example 116

4-氟-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

a)4-氟-3-異丙基-1H-吡唑-5-羧酸乙酯a) ethyl 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxylate

在0℃下，向3-異丙基-1H-吡唑-5-羧酸乙酯(5.0g，0.027mmol，CAS：78208-72-7)在CH3CN(300mL)中之溶液中添加Selectfluor®(12.7g，35.7mmol，CAS：140681-55-6)。然後將該溶液加熱至70℃。持續攪拌15小時。使該反應溶液冷卻至室溫並於減壓下濃縮。用水性HCl(3N，200mL)稀釋殘餘物並用二氯甲烷(100mL x 2)萃取。用鹽水(50mL)清洗合併之有機層，經Na2SO4乾燥並於減壓下濃縮。透過矽膠管柱層析法(以體積計二氯甲烷/MeOH=200/1~100/1)之純化產生呈黃色油之4-氟-3-異丙基-1H-吡唑-5-羧酸乙酯(900mg，產率：17%)。 At 0 ℃, to -1H- pyrazole-3-isopropyl-5-carboxylate (5.0g, 0.027mmol, CAS: 78208-72-7 ) was added at the 3 CN (300mL) solution in CH Selectfluor® (12.7 g, 35.7 mmol, CAS: 140681-55-6). The solution was then heated to 70 °C. Stirring was continued for 15 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with aqueous HCl (3N,EtOAc) Combined organic layers were washed with brine (50mL), dried over Na 2 SO 4 and concentrated under reduced pressure. Purification by gel column chromatography (dichloromethane/MeOH = 200/1~100/1) afforded 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxy as a yellow oil. Ethyl acetate (900 mg, yield: 17%).

MS(ESI)：223.1(M+Na)+、201.1(M+H)+。 MS (ESI): 223.1 (M + Na) +, 201.1 (M + H) +.

b)4-氟-3-異丙基-1H-吡唑-5-羧酸b) 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxylic acid

在0℃下，向4-氟-3-異丙基-1H-吡唑-5-羧酸乙酯(900mg，4.49mmol)在THF/MeOH(10/10mL)中之溶液中添加1M aq NaOH(9mL，9mmol)。然後將該溶液回流3小時。將該反應溶液倒入水中。用濃縮HCl將pH調整至1。用乙酸乙酯(100mL x 2)萃取該混合物。用鹽水清洗合併之有機層並在真空下濃縮。自乙酸乙酯(10mL)中再結晶殘餘物以產生呈白色固體之4-氟-3-異丙基-1H-吡唑-5-羧酸(450mg，產率：58%)。 Add 1 M aq NaOH to a solution of ethyl 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxylate (900 mg, 4.49 mmol) in THF / MeOH (10 mL) (9 mL, 9 mmol). The solution was then refluxed for 3 hours. The reaction solution was poured into water. The pH was adjusted to 1 with concentrated HCl. The mixture was extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with brine and concentrated in vacuo. The residue was recrystallized from ethyl acetate (10 mL) toield of 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxylic acid (450 mg, yield: 58%).

1H NMR(400MHz，甲醇-d4)：δ 3.08(m,1H)、1.32(d,6H)。 1 H NMR (400 MHz, methanol-d 4 ): δ 3.08 (m, 1H), 1.32 (d, 6H).

MS(ESI)：173.1(M+H)+。 MS (ESI): 173.1 (M + H) + .

c)4-氟-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺c) 4-fluoro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例66之方式使用4-氟-3-異丙基-1H-吡唑-5-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 The title compound was obtained in a similar manner to Example 66 using 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxylic acid instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. White solid.

1H NMR(400MHz，甲醇-d4)：δ 8.93(d,1H)、8.27(dd,1H)、7.59(d,1H)、4.87(m,1H)、4.24(dd,1H)、4.01(t,1H)、3.67(d,1H)、3.34(m,1H)、3.30(m,2H)、3.11(m,1H)、1.35(d,6H)。 1 H NMR (400MHz, methanol -d 4): δ 8.93 (d , 1H), 8.27 (dd, 1H), 7.59 (d, 1H), 4.87 (m, 1H), 4.24 (dd, 1H), 4.01 ( t, 1H), 3.67 (d, 1H), 3.34 (m, 1H), 3.30 (m, 2H), 3.11 (m, 1H), 1.35 (d, 6H).

MS(ESI)：334.1(M+H)+。 MS (ESI): 334.1 (M+H) + .

實例117 Example 117

(RS)-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺 (RS)-N-(5-methyl-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

a)2-[5-(二苯亞甲基胺基)-3-甲基-2-吡啶基]嗎啉-4-羧酸第三丁酯a) 2-[5-(diphenylmethyleneamino)-3-methyl-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester

在N2氣氛下，向2-(5-溴-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯(0.28g，0.78mmol)及二苯甲酮亞胺(156mg，0.86mmol，CAS：1013-88-3)在二噁烷(20mL)中之溶液中添加Xantphos(4,5-雙(二苯基膦基)-9,9-二甲基呫噸，90mg，0.156mmol，CAS：161265-03-8)、Cs2CO3(0.77g，2.34mmol)及叁(二亞苄基丙酮)二鈀(0)(72mg，0.078mmol，CAS：51364-51-3)。在90℃下將該混合物攪拌12小時。然後用水(50mL)稀釋該反應混合物並用乙酸乙酯(100mL x 2)萃取。用鹽水清洗合併之有機層，經Na2SO4乾燥並於減壓下濃縮。在高真空下之進一步乾燥產生呈黃色油之2-[5-(二苯亞甲基胺基)-3-甲基-2-吡 啶基]嗎啉-4-羧酸第三丁酯(360mg)，其直接用於下一步驟中。 To a solution of 2-(5-bromo-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (0.28 g, 0.78 mmol) and benzophenone imine under N 2 atmosphere ( 156 mg, 0.86 mmol, CAS: 1013-88-3) Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene was added to a solution in dioxane (20 mL). 90 mg, 0.156 mmol, CAS: 161265-03-8), Cs 2 CO 3 (0.77 g, 2.34 mmol) and hydrazine (dibenzylideneacetone) dipalladium (0) (72 mg, 0.078 mmol, CAS: 51364-51 -3). The mixture was stirred at 90 ° C for 12 hours. The reaction mixture was then diluted with water (50 mL) andEtOAcEtOAc The combined organic layers were washed with brine, dried over Na 2 CH 4 Further drying under high vacuum yielded 2-[5-(diphenylmethyleneamino)-3-methyl-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester (360 mg) as a yellow oil ), which is used directly in the next step.

b)2-(5-胺基-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯b) 2-(5-Amino-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester

向2-[5-(二苯亞甲基胺基)-3-甲基-2-吡啶基]嗎啉-4-羧酸第三丁酯(360mg，0.78mmol)在甲醇(10mL)中之溶液中添加乙酸鈉(250mg，2.34mmol)及羥胺鹽酸鹽(82mg，1.17mmol)。在室溫下將該混合物攪拌3小時。將該溶液倒入水(50mL)中並用CH2Cl2(100mL×2)萃取。經Na2SO4乾燥合併之有機層，於真空下濃縮並透過管柱層析法(以體積計CH2Cl2/甲醇=100/1~50/1)純化以產生呈灰白色固體之2-(5-胺基-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯(150mg，產率：65%)。 To 2-[5-(diphenylmethyleneamino)-3-methyl-2-pyridyl]morpholine-4-carboxylic acid tert-butyl ester (360 mg, 0.78 mmol) in methanol (10 mL) Sodium acetate (250 mg, 2.34 mmol) and hydroxylamine hydrochloride (82 mg, 1.17 mmol) were added to the solution. The mixture was stirred at room temperature for 3 hours. The solution was poured into water (50mL) and extracted with CH 2 Cl 2 (100mL × 2 ). SO 4 by the combined organic layers were dried Na 2, concentrated in vacuo and purified via column chromatography (volume of CH 2 Cl 2 / methanol = 100/1 ~ 50/1) to give an off-white solid of 2- (5-Amino-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (150 mg, yield: 65%).

c)(RS)-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺c) (RS)-N-(5-Methyl-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide

向2-(三氟甲基)吡啶-4-羧酸(29mg，0.15mmol，CAS：131747-41-6)在DMF(1mL)中之溶液中添加HATU(56mg，0.15mmol，CAS：148893-10-1)、N,N-二異丙基乙胺(52mg，0.40mmol，CAS：7087-68-5)及2-(5-胺基-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯(40mg，0.14mmol)。在室溫下將該溶液攪拌整夜。用二氯甲烷(50mL)稀釋該反應溶液。然後用水(50mL)及鹽水(50mL)清洗該溶液，經Na2SO4乾燥，於減壓下濃縮並在高真空下乾燥。將殘餘物溶解於二氯甲烷(1mL)及三氟乙酸(1mL)中。在室溫下將該溶液攪拌2小時。於減壓下濃縮該反應溶液。透過製備型HPLC(0.5%TFA之CH3CN溶液)純化殘餘物之以產生呈白色固體之(RS)-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺(4mg)。 Add HATU (56 mg, 0.15 mmol, CAS: 148893-) to a solution of 2-(trifluoromethyl)pyridine-4-carboxylic acid (29 mg, 0.15 mmol, CAS: 131747-41-6) in DMF (1 mL) 10-1), N,N-diisopropylethylamine (52 mg, 0.40 mmol, CAS: 7807-68-5) and 2-(5-amino-3-methyl-2-pyridyl)morpholine 4-carboxylic acid tert-butyl ester (40 mg, 0.14 mmol). The solution was stirred overnight at room temperature. The reaction solution was diluted with dichloromethane (50 mL). Then washed with water (50mL) and brine (50mL) and the solution washed, dried over Na 2 SO 4, concentrated under reduced pressure and dried under high vacuum. The residue was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (1 mL). The solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. Via preparative HPLC (0.5% TFA solution of CH 3 CN) to yield the residue was purified as a white solid of (RS) -N- (5- methyl-6-morpholin-2-yl-3-pyridinyl) -2-(Trifluoromethyl)pyridine-4-carbamide (4 mg).

1H NMR(400MHz，甲醇-d4)：δ 8.95(d,1H)、8.85(d,1H)、8.34(s,1H)、8.15(dd,1H)、5.13(dd,1H)、4.04(m,2H)、3.77(m,1H)、3.61(dd,1H)、3.38~3.30(m,2H)、2.49(s,3H)。 1 H NMR (400 MHz, methanol-d 4 ): δ 8.95 (d, 1H), 8.85 (d, 1H), 8.34 (s, 1H), 8.15 (dd, 1H), 5.13 (dd, 1H), 4.04 ( m, 2H), 3.77 (m, 1H), 3.61 (dd, 1H), 3.38 to 3.30 (m, 2H), 2.49 (s, 3H).

MS(ESI)：367.1(M+H)+。 MS (ESI): 367.1 (M+H) + .

實例118 Example 118

(RS)-4-氯-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺 (RS)-4-chloro-N-(5-methyl-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide

以類似實例117之方式使用4-氯-5-丙基-1H-吡唑-3-羧酸(CAS：1340578-20-2)代替2-(三氟甲基)吡啶-4-羧酸獲得標題化合物。白色固體。MS(ESI)：366.0([{37Cl}M+H]+)、364.0([{35Cl}M+H]+)。 In a similar manner to Example 117, 4-chloro-5-propyl-1H-pyrazole-3-carboxylic acid (CAS: 1340578-20-2) was used instead of 2-(trifluoromethyl)pyridine-4-carboxylic acid. Title compound. White solid. MS (ESI): 366.0 ([ {37 Cl} M + H] +), 364.0 ([{35 Cl} M + H] +).

實例119 Example 119

(RS)-1-(3-氯苯基)-3-(5-甲基-6-嗎啉-2-基-3-吡啶基)脲 (RS)-1-(3-chlorophenyl)-3-(5-methyl-6-morpholin-2-yl-3-pyridyl)urea

向2-(5-胺基-3-甲基-2-吡啶基)嗎啉-4-羧酸第三丁酯(30mg，0.1mmol)在二氯甲烷(1mL)中之溶液中添加Et3N(30mg，0.3mmol)及異氰酸3-氯苯酯(16mg，0.1mmol，CAS：2909-38-8)。在室溫下將該溶液攪拌整夜。用二氯甲烷(50mL)稀釋該反應溶液。然後用鹽水(50mL×2)清洗該溶液，經Na2SO4乾燥，於減壓下濃縮並在高真空下乾燥。將殘餘物溶解於二氯甲烷(1mL)及三氟乙酸(1mL)中。在室溫下將該溶液攪拌2小時。於減壓下濃縮該反應溶液。透過製備型HPLC(0.5%TFA之CH3CN溶液)純化殘餘物，以產生呈白色固體之(RS)-1-(3-氯苯基)-3-(5-甲基-6-嗎啉-2-基-3-吡啶基)脲(32mg)。 Add Et 3 to a solution of 2-(5-amino-3-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester (30 mg, 0.1 mmol) in dichloromethane (1 mL) N (30 mg, 0.3 mmol) and 3-chlorophenyl isocyanate (16 mg, 0.1 mmol, CAS: 2909-38-8). The solution was stirred overnight at room temperature. The reaction solution was diluted with dichloromethane (50 mL). Then washed with brine (50mL × 2) The solution, dried over Na 2 SO 4, concentrated under reduced pressure and dried under high vacuum. The residue was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (1 mL). The solution was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. Via preparative HPLC (0.5% TFA solution of CH 3 CN) to give the residue, to yield a white solid of (RS) -1- (3- chlorophenyl) -3- (5-methyl-6-morpholino -2-yl-3-pyridyl)urea (32 mg).

1H NMR(400MHz,DMSO-d6)：δ 9.36(d,2H)、9.04(m,1H)、 8.47(s,1H)、7.84(d,1H)、7.73(s,1H)、7.32(m,2H)、7.05(m,1H)、4.91(dd,1H)、4.00(m,1H)、3.89(m,1H)、3.58(m,2H)、3.27(d,1H)、3.15(m,1H)、2.35(s,3H)。 1 H NMR (400MHz, DMSO- d 6): δ 9.36 (d, 2H), 9.04 (m, 1H), 8.47 (s, 1H), 7.84 (d, 1H), 7.73 (s, 1H), 7.32 ( m, 2H), 7.05 (m, 1H), 4.91 (dd, 1H), 4.00 (m, 1H), 3.89 (m, 1H), 3.58 (m, 2H), 3.27 (d, 1H), 3.15 (m) , 1H), 2.35 (s, 3H).

MS(ESI)：347.0([{35Cl}M+H]+)、349.0([{37Cl}M+H]+)。 MS (ESI): 347.0 ([ {35 Cl} M + H] +), 349.0 ([{37 Cl} M + H] +).

實例120 Example 120

4-氯-3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-chloro-3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-氯-5-丙烷-2-基-2H-吡唑-3-羧酸(CAS：1291271-55-0)代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 In a similar manner to Example 67, 4-chloro-5-propan-2-yl-2H-pyrazole-3-carboxylic acid (CAS: 1291271-55-0) was used instead of 3-ethyl-4-methyl-1H- The title compound was obtained as the pyrazole-5-carboxylic acid. White solid.

MS(ESI)：350.1({35Cl}M+H)+、352.1({37Cl}M+H)+。 MS (ESI): 350.1 ({ 35 Cl} M + H) +, 352.1 ({37 Cl} M + H) +.

實例121 Example 121

4-氟-3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-fluoro-3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide

以類似實例67之方式使用4-氟-3-異丙基-1H-吡唑-5-羧酸代替3-乙基-4-甲基-1H-吡唑-5-羧酸獲得標題化合物。白色固體。 The title compound was obtained in a similar manner to Example 67 using 4-fluoro-3-isopropyl-1H-pyrazole-5-carboxylic acid instead of 3-ethyl-4-methyl-1H-pyrazole-5-carboxylic acid. White solid.

MS(ESI)：334.2(M+H)+。 MS (ESI): 334.2 (M+H) + .

式I之化合物及其等醫藥上可用之加成鹽具有有價值之藥理學性質。具體言之，已經發現本發明之化合物對痕量胺相關受體(TAARs)(特別係TAAR1)具有良好的親和性。 The compounds of formula I and their pharmaceutically acceptable addition salts have valuable pharmacological properties. In particular, it has been found that the compounds of the invention have good affinity for trace amine related receptors (TAARs), particularly TAAR1.

根據下文給出之測試研究該等化合物。 The compounds were studied according to the tests given below.

材料及方法 Materials and methods

TAAR表現質體及穩定轉染之細胞系之建構TAAR represents the construction of plastid and stably transfected cell lines

為建構表現質體，自基因體DNA擴增人類、大鼠及小鼠TAAR 1之編碼序列，基本上如Lindemann等人[14]描述。使用擴增高保真PCR系統(High Fidelity PCR System)(Roche Diagnostics)及1.5mM Mg2+並遵循該製造商之說明將純化PCR產物選殖至pCR2.1-TOPO選殖載體(Invitrogen)中。將PCR產物次選殖至pIRESneo2載體(BD Clontech，Palo Alto，California)中，及在引入細胞系中之前驗證表現載體之序列。 To construct a plastid, the coding sequence for human, rat and mouse TAAR 1 was amplified from genomic DNA, essentially as described by Lindemann et al. [14]. Purified PCR products were cloned into pCR2.1-TOPO selection vector (Invitrogen) using the High Fidelity PCR System (Roche Diagnostics) and 1.5 mM Mg2+ and following the manufacturer's instructions. The PCR product was subcloned into the pIRESneo2 vector (BD Clontech, Palo Alto, California) and the sequence of the expression vector was verified prior to introduction into the cell line.

基本上如Lindemann等人(2005)所述培養HEK293細胞(ATCC # CRL-1573)。為產生穩定轉染之細胞系，根據該製造商之說明，用含有TAAR編碼序列(如上所述)之pIRESneo2表現質體及Lipofectamine 2000(Invitrogen)轉染HEK293細胞，及轉染後之24h，用1mg/ml G418(Sigma，Buchs，Switzerland)補充培養基。在培養約10天時間後，分離純系，擴增及遵循該製造商提供之非乙醯化EIA程序用cAMP Biotrak酵素免疫分析法(EIA)系統(阿麥斯罕)測試對痕量胺(所有化合物購買自Sigma)之反應性。在15個繼代培養時間內展示穩定EC50之單株細胞系用於所有隨後之研究。 HEK293 cells (ATCC # CRL-1573) were cultured essentially as described by Lindemann et al. (2005). To generate stably transfected cell lines, HEK293 cells were transfected with pIRESneo2 expressing plastids and Lipofectamine 2000 (Invitrogen) containing the TAAR coding sequence (described above) according to the manufacturer's instructions, and 24 h after transfection. 1 mg/ml G418 (Sigma, Buchs, Switzerland) supplemented with medium. After approximately 10 days of culture, isolate the pure line, amplify and follow the manufacturer's non-acetylated EIA program using the cAMP Biotrak Enzyme Immunoassay (EIA) System (Amesham) to test for trace amines (all The reactivity of the compound purchased from Sigma). In 15, following in the culture time to show stable monoclonal cell line 50 of the EC for all of the subsequent research.

對大鼠TAAR1之放射性配體結合分析Radioligand Binding Analysis of Rat TAAR1

膜製備及放射性配體結合。 Membrane preparation and radioligand binding.

將穩定表現大鼠TAAR1之HEK-293細胞保持在37℃及5%CO2下之DMEM高葡萄糖培養基中，該培養基含有胎牛血清(10%，在56℃下熱 滅活30min)、青黴素/鏈黴素(1%)及375μg/ml遺傳黴素(Gibco)。使用胰蛋白酶/EDTA釋放培養瓶中之細胞，收集，以冰冷PBS(無Ca2+及Mg2+)清洗兩次，在4℃與1,000rpm下離心集結成粒5分鐘，冷凍並儲存在-80℃下。將冷凍集結粒懸浮於20ml含有10mM EDTA之HEPES-NaOH(20mM，pH 7.4)中並用Polytron(PT 6000，Kinematica)以14,000rpm均質化20s。在4℃下以48,000 x g將均質物離心30min。接著，移除上清液並廢棄，並使用Polytron(以14,000rpm進行20s)將集結粒再懸浮於20ml含有0.1mM EDTA之HEPES-NaOH(20mM，pH 7.4)中。重複該程序並將最終之集結粒再懸浮於含有0.1mM EDTA之HEPES-NaOH中並使用Polytron均質化。通常，2ml膜部分等分試樣儲存於-80℃下。經由飽和曲線判定每批新膜之離解常數(Kd)。在等於計算之Kd值之濃度(通常約2.3nM)下使用TAAR1放射性配體3[H]-(S)-4-[(乙基-苯基-胺基)-甲基]-4,5-二氫-噁唑-2-基胺(描述於WO 2008/098857中)，從而導致約0.2%之放射性配體結合及表示總結合之約85%之特異性結合。非特異性結合定義為在10μM未標記配體之存在下所結合之3[H]-(S)-4-[(乙基-苯基-胺基)-甲基]-4,5-二氫-噁唑-2-基胺的量。在大範圍濃度(10pM至10μM)下二重複測試所有化合物。將該等測試化合物(20μl/孔)轉移至96深孔盤(TreffLab)中，並添加180μl含有MgCl2(10mM)及CaCl2(2mM)(結合緩衝液)之HEPES-NaOH(20mM，pH 7.4)、300μl濃度為3.3 x Kd(以nM計)之放射性配體3[H]-(S)-4-[(乙基-苯基-胺基)-甲基]-4,5-二氫-噁唑-2-基胺及500μl膜(以50μg蛋白質/ml再懸浮)。在4℃下將96深孔盤培養1h。藉由通過於聚次乙亞胺(0.3%)中預浸泡1h並用1ml冷結合緩衝液清洗3次之Unifilter-96盤(Packard Instrument Company)及玻璃過濾器GF/C(Perkin Elmer)快速過濾來中止培養。添加45μl Microscint 40(PerkinElmer)後，密封Unifilter-96盤及1h後使用TopCount微孔盤閃爍計數器(Packard Instrument Company)計數放射活性。 HEK-293 cells stably expressing rat TAAR1 were maintained in DMEM high glucose medium at 37 ° C and 5% CO 2 containing fetal bovine serum (10%, heat inactivated at 56 ° C for 30 min), penicillin / Streptomycin (1%) and 375 μg/ml geneticin (Gibco). The cells in the culture flask were released using trypsin/EDTA, collected, washed twice with ice-cold PBS (no Ca 2+ and Mg 2+ ), granulated by centrifugation at 1,000 ° C for 5 min at 4 ° C, frozen and stored in - At 80 ° C. The frozen aggregate pellet was suspended in 20 ml of HEPES-NaOH (20 mM, pH 7.4) containing 10 mM EDTA and homogenized with a Polytron (PT 6000, Kinematica) at 14,000 rpm for 20 s. The homogenate was centrifuged at 48,000 xg for 30 min at 4 °C. Next, the supernatant was removed and discarded, and the pellet was resuspended in 20 ml of HEPES-NaOH (20 mM, pH 7.4) containing 0.1 mM EDTA using a Polytron (20 s at 14,000 rpm). This procedure was repeated and the final pellet was resuspended in HEPES-NaOH containing 0.1 mM EDTA and homogenized using a Polytron. Typically, 2 ml membrane fraction aliquots were stored at -80 °C. The dissociation constant (K d ) of each batch of new membrane was determined via a saturation curve. Used at a concentration (typically about 2.3nM) d is equal to the calculated K values TAAR1 radioligand 3 [H] - (S) -4 - [( ethyl - phenyl - amino) - methyl] -4, 5-Dihydro-oxazol-2-ylamine (described in WO 2008/098857), resulting in about 0.2% radioligand binding and representing about 85% specific binding of total binding. Non-specific binding is defined as the binding of 3 [H]-(S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-di in the presence of 10 μM unlabeled ligand. The amount of hydrogen-oxazol-2-ylamine. All compounds were tested repeatedly at a wide range of concentrations (10 pM to 10 [mu]M). The test compounds (20 μl/well) were transferred to a 96-deep well plate (TreffLab), and 180 μl of HEPES-NaOH (20 mM, pH 7.4) containing MgCl 2 (10 mM) and CaCl 2 (2 mM) (binding buffer) was added. 300 μl of radioligand 3 [H]-(S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-di at a concentration of 3.3 x K d (in nM) Hydrogen-oxazol-2-ylamine and 500 μl membrane (resuspended at 50 μg protein/ml). 96 deep well plates were incubated for 1 h at 4 °C. Unifilter-96 (Packard Instrument Company) and glass filter GF/C (Perkin Elmer) were quickly filtered by pre-soaking for 1 h in polyethylenimine (0.3%) and 3 times with 1 ml of cold binding buffer. Stop training. After addition of 45 μl of Microscint 40 (PerkinElmer), the Unifilter-96 disk was sealed and after 1 h, the radioactivity was counted using a TopCount microplate scintillation counter (Packard Instrument Company).

對小鼠TAAR1之放射性配體結合分析Radioligand Binding Analysis of Mouse TAAR1

膜製備及放射性配體結合 Membrane preparation and radioligand binding

將穩定表現小鼠TAAR1之HEK-293細胞保持在37℃及5%CO2下之DMEM高葡萄糖培養基中，該培養基含有胎牛血清(10%，在56℃下熱滅活30min)、青黴素/鏈黴素(1%)及375μg/ml遺傳黴素(Gibco)。使用胰蛋白酶/EDTA釋放培養瓶中之細胞，收集，以冰冷PBS(無Ca2+及Mg2+)清洗兩次，在4℃與1,000rpm下離心集結成粒5分鐘，冷凍並儲存在-80℃下。將冷凍集結粒懸浮於20ml含有10mM EDTA之HEPES-NaOH(20mM，pH 7.4)中並用Polytron(PT 6000，Kinematica)以14,000rpm均質化20s。在4℃下以48,000 x g將均質物離心30min。接著，移除上清液並廢棄，並使用Polytron(以14,000rpm進行20s)將集結粒再懸浮於20ml含有0.1mM EDTA之HEPES-NaOH(20mM，pH 7.4)中。重複該程序並將最終之集結粒再懸浮於含有0.1mM EDTA之HEPES-NaOH中並使用Polytron均質化。通常，將每份2ml膜等分試樣儲存於-80℃下。經由飽和曲線判定每批新膜之離解常數(Kd)。在等於計算之Kd值之濃度(通常約0.7nM)下使用TAAR1放射性配體3[H]-(S)-4-[(乙基-苯基-胺基)-甲基]-4,5-二氫-噁唑-2-基胺(描述於WO 2008/098857中)，從而導致約0.5%之放射性配體結合，及表示佔總結合之約70%之特異性結合。非特異性結合定義為在10μM未標記配體之存在下所結合之3[H]-(S)-4-[(乙基-苯基-胺基)-甲基]-4,5-二氫-噁唑-2-基胺的量。在大範圍濃度(10pM至10μM)下二重複測試所有化合物。將該等測試化合物(20μl/孔)轉移至96深孔盤(TreffLab)中，並添加180μl含有MgCl2(10mM)及CaCl2(2mM)(結合緩衝液)之HEPES-NaOH(20mM，pH 7.4)、300μl濃度為3.3 x Kd(以nM計)之放射性配體3[H]-(S)-4-[(乙基-苯基-胺基)-甲基]-4,5-二氫-噁唑-2-基胺及500μl 膜(再懸浮成60μg蛋白質/ml)。在4℃下培養96深孔盤1h。藉由通過於聚次乙亞胺(0.3%)中預浸泡1h並用1ml冷結合緩衝液清洗3次之Unifilter-96盤(Packard Instrument Company)及玻璃過濾器GF/C(Perkin Elmer)快速過濾來中止培養。添加45μl Microscint 40(PerkinElmer)後，密封Unifilter-96盤及1h後使用TopCount微孔盤閃爍計數器(Packard Instrument Company)計數放射活性。 HEK-293 cells stably expressing mouse TAAR1 were maintained in DMEM high glucose medium at 37 ° C and 5% CO 2 containing fetal bovine serum (10%, heat inactivated at 56 ° C for 30 min), penicillin / Streptomycin (1%) and 375 μg/ml geneticin (Gibco). The cells in the culture flask were released using trypsin/EDTA, collected, washed twice with ice-cold PBS (no Ca 2+ and Mg 2+ ), granulated by centrifugation at 1,000 ° C for 5 min at 4 ° C, frozen and stored in - At 80 ° C. The frozen aggregate pellet was suspended in 20 ml of HEPES-NaOH (20 mM, pH 7.4) containing 10 mM EDTA and homogenized with a Polytron (PT 6000, Kinematica) at 14,000 rpm for 20 s. The homogenate was centrifuged at 48,000 xg for 30 min at 4 °C. Next, the supernatant was removed and discarded, and the pellet was resuspended in 20 ml of HEPES-NaOH (20 mM, pH 7.4) containing 0.1 mM EDTA using a Polytron (20 s at 14,000 rpm). This procedure was repeated and the final pellet was resuspended in HEPES-NaOH containing 0.1 mM EDTA and homogenized using a Polytron. Typically, each 2 ml membrane aliquot was stored at -80 °C. The dissociation constant (K d ) of each batch of new membrane was determined via a saturation curve. Used at a concentration (typically about 0.7nM) d is equal to the calculated K values TAAR1 radioligand 3 [H] - (S) -4 - [( ethyl - phenyl - amino) - methyl] -4, 5-Dihydro-oxazol-2-ylamine (described in WO 2008/098857), resulting in about 0.5% radioligand binding, and representing about 70% specific binding of total binding. Non-specific binding is defined as the binding of 3 [H]-(S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-di in the presence of 10 μM unlabeled ligand. The amount of hydrogen-oxazol-2-ylamine. All compounds were tested repeatedly at a wide range of concentrations (10 pM to 10 [mu]M). The test compounds (20 μl/well) were transferred to a 96-deep well plate (TreffLab), and 180 μl of HEPES-NaOH (20 mM, pH 7.4) containing MgCl 2 (10 mM) and CaCl 2 (2 mM) (binding buffer) was added. 300 μl of radioligand 3 [H]-(S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-di at a concentration of 3.3 x K d (in nM) Hydrogen-oxazol-2-ylamine and 500 μl membrane (resuspended to 60 μg protein/ml). 96 deep well plates were incubated for 1 h at 4 °C. Unifilter-96 (Packard Instrument Company) and glass filter GF/C (Perkin Elmer) were quickly filtered by pre-soaking for 1 h in polyethylenimine (0.3%) and 3 times with 1 ml of cold binding buffer. Stop training. After addition of 45 μl of Microscint 40 (PerkinElmer), the Unifilter-96 disk was sealed and after 1 h, the radioactivity was counted using a TopCount microplate scintillation counter (Packard Instrument Company).

如下表所示，該等化合物顯示對小鼠或大鼠TAAR1(以μM計)之Ki值(μM)。 As shown in the table below, these compounds show K i values (μM) for mouse or rat TAAR1 (in μM).

式I之化合物及式I化合物之醫藥上可接受之鹽可用作藥劑，例如，呈醫藥製劑之形式。可口服投與該等醫藥製劑，例如，呈錠劑、包衣錠劑、糖衣錠劑、硬質或軟質明膠膠囊、溶液、乳液或懸浮液之形式。然而，該投與亦可經直腸(例如，呈栓劑之形式)或非經腸(例如，呈注射溶液之形式)實現。 The compound of formula I and a pharmaceutically acceptable salt of a compound of formula I are useful as medicaments, for example, in the form of a pharmaceutical preparation. The pharmaceutical preparations can be administered orally, for example, in the form of a troche, a coated lozenge, a dragee, a hard or soft gelatin capsule, a solution, an emulsion or a suspension. However, the administration can also be effected either in the rectum (for example in the form of a suppository) or parenterally (for example in the form of an injectable solution).

式I之化合物可與醫藥上惰性、無機或有機載劑一起加工以製造醫藥製劑。可使用乳糖、玉米澱粉或其衍生物、滑石、硬酯酸或其鹽及類似物例如作為用於錠劑、包衣錠劑、糖衣錠劑及硬質明膠膠囊之此類載劑。適用於軟質明膠膠囊之載劑係(例如)植物油、蠟、脂肪、半固體及液體多元醇及類似物。然而視活性物質之性質，在軟質明膠膠囊之情況下通常無需載劑。適用於製造溶液及糖漿之載劑係(例如)水、多元醇、甘油、植物油及類似物。適用於栓劑之載劑係(例如)天然油或硬化油、蠟、脂肪、半液體或液體多元醇及類似物。 The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers to produce pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for use in lozenges, coated lozenges, dragees and hard gelatin capsules. Carriers suitable for use in soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. However, depending on the nature of the active substance, in the case of soft gelatin capsules, no carrier is usually required. Carriers suitable for use in the manufacture of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like. Carriers suitable for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

此外，該等醫藥製劑可含有防腐劑、增溶劑、穩定劑、潤濕劑、乳化劑、甜味劑、著色劑、調味劑、改變滲透壓之鹽、緩衝液、遮蔽劑或抗氧化劑。其等亦可含有其他治療上有價值之物質。 Further, the pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They may also contain other therapeutically valuable substances.

含有式I之化合物或其醫藥上可接受之鹽及治療上惰性載劑之藥劑亦係本發明之目標，正如一種其製造方法，其包括使一種或多種式I之化合物及/或醫藥上可接受之酸加成鹽，及若需要之一種或多種其他治療上有價值之物質連同一種或多種治療上惰性載劑形成蓋倫製劑投與形式(galenical administration form)。 An agent comprising a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier is also an object of the invention, as a method of making the same, which comprises one or more compounds of formula I and/or pharmaceutically acceptable The accepted acid addition salt, and if desired one or more other therapeutically valuable substances, together with one or more therapeutically inert carriers, form a gallenical administration form.

本發明之最佳適應症係彼等包含中樞神經系統疾病者，例如，治療或預防抑鬱症、精神病、帕金森氏病、焦慮症、注意力不足過動症(ADHD)及糖尿病。 The best indications of the present invention are those comprising central nervous system disorders, for example, treating or preventing depression, psychosis, Parkinson's disease, anxiety, attention deficit hyperactivity disorder (ADHD), and diabetes.

劑量可在廣泛範圍內變化，及當然將必須在每一特定情況下針對個別要求作出調整。在口服投與之情況下，用於成人之劑量可在每天約0.01mg至約1000mg通式I之化合物或相應量的其醫藥上可接受之鹽之範圍內變化。可作為單一劑量或分次劑量投與日劑量，及此外，當發現適用時，亦可超過上限。 The dosage can vary over a wide range and will of course have to be adjusted for individual requirements in each particular case. In the case of oral administration, the dosage for an adult can vary from about 0.01 mg to about 1000 mg of a compound of formula I or a corresponding amount of a pharmaceutically acceptable salt thereof per day. The daily dose can be administered as a single dose or in divided doses, and in addition, the upper limit can also be exceeded when found to be applicable.

錠劑調配物(濕法製粒) Lozenge formulation (wet granulation)

製程Process

1.混合項目1、2、3及4並以純化水製粒。 1. Mix items 1, 2, 3 and 4 and granulate with purified water.

2.在50℃下乾燥顆粒。 2. Dry the granules at 50 °C.

3.使該等顆粒通過合適之研磨設備。 3. Pass the particles through a suitable grinding apparatus.

4.添加項目5並混合三分鐘；並在合適之壓錠機上壓製。 4. Add item 5 and mix for three minutes; and press on a suitable tablet press.

膠囊調配物 Capsule formulation

製程Process

1.在合適之混合器中將項目1、2及3混合30分鐘。 1. Mix items 1, 2 and 3 for 30 minutes in a suitable mixer.

2.添加項目4及5並混合3分鐘。 2. Add items 4 and 5 and mix for 3 minutes.

3.填充至合適之膠囊中。 3. Fill into a suitable capsule.

Claims (14)

一種式I之化合物， 其中X係CR或N；R係氫、鹵素或C1-7烷基；L係鍵結、-C(O)-或-C(O)NH-；Ar係苯基或含有一個或兩個N原子之五員或六員雜芳基；R1係鹵素、C1-7烷基、經鹵素取代之C1-7烷基、C1-7烷氧基、經鹵素取代之C1-7烷氧基或環烷基；n係0、1、2或3；或其醫藥上可接受之酸加成鹽、所有其等相應之鏡像異構物及/或其光學異構物。 a compound of formula I, Wherein X is CR or N; R is hydrogen, halogen or C 1-7 alkyl; L is bonded, -C(O)- or -C(O)NH-; Ar is phenyl or contains one or two five or six N atoms heteroaryl; R 1 Department of halo, C 1-7 alkyl, the halogen substituted C 1-7 alkyl, C 1-7 alkoxy, halogen substituted C 1- of 7 alkoxy or cycloalkyl; n is 0, 1, 2 or 3; or a pharmaceutically acceptable acid addition salt thereof, all such corresponding mirror image isomers and/or optical isomers thereof. 如請求項1之式I之化合物，其中「L」係鍵結且該等其他取代基係如請求項1中所述。 A compound of formula I according to claim 1, wherein the "L" linkage and the other substituents are as described in claim 1. 如請求項2之式I之化合物，其中該等化合物係(RS)-N-(4-氯苯基)-6-嗎啉-2-基-吡啶-3-胺(RS)-N-(4-溴苯基)-6-嗎啉-2-基-吡啶-3-胺(RS)-N-(4-乙氧苯基)-6-嗎啉-2-基-吡啶-3-胺(RS)-N-(3-氯苯基)-6-嗎啉-2-基-吡啶-3-胺(RS)-N-(4-氟苯基)-6-嗎啉-2-基-吡啶-3-胺(RS)-6-嗎啉-2-基-N-[4-(三氟甲基)苯基]吡啶-3-胺 (RS)-N-(6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)嘧啶-4-胺N-(4-氯苯基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺6-[(2S)-嗎啉-2-基]-N-[4-(三氟甲基)苯基]吡啶-3-胺N-(5-氯-2-吡啶基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺N-(5-溴-2-吡啶基)-6-[(2S)-嗎啉-2-基]吡啶-3-胺6-[(2S)-嗎啉-2-基]-N-[6-(三氟甲基)-3-吡啶基]吡啶-3-胺6-[(2S)-嗎啉-2-基]-N-[4-(三氟甲基)-2-吡啶基]吡啶-3-胺N-(4-氯苯基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺6-[(2R)-嗎啉-2-基]-N-[4-(三氟甲基)苯基]吡啶-3-胺N-(5-氯-2-吡啶基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺6-[(2R)-嗎啉-2-基]-N-[6-(三氟甲基)-3-吡啶基]吡啶-3-胺6-[(2R)-嗎啉-2-基]-N-[4-(三氟甲基)-2-吡啶基]吡啶-3-胺N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(三氟甲基)吡啶-2-胺N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-6-(三氟甲基)吡啶-2-胺N-(5-溴-2-吡啶基)-6-[(2R)-嗎啉-2-基]吡啶-3-胺N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-(三氟甲基)吡啶-2-胺N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-6-(三氟甲基)吡啶-2-胺(RS)-N-(4-氯苯基)-2-嗎啉-2-基-嘧啶-5-胺(RS)-2-嗎啉-2-基-N-[4-(三氟甲基)苯基]嘧啶-5-胺(RS)-5-氯-N-(5-氯-2-吡啶基)-6-嗎啉-2-基-吡啶-3-胺(RS)-5-氯-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺(RS)-5-甲基-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺(RS)-N-(5-氯-2-吡啶基)-5-氟-6-嗎啉-2-基-吡啶-3-胺或(RS)-5-氟-6-嗎啉-2-基-N-[5-(三氟甲基)-2-吡啶基]吡啶-3-胺。 A compound of formula I according to claim 2, wherein the compound is (RS)-N-(4-chlorophenyl)-6-morpholin-2-yl-pyridin-3-amine (RS)-N-( 4-bromophenyl)-6-morpholin-2-yl-pyridin-3-amine (RS)-N-(4-ethoxyphenyl)-6-morpholin-2-yl-pyridin-3-amine (RS)-N-(3-chlorophenyl)-6-morpholin-2-yl-pyridin-3-amine (RS)-N-(4-fluorophenyl)-6-morpholin-2-yl -pyridin-3-amine (RS)-6-morpholin-2-yl-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine (RS)-N-(6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyrimidine-4-amine N-(4-chlorophenyl)-6-[(2S )-morpholin-2-yl]pyridin-3-amine 6-[(2S)-morpholin-2-yl]-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine N- (5-Chloro-2-pyridyl)-6-[(2S)-morpholin-2-yl]pyridin-3-amine N-(5-bromo-2-pyridyl)-6-[(2S)- Morpholin-2-yl]pyridin-3-amine 6-[(2S)-morpholin-2-yl]-N-[6-(trifluoromethyl)-3-pyridyl]pyridin-3-amine 6 -[(2S)-morpholin-2-yl]-N-[4-(trifluoromethyl)-2-pyridyl]pyridin-3-amine N-(4-chlorophenyl)-6-[( 2R)-morpholin-2-yl]pyridin-3-amine 6-[(2R)-morpholin-2-yl]-N-[4-(trifluoromethyl)phenyl]pyridin-3-amine N -(5-chloro-2-pyridyl)-6-[(2R)-morpholin-2-yl]pyridin-3-amine 6-[(2R)-morpholin-2-yl]-N-[6 -(trifluoromethyl)-3-pyridyl]pyridin-3-amine 6-[(2R)-morpholin-2-yl]-N-[4-(trifluoromethyl)-2-pyridinyl] Pyridin-3-amine N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(trifluoromethyl)pyridin-2-amine N-[6-[(2S )-morpholin-2-yl]-3-pyridyl]-6-(trifluoromethyl)pyridin-2-amine N-(5-bromo-2-pyridyl)-6-[(2R)-?啉-2-yl]pyridin-3-amine N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-(trifluoromethyl)pyridin-2-amine N- [6-[(2R)-morpholin-2-yl]-3-pyridyl -6-(Trifluoromethyl)pyridin-2-amine (RS)-N-(4-chlorophenyl)-2-morpholin-2-yl-pyrimidin-5-amine (RS)-2-?啉-2-yl-N-[4-(trifluoromethyl)phenyl]pyrimidin-5-amine (RS)-5-chloro-N-(5-chloro-2-pyridyl)-6-morpholine -2-yl-pyridin-3-amine (RS)-5-chloro-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine ( RS)-5-Methyl-6-morpholin-2-yl-N-[5-(trifluoromethyl)-2-pyridyl]pyridin-3-amine (RS)-N-(5-chloro- 2-pyridyl)-5-fluoro-6-morpholin-2-yl-pyridin-3-amine or (RS)-5-fluoro-6-morpholin-2-yl-N-[5-(trifluoro Methyl)-2-pyridyl]pyridin-3-amine. 如請求項1之式I之化合物，其中「L」係-C(O)-且該等其他取代基係如請求項1中所述。 A compound of formula I according to claim 1, wherein "L" is -C(O)- and the other substituents are as described in claim 1. 如請求項4之式I之化合物，其中該等化合物係(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺(RS)-3-氯-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺(RS)-4-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺(RS)-4-氟-N-(6-嗎啉-2-基-3-吡啶基)苯甲醯胺(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺(RS)-N-(6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]苯甲醯胺3-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]苯甲醯胺N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-4-(三氟甲基)苯甲醯胺N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(三氟甲基)吡啶-4-甲醯胺N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)苯甲醯胺N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-6-(2,2,2-三氟乙氧基)吡啶-3-甲醯胺2-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]嘧啶-5-甲醯胺3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺4-氯-3-環丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)-1H-吡唑-5-甲醯胺4-氯-3-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-1-甲基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-丙基-吡唑-3- 甲醯胺4-氯-1-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-丙基-吡唑-3-甲醯胺4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]苯甲醯胺3-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]苯甲醯胺N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-4-(三氟甲基)苯甲醯胺N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-2-(三氟甲基)吡啶-4-甲醯胺N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)苯甲醯胺N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-6-(2,2,2-三氟乙氧基)吡啶-3-甲醯胺2-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]嘧啶-5-甲醯胺3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺4-氯-3-環丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-(三氟甲基)-1H-吡唑-5-甲醯胺4-氯-3-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-甲基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺(R)-3-乙基-4-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-1H-吡唑-5-甲醯胺(S)-3-乙基-4-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-1H-吡唑-5-甲醯胺(R)-6-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-2-(三氟甲基)嘧啶-4-甲 醯胺(S)-6-甲基-N-(6-(嗎啉-2-基)吡啶-3-基)-2-(三氟甲基)嘧啶-4-甲醯胺(RS)-4-氯-N-(2-嗎啉-2-基嘧啶-5-基)苯甲醯胺(RS)-4-氯-3-乙氧基-N-(6-嗎啉-2-基-3-吡啶基)-1H-吡唑-5-甲醯胺(RS)-4-氯-N-(6-嗎啉-2-基-3-吡啶基)-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺4-氯-3-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-乙基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-溴-3-乙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺3-環丙基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-溴-3-環丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-3-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-乙基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-溴-3-乙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺 4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-丙基-1H-吡唑-5-甲醯胺3-環丙基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-溴-3-環丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氟-3-異丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-丁基-4-氟-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-丁基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺5-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺2-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺3-異丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氟-3-異丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-丁基-4-氟-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺3-丁基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺5-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-2-(2,2,2-三氟乙基)吡唑-3-甲醯胺2-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-5-(2,2,2-三氟乙氧基)吡唑-3-甲醯胺 4-氯-3-乙氧基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氯-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-(2,2,2-三氟乙氧基)-1H-吡唑-5-甲醯胺4-氯-3-乙氧基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺(RS)-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺(RS)-4-氯-N-(5-氯-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺(RS)-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺(RS)-4-氯-N-(5-氟-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺4-氯-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺4-氟-3-異丙基-N-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺(RS)-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-2-(三氟甲基)吡啶-4-甲醯胺(RS)-4-氯-N-(5-甲基-6-嗎啉-2-基-3-吡啶基)-3-丙基-1H-吡唑-5-甲醯胺4-氯-3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺或4-氟-3-異丙基-N-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-1H-吡唑-5-甲醯胺。 A compound of formula I according to claim 4, wherein the compound is (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)benzamide (RS)-3- Chloro-N-(6-morpholin-2-yl-3-pyridyl)benzamide (RS)-4-ethoxy-N-(6-morpholin-2-yl-3-pyridyl) Benzalamine (RS)-4-fluoro-N-(6-morpholin-2-yl-3-pyridyl)benzamide (RS)-4-chloro-N-(6-morpholine-2 -yl-3-pyridyl)-3-propyl-1H-pyrazole-5-formamide (RS)-N-(6-morpholin-2-yl-3-pyridyl)-2-(three Fluoromethyl)pyridine-4-carboxamide 4-chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]benzamide-3-chloro-N-[6 -[(2S)-morpholin-2-yl]-3-pyridyl]benzamide N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-4-( Trifluoromethyl)benzamide N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(trifluoromethyl)pyridine-4-carboxamide N- [6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)benzamide N-[6-[(2S)-morpholin-2-yl ]-3-pyridyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide 2-ethyl-N-[6-[(2S)-morpholin-2- ]]-3-pyridyl]pyrimidine-5-carboxamide 3-isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole- 5-Protonamine 4-chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-propan -1H-pyrazole-5-carboxamide 4-chloro-3-cyclopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole- 5-Protonamine 4-chloro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(trifluoromethyl)-1H-pyrazole-5-A Indole 4-chloro-3-methyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-methyl- N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-chloro-1-methyl-N-[6-[( 2S)-morpholin-2-yl]-3-pyridyl]-5-propyl-pyrazole-3- Methionine 4-chloro-1-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-propyl-pyrazole-3-carboxamide 4 -Chloro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]benzamide-5-chloro-N-[6-[(2R)-morpholin-2-yl ]-3-pyridyl]benzamide N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-4-(trifluoromethyl)benzamide N-[ 6-[(2R)-morpholin-2-yl]-3-pyridyl]-2-(trifluoromethyl)pyridine-4-carboxamide N-[6-[(2R)-morpholine-2 -yl]-3-pyridyl]-3-(trifluoromethyl)benzamide N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-6-(2 , 2,2-trifluoroethoxy)pyridine-3-carboxamide 2-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]pyrimidine-5- Methotrexate 3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-chloro-N-[ 6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide 4-chloro-3-cyclopropyl-N-[6 -[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-chloro-N-[6-[(2R)-morpholin-2-yl ]-3-pyridyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide 4-chloro-3-methyl-N-[6-[(2R)-morpholine-2 -yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-methyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H -pyrazole-5-formamide (R)-3- Ethyl-4-methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-1H-pyrazole-5-carboxamide (S)-3-ethyl-4-methyl --N-(6-(morpholin-2-yl)pyridin-3-yl)-1H-pyrazole-5-carboxamide (R)-6-methyl-N-(6-(morpholine- 2-yl)pyridin-3-yl)-2-(trifluoromethyl)pyrimidine-4-methyl Indoleamine (S)-6-methyl-N-(6-(morpholin-2-yl)pyridin-3-yl)-2-(trifluoromethyl)pyrimidine-4-carboxamide (RS)- 4-Chloro-N-(2-morpholin-2-ylpyrimidin-5-yl)benzamide (RS)-4-chloro-3-ethoxy-N-(6-morpholin-2-yl -3-pyridyl)-1H-pyrazole-5-carboxamide (RS)-4-chloro-N-(6-morpholin-2-yl-3-pyridyl)-3-(2,2, 2-trifluoroethoxy)-1H-pyrazole-5-carboxamide 4-chloro-3-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl -1H-pyrazole-5-carboxamide 3-ethyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole- 5-Protonamine 4-bromo-3-ethyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4- Fluorine-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide 3-cyclopropyl-4-fluoro -N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-bromo-3-cyclopropyl-N-[6- [(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-chloro-3-ethyl-N-[6-[(2R)-morpholine -2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 3-ethyl-4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3 -pyridyl]-1H-pyrazole-5-carboxamide 4-bromo-3-ethyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H- Pyrazole-5-formamide 4-fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-propyl-1H-pyrazole-5-carboxamide 3-cyclopropyl-4 -Fluoro-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-bromo-3-cyclopropyl-N-[ 6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 3-isobutyl-N-[6-[(2S)-morpholine- 2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-fluoro-3-isobutyl-N-[6-[(2S)-morpholin-2-yl]-3 -pyridyl]-1H-pyrazole-5-carboxamide 3-butyl-4-fluoro-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H- Pyrazole-5-carbamide 3-butyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 5-iso propyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxamide 2 -isopropyl-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole-3-methyl Indole 3-isobutyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-fluoro-3-isobutyl --N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 3-butyl-4-fluoro-N-[6- [(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 3-butyl-N-[6-[(2R)-morpholin-2-yl ]-3-pyridyl]-1H-pyrazole-5-carboxamide 5-isopropyl -N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxamide 2-iso propyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-5-(2,2,2-trifluoroethoxy)pyrazole-3-carboxamide 4-chloro-3-ethoxy-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide 4-chloro-N- [6-[(2S)-morpholin-2-yl]-3-pyridyl]-3-(2,2,2-trifluoroethoxy)-1H-pyrazole-5-carboxamide-4 Chloro-3-ethoxy-N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide (RS)-N-(5 -Chloro-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide (RS)-4-chloro-N-(5-chloro-6- Morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide (RS)-N-(5-fluoro-6-morpholin-2-yl-3- Pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide (RS)-4-chloro-N-(5-fluoro-6-morpholin-2-yl-3-pyridyl)-3 -propyl-1H-pyrazole-5-carboxamide 4-chloro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H- Pyrazole-5-carbamide 4-fluoro-3-isopropyl-N-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5- Indoleamine (RS)-N-(5-methyl-6-morpholin-2-yl-3-pyridyl)-2-(trifluoromethyl)pyridine-4-carboxamide (RS)-4- Chloro-N-(5-methyl-6-morpholin-2-yl-3-pyridyl)-3-propyl-1H-pyrazole-5-carboxamide 4-chloro-3-isopropyl- N-[6-[(2S)-morpholin-2-yl]-3-pyridyl]-1H-pyrazole-5-carboxamide or 4-fluoro-3-isopropyl-N-[6- [(2S)-morpholin-2-yl]-3-pyridine ] -1H- pyrazole-5-acyl amine. 如請求項1之式I之化合物，其中「L」係-C(O)NH-。 A compound of formula I according to claim 1, wherein "L" is -C(O)NH-. 如請求項6之式I之化合物，其中該等化合物係(RS)-1-(3-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲(RS)-1-(4-氟苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲(RS)-1-(6-嗎啉-2-基-3-吡啶基)-3-[4-(三氟甲基)苯基]脲(RS)-1-(4-氯苯基)-3-(6-嗎啉-2-基-3-吡啶基)脲1-(3-氯苯基)-3-[6-[(2S)-嗎啉-2-基]-3-吡啶基]脲1-[6-[(2S)-嗎啉-2-基]-3-吡啶基]-3-[3-(三氟甲基)苯基]脲1-(3-氯苯基)-3-[6-[(2R)-嗎啉-2-基]-3-吡啶基]脲1-[6-[(2R)-嗎啉-2-基]-3-吡啶基]-3-[3-(三氟甲基)苯基]脲(RS)-1-(3-氯苯基)-3-(2-嗎啉-2-基嘧啶-5-基)脲(RS)-1-(5-氯-6-嗎啉-2-基-3-吡啶基)-3-(3-氯苯基)脲(RS)-1-(3-氯苯基)-3-(5-氟-6-嗎啉-2-基-3-吡啶基)脲或(RS)-1-(3-氯苯基)-3-(5-甲基-6-嗎啉-2-基-3-吡啶基)脲。 A compound of formula I according to claim 6 wherein the compound is (RS)-1-(3-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea (RS) 1-(4-fluorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea (RS)-1-(6-morpholin-2-yl-3-pyridyl) -3-[4-(trifluoromethyl)phenyl]urea (RS)-1-(4-chlorophenyl)-3-(6-morpholin-2-yl-3-pyridyl)urea 1- (3-Chlorophenyl)-3-[6-[(2S)-morpholin-2-yl]-3-pyridyl]urea 1-[6-[(2S)-morpholin-2-yl]- 3-pyridyl]-3-[3-(trifluoromethyl)phenyl]urea 1-(3-chlorophenyl)-3-[6-[(2R)-morpholin-2-yl]-3 -pyridyl]urea 1-[6-[(2R)-morpholin-2-yl]-3-pyridyl]-3-[3-(trifluoromethyl)phenyl]urea (RS)-1- (3-chlorophenyl)-3-(2-morpholin-2-ylpyrimidin-5-yl)urea(RS)-1-(5-chloro-6-morpholin-2-yl-3-pyridyl )-3-(3-chlorophenyl)urea(RS)-1-(3-chlorophenyl)-3-(5-fluoro-6-morpholin-2-yl-3-pyridyl)urea or RS)-1-(3-chlorophenyl)-3-(5-methyl-6-morpholin-2-yl-3-pyridyl)urea. 一種製造如請求項1至7中任一項所定義之式I之化合物之方法，該方法包括：a)使式14之化合物 與式15-a之化合物反應 以形成式16-a之化合物 ，接著使該Boc基團脫除保護基，以形成式I之化合物 其中L係-C(O)-且該等其他取代基係如請求項1中所述，或b)使式14之化合物 與式15-b之化合物反應 以形成式16-b之化合物 ，接著使該Boc基團脫除保護基，以形成式I之化合物 其中L係-NHC(O)-且該等其他取代基係如請求項1中所述，或c)使式8、9或10之化合物 與式11之化合物反應 以形成式12之化合物 ，接著使該Boc基團脫除保護基，以形成式I之化合物 其中L係鍵結且該等其他取代基係如請求項1中所述，或若需要，可將獲得之該等化合物轉化為醫藥上可接受之酸加成鹽。 A method of producing a compound of formula I as defined in any one of claims 1 to 7, which comprises: a) bringing a compound of formula 14 Reacts with the compound of formula 15-a To form a compound of formula 16-a And then removing the protecting group from the Boc group to form a compound of formula I Wherein L is -C(O)- and the other substituents are as described in claim 1, or b) are compounds of formula 14 Reacts with the compound of formula 15-b To form a compound of formula 16-b And then removing the protecting group from the Boc group to form a compound of formula I Wherein L is -NHC(O)- and the other substituents are as described in claim 1, or c) are compounds of formula 8, 9 or 10 Reacts with the compound of formula 11 To form a compound of formula 12 And then removing the protecting group from the Boc group to form a compound of formula I Wherein L is a linkage and the other substituents are as described in claim 1, or if desired, the obtained compound can be converted to a pharmaceutically acceptable acid addition salt. 如請求項1至7中任一項之化合物，其係藉由如請求項8之方法製造。 A compound according to any one of claims 1 to 7, which is produced by the method of claim 8. 一種醫藥組合物，其包含如請求項1至7中任一項之化合物及醫藥可接受之載劑及/或佐劑。 A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier and/or adjuvant. 一種包含如請求項1至7中任一項之化合物及醫藥可接受之載劑及/或佐劑之藥物組合物，其用於治療抑鬱症、焦慮症、躁鬱症、注意力不足過動症(ADHD)、壓力相關障礙症、精神性失 常、精神分裂症、神經性疾病、帕金森氏病、神經退行性疾病、阿茲海默氏病、癲癇、偏頭痛、高血壓、藥物濫用、代謝失調、飲食障礙症、糖尿病、糖尿病併發症、肥胖症、異常血脂症、能量消耗及同化失調症、體溫穩衡失調症及功能障礙、睡眠及晝夜節律性異常及心血管疾病。 A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier and/or adjuvant for the treatment of depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress related disorders, mental loss Often, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative diseases, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetes complications , obesity, abnormal dyslipidemia, energy expenditure and assimilation disorders, body temperature imbalance disorders and dysfunction, sleep and circadian rhythm and cardiovascular disease. 如請求項1至7中任一項之化合物，其用作治療活性物質於治療關於痕量胺相關受體之生物功能之疾病。 A compound according to any one of claims 1 to 7 for use as a therapeutically active substance for the treatment of a biological function with respect to trace amine-related receptors. 如請求項1至7中任一項之化合物，其係用作治療活性物質用以治療：抑鬱症、焦慮症、躁鬱症、注意力不足過動症(ADHD)、壓力相關障礙症、精神性失常、精神分裂症、神經性疾病、帕金森氏病、神經退行性疾病、阿茲海默氏病、癲癇、偏頭痛、高血壓、藥物濫用、代謝失調、飲食障礙症、糖尿病、糖尿病併發症、肥胖症、異常血脂症、能量消耗及同化失調症、體溫穩衡失調症及功能障礙、睡眠及晝夜節律性異常及心血管疾病。 A compound according to any one of claims 1 to 7 for use as a therapeutically active substance for the treatment of depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress related disorders, psychosis Disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative diseases, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetes complications , obesity, abnormal dyslipidemia, energy expenditure and assimilation disorders, body temperature imbalance disorders and dysfunction, sleep and circadian rhythm and cardiovascular disease. 一種如請求項1至7中任一項之化合物之用途，其用於製備藥劑用以治療性治療：抑鬱症、焦慮症、躁鬱症、注意力不足過動症(ADHD)、壓力相關障礙症、精神性失常、精神分裂症、神經性疾病、帕金森氏病、神經退行性疾病、阿茲海默氏病、癲癇、偏頭痛、高血壓、藥物濫用、代謝失調、飲食障礙症、糖尿病、糖尿病併發症、肥胖症、異常血脂症、能量消耗及同化失調症、體溫穩衡失調症及功能障礙、睡眠及晝夜節律性異常及心血管疾病。 Use of a compound according to any one of claims 1 to 7 for the preparation of a medicament for therapeutic treatment: depression, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress related disorder , mental disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative diseases, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, Diabetes complications, obesity, abnormal dyslipidemia, energy expenditure and assimilation disorders, body temperature imbalance disorders and dysfunction, sleep and circadian rhythm and cardiovascular disease.
TW104113768A 2014-04-30 2015-04-29 Morpholine-pyridine derivative TWI576345B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/076623 WO2015165085A1 (en) 2014-04-30 2014-04-30 Morpholin-pyridine derivatives

Publications (2)

Publication Number Publication Date
TW201546067A TW201546067A (en) 2015-12-16
TWI576345B true TWI576345B (en) 2017-04-01

Family

ID=53174989

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104113768A TWI576345B (en) 2014-04-30 2015-04-29 Morpholine-pyridine derivative

Country Status (12)

Country Link
US (1) US9840501B2 (en)
EP (1) EP3137459B1 (en)
JP (1) JP6255516B2 (en)
KR (1) KR101842382B1 (en)
CN (1) CN106255688B (en)
AR (1) AR100210A1 (en)
BR (1) BR112016022796B1 (en)
CA (1) CA2943575C (en)
MX (1) MX2016013412A (en)
RU (1) RU2690154C2 (en)
TW (1) TWI576345B (en)
WO (2) WO2015165085A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952083C (en) 2014-07-17 2023-01-24 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
SG11201807516UA (en) * 2016-03-17 2018-09-27 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
EP3463359A4 (en) * 2016-06-02 2020-08-26 Purdue Pharma LP Trace amine associated receptor 1 agonists and partial agonists for pain treatment
CN113754580B (en) * 2020-06-05 2023-04-25 上海中泽医药科技有限公司 A kind of pyridine morpholine compound, its preparation method and its application
JP2024542057A (en) 2021-11-04 2024-11-13 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 2-(aryl-2-yl)morpholines and their deuterated derivatives, preparation methods and applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012016879A1 (en) * 2010-08-02 2012-02-09 F. Hoffmann-La Roche Ag Combinations comprising atypical antipsychotics and taar1 agonists
CN102686563A (en) * 2009-12-22 2012-09-19 霍夫曼-拉罗奇有限公司 Substituted benzamide derivatives
WO2012168260A1 (en) * 2011-06-09 2012-12-13 F. Hoffmann-La Roche Ag Pyrazole derivatives
CN103443074A (en) * 2011-03-24 2013-12-11 霍夫曼-拉罗奇有限公司 Heterocyclic amine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
KR101222412B1 (en) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 2-aminooxazolines as taar1 ligands
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102686563A (en) * 2009-12-22 2012-09-19 霍夫曼-拉罗奇有限公司 Substituted benzamide derivatives
WO2012016879A1 (en) * 2010-08-02 2012-02-09 F. Hoffmann-La Roche Ag Combinations comprising atypical antipsychotics and taar1 agonists
CN103443074A (en) * 2011-03-24 2013-12-11 霍夫曼-拉罗奇有限公司 Heterocyclic amine derivatives
WO2012168260A1 (en) * 2011-06-09 2012-12-13 F. Hoffmann-La Roche Ag Pyrazole derivatives

Also Published As

Publication number Publication date
AR100210A1 (en) 2016-09-21
CA2943575A1 (en) 2015-11-05
KR101842382B1 (en) 2018-03-26
US20170044145A1 (en) 2017-02-16
RU2690154C2 (en) 2019-05-31
RU2016146560A3 (en) 2018-11-26
BR112016022796B1 (en) 2023-03-07
JP6255516B2 (en) 2017-12-27
TW201546067A (en) 2015-12-16
CA2943575C (en) 2022-08-30
CN106255688A (en) 2016-12-21
KR20160147033A (en) 2016-12-21
JP2017513912A (en) 2017-06-01
EP3137459A1 (en) 2017-03-08
MX2016013412A (en) 2017-01-18
US9840501B2 (en) 2017-12-12
CN106255688B (en) 2019-11-08
BR112016022796A2 (en) 2017-08-15
RU2016146560A (en) 2018-06-01
WO2015165085A1 (en) 2015-11-05
WO2015165835A1 (en) 2015-11-05
EP3137459B1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
TWI440636B (en) Pyrazole derivative
TWI583687B (en) 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives
TWI576345B (en) Morpholine-pyridine derivative
CN107001259B (en) Substituted azetidine derivatives as TAAR ligands
US9487501B2 (en) Pyrazole carboxamide compounds and uses thereof
EP3149002B1 (en) 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators
NZ718251B2 (en) Piperazine derivatives and the use thereof as medicament

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees